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Human Immunodeficiency Virus type 1 (HIV-1) and Mycobacterium tuberculosis (Mtb) co-
infection results in a rapid loss of numerous immunological functions and ultimately leads to 
death when not treated. The WHO estimated in 2015 that 13 million people were infected 
by both pathogens, with 390,000 deaths related to tuberculosis among HIV-infected 
individuals. Mtb and HIV-1 can induce profound changes in the host immune response 
resulting in Mtb infections causing active disease or the exacerbation of HIV-1 infection. For 
aiding in the development of new treatments a better understanding of the interactions 
between both pathogens and the host is crucial. This thesis follows this perspective by aiming 
to characterise the impact Mtb glycolipids have on modulating HIV-1 infection and to identify 
Mtb strains that differentially modulate HIV-1 infection and immune cell innate signalling. 
A technique was developed allowing for incorporation of Mtb glycolipids into liposomes, 
thereby mimicking the lipid distribution and antigen presentation found within the 
mycobacterial cell wall. Liposomes were produced with total lipid extracts from various 
pathogenic and non-pathogenic mycobacteria strains: BCG, M. smegmatis, and Mtb H37Rv, 
HN878, CDC1551 and EU127. We demonstrated the successful incorporation of specific 
mycobacterial cell wall glycolipids into liposomes. In order to study the impact of these Mtb 
glycolipids on the immune response, potentially influencing HIV-1 infection (indirectly), we 
measured the effect of Mtb liposomes on macrophage, DC and CD4+ T cell activation in vitro 
by measuring cytokine production and expression of cellular activation markers. From these 
analyses we demonstrated a strong heterogeneity of Mtb liposome effects on modulating 
immune cell responses depending on cell type and the Mtb strains studied. The Mtb 
generated liposomes were subsequently tested in the context of various HIV-1 in vitro co-
culture systems using both HIV-1 X4 and R5 strains. We investigated the effects on HIV-1 cis-
infection and trans-infection mediated by DCs, believed to be involved with HIV-1 
transmission and disease progression. We observed that Mtb glycolipids differentially 
modified cytokines and chemokines production from infected cells. These modulations are 
associated with heterogenous impacts on HIV-1 infection depending on virus tropism, the 
culture system being tested and Mtb strains. Mtb glycolipids did not show the capacity to 
interfere with HIV-1 cell attachment and cell entry via co-receptors recognition. However, 
HIV-1 trans-infection mediated by DC-SIGN receptor was impaired in the presence of Mtb 
glycolipids from BCG, H37Rv and EU127 strains. SL1 and TDM glycolipids were identified to 
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be involved in DC-SIGN recognition and impairment of HIV-1 trans-infection. These findings 
indicate that variant strains of Mtb have differential effects on modulating immune 
activation, primarily through DC interactions, and which affect HIV-1 infection and/or 
replication, which in all likelihood will influence HIV-1 disease course in co-infected 
individuals.  
Finally, in the perspective of better understanding the role of extra-vesicles (EVs) in 
influencing HIV-1 infectivity in the context of Mtb co-infection, we developed and compared 
different techniques for generating EVs from plasma, namely utilising ultra-centrifugation 
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Human Immunodeficiency Virus HIV is a lentivirus causing Acquired Immune Deficiency 
Syndrome (AIDS). We count in 2017, 36.9 million people living with HIV and 1.8 million newly 
infected. Despite the increasing availability of Antiretroviral Therapy (ART), approximately 1 
million deaths are attributed to HIV-1 each year. Tuberculosis (TB) is the most common 
disease to be diagnosed in people living with HIV and provides for the highest mortality rates 
amongst HIV-infected patients (390,000 tuberculosis-related death in 2015), especially in 
sub-Saharan Africa (WHO). 
 
 
I. HIV-1 Infection 
The Centre of Disease Control (CDC) observed in 1981, an increase of rare opportunistic 
infections such as Pneumocystis carinii pneumonia and Kaposi sarcomas (Gottlieb et al., 
1981; Masur et al., 1981). These infections were linked with a severe immune deficiency 
syndrome named AIDS in 1982. In 1983, researchers from the Pasteur Institute identify the 
lymphadenopathy-associated virus (LAV) in AIDS patients without demonstrating the 
causality between infection and AIDS (Barré-Sinoussi et al., 1983). However in 1984, the CDC 
announced the isolation of the etiological agent of AIDS: the Human T-Lymphotropic Virus 
type III (HTLV-III) (Popovic et al., 1984). HTLV-III and LAV, as well as a third virus named AIDS-
associated retrovirus (ARV) described in 1984 (Levy et al., 1984), were later characterised to 
be the same virus (Ratner, Gallo and Wong-Staal, 1985) and renamed HIV in 1986. A second 
retrovirus was isolated in West African patients (Clavel et al., 1986) and named HIV type 2 
(HIV-2) against the first described named HIV type 1 (HIV-1). The two viruses shared similar 
genetic and biological properties, but compared to HIV-1, HIV-2 is less virulent and 
transmissible (Marlink et al., 1994; Vidya Vijayan et al., 2017). Phylogenetic analysis 
established links between HIV-1 groups and the simian immunodeficiency virus SIVcpz (virus 
infecting chimpanzees) and SIVgor (virus infecting gorillas). HIV-1 is divided into four genetic 
subgroups M, O, N (Gao et al., 1999; Takehisa et al., 2009) and more recently P (Plantier et 
al., 2009) where subgroup M is responsible of the majority of HIV-1 cases. 
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i. Viral Particle 
HIV is a lentivirus belonging to the Retroviridae family. As a retrovirus, it is characterised by 
a genome composed of positive single stranded RNA. Two copies of RNAs are encased by 
nucleocapsid p7 (NC) forming the core of the viral particle. The association of ARN/p7 and 
viral proteins essential for viral replication are contained in a conical capsid composed of 
protein p24 (CA). The capsid is surrounded by a cavity defined by the matrix protein p17 (MA) 
fixed in lipids and incorporating the viral envelope protein (Env). The Env consists of a lipid 
bilayer membrane, derived from the host cell budding and a viral trimeric envelope protein 
complex. The trimeric structure is composed of a transmembrane sub-unit gp41 (TM) and a 
surface sub-unit gp120 (SU). All the above elements form a viral particle which range in size 
between 80-120nm and represented Figure 1 (Barré-Sinoussi, 1996; Ganser-Pornillos, Yeager 
and Sundquist, 2008; Ganser-Pornillos, Yeager and Pornillos, 2012). 
 
Figure 1 : Organisation of HIV-1 genome and virion 
Adapted from (Frankel and Young, 1998) 
HIV-1 genome encodes nine open reading frames. Three of these encode the Gag, Pol, and Env polyproteins. The 
four Gag proteins, MA (matrix), CA (capsid), NC (nucleocapsid), and p6, and the two Env proteins, SU (gp120) and 
TM (gp41), are structural components that make up the core of the virion and outer membrane envelope. The 
three Pol proteins, PR (protease), RT (reverse transcriptase), and IN (integrase), provide essential enzymatic 
functions and are also encapsulated within the particle. HIV-1 encodes six additional proteins: Vif, Vpr, and Nef 
found in the viral particle; Tat and Rev, essential in virus replication; and Vpu. The retroviral genome is encoded 
by an∼9-kb RNA and two genomic-length RNA molecules are also packaged in the particle. 
 
ii. Viral Genome 
The two copies of single stranded RNA (ssRNA) are approximately 9.7 kb in length each. 
Retroviruses are distinguished by the capacity to retro-transcribe the viral RNA molecules 
into double strained DNA (dsDNA) using the viral reverse-transcriptase (RT) protein 
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incorporated into the virion. At the 5’ and 3’ ends of the genome, two identical non-coding 
regions are found and called the long terminal repeat (LTR) regions. The LTRs are involved 
with the control of viral gene expression and integration of the viral genome into the host 
chromosome and encompasses nine viral open rending frames (ORF). The 5’ LTR contains 
transcription regulatory factors promoting viral genome expression.  
The ORFs gag, pol and env encode for polyproteins common to all retroviruses. Gag and Pol 
precursors are cleaved by the viral protease p11 (PR) and Env by the cellular furin protein. 
Gag is proteolytically cleaved to produce MA, CA, NC and p6 viral proteins fundamental for 
virus assembly while the Pol precursor produces protease PR, RT and integrase (IN). The RT 
is involved in reverse-transcription of viral RNA into DNA and the IN regulates the integration 
of the linear viral DNA obtained after the retro-transcription. Finally, Env precursor gp160 is 
cleaved in gp120 and gp41 to form the Envelope protein. The ORFs Tat and Rev encode for 
proteins important in viral replication and pathogenicity including vif, vpr, vpu and nef. Tat 
and Rev play an essential role in the viral life-cycle, whilst Vif, Vpr, Vpu and Nef are involved 
in viral pathogenesis (Frankel and Young, 1998; Tang, Kuhen and Wong-Staal, 1999). 
  
iii. Replicative cycle  
The life-cycle of HIV-1 is divided into several stages (Appendix 1). The first step is the 
attachment of the virus at the surface of the target cell followed by the fusion of the viral 
and cell membrane allowing the entry of the capsid into the cells. The viral RNA genome is 
then reverse-transcribed into DNA in the cytoplasm and translocated to the nucleus for 
integration. The proviral DNA is then transcribed and subsequently translated to express the 
viral proteins required for production of immature virions containing two copies of viral 
genome. After budding of new virions, maturation occurs, allowing for the production of 
mature viral particles capable of infecting new cells.  
a) Entry to target cells 
The functional envelope protein of HIV is composed of a trimer of non-covalently linked 
gp120 to gp41 molecules. The gp120 sub-unit initiates entry of the virus by initially binding 
to the CD4 receptor present on the surface of various cells, such as lymphocytes, 
macrophages and dendritic cells (DCs). Viral gp120 has a high affinity with CD4 and once 
bound a conformational change occurs exposing the variable loop 3 (V3) of gp120 and 
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allowing the molecule to bind to its secondary co-receptors, which are typically CCR5 and 
CXCR4. The simultaneous binding of receptor and co-receptor with gp120 induces disruption 
of the interaction between the gp120 and gp41 trans-membrane fusion protein. The N-
terminal of gp41 inserts into the host membrane and allows for fusion to occur via a typical 
spring-loaded  mechanism allowing for the membranes to fuse and the capsid structure to 
enter the cell (Figure 2) (Wilen, Tilton and Doms, 2012).  
 
Figure 2 : HIV-1 entry  
Adapted from (Wilen, Tilton and Doms, 2012) 
1. HIV Env, composed of gp120 and gp41 subunits, attaches to the host cell by 2. binding CD4 via gp120. This 
causes conformational changes in Env, allowing 3. co-receptor binding mediated in part by the V3 loop of Env. 
This initiates 4. the membrane fusion process as the fusion peptide of gp41 inserts into the target membrane, 
followed by six-helix bundle formation and complete membrane fusion. 
The co-receptors utilised during virus entry define the tropism of HIV-1, where CCR5 (R5) 
viruses utilise the CCR5 chemokine receptor and CXCR4 (X4) viruses use the CXCR4 receptor 
for entry, whilst some viruses (R5X4) utilise both and are termed dual-tropic viruses.   
b) Reverse Transcription 
Once the core has entered the cell it is uncoated through removal of CA p24 protein to 
release the viral RNA genome with its associated enzymes into the cytoplasm. The capsid is 
brought to the nucleus by interactions with the micro-tubular system and disassembled in 
the process (Arhel et al., 2006; Ambrose and Aiken, 2014; Campbell and Hope, 2015). During 
transportation, the reverse transcription complex (RTF) is formed and RNA reverse 
transcription is initiated with binding of the host transfer RNA (tARNLys3) on the primer 
binding site (PB) at the 5’ end of the genome. RT allows for the generation of a minus 
stranded DNA molecule and degrades the complementary RNA by its RNase H activity. The 
DNA-tRNA hybrid subsequently produced is then transferred to the 3’ end of the genome 
and used as a primer for the synthesis of the first DNA strand. The ssRNA molecule is 
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degraded by RT, except the PP site that serves for priming synthesis the second DNA strand. 
After degradation of the tRNA, hybridisation at the PB site occurs and for elongation of the 
second DNA strand by RT and allowing for the generation of dsDNA and its LTRs (U3-R-U5) 
(Appendix 2) (Hu and Hughes, 2012; Modrow et al., 2013). The viral DNA associated with 
cellular and viral proteins (such as MA, CA, Vpr, or IN), form the pre-integration complex (PIC) 
which is then translocated to the nucleus through the nuclear pore complex (NPC) (Jayappa, 
Ao and Yao, 2012).  
c) Integration and gene expression 
Once in the nucleus, the integration of the viral dsDNA into the host genome is mediated by 
the integrase protein (IN). Integration process occurs preferentially in actively transcribed 
units to favour efficient viral gene expression. IN catalyses two distinct reactions: the 3’-
processing where nucleotides are added at its 3’ ends, and stand transfer where the viral 
DNA ends are inserted into host chromosomal DNA. The integration process is facilitated 
with the help of host factors such as LEDGF that promotes viral integration in transcriptionally 
active regions by binding IN (Craigie and Bushman, 2012; Kvaratskhelia et al., 2014; 
Grawenhoff and Engelman, 2017). A fraction of non-integrated viral DNAs can remain in the 
nucleus in circular forms (1-LTR or 2-LTR) or linear forms (Ruggiero et al., 2017).  
Integrated HIV-1 DNA, termed provirus, is then transcribed using the cellular transcriptional 
machinery, following early and late phases. The 5’-LTR region possesses a number of 
regulatory sequences similar to human cellular genes that allow for fixation of host 
transcription factors promoting gene expression such as Sp, NF-κB, C/EBP, NFAT or AP-1.  
Initially, the proviral DNA is transcribed by the cellular RNA polymerase II (RNApol-II) enzyme, 
allowing for the synthesis of mRNAs. The majority of the transcripts produced are short due 
to the low stability of the RNApol-II protein. However, full transcripts are produced that are 
subsequently multiply spliced and which migrate to the cytoplasm allowing for the 
expression of the regulatory proteins Tat, Rev and Nef.  Once the proteins Tat and Rev are 
produced in sufficient quantity they promote the late transcription of the provirus genome. 
Tat is a trans-activator that interacts with the TAR region of new HIV-1 transcripts allowing 
for the recruitment of the positive transcription elongation factor (pTEFb) and thereby 
promoting elongation of the transcript. The protein Rev binds to the RRE structure of 
unspliced or partially spliced HIV-1 transcripts and enables for them to be exported from the 
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nucleus. The HIV-mRNA produced then is translated into the last viral proteins (Lawn et al., 
2001; Karn and Stoltzfus, 2012; Modrow et al., 2013).  
d) Viral particle assembly, budding and maturation  
The HIV-mRNA unspliced or partially spliced forms encode polyproteins Env, Gag and Gag-
Pol. The newly synthesised viral proteins are assembled to form new viral particles. The Env 
polyproteins are transported from the rough endoplasmic reticulum (RER) to lipid rafts within 
the cellular membrane via the typical secretory pathways. Gag and Gag-Pol precursors 
generate viral proteins involved in particle assembly. Gag precursors contain MA, CA, NC and 
p6 domains. Gag recruits the viral genomic RNA (by the NC domain) to migrate and 
multimerise (by the CA domain) at the plasma membrane under the same rafts. After 
incorporation of Env (by the MA domain), the endosomal sorting complex, required for 
transport (ESCRT-I), is recruited via the p6 domain catalysing membrane fission and 
completing the budding process. Additionally, the p6 protein of Gag additionally allows for 
recruitment of Vpr, Vif and Nef to associate with viral particles before budding. The particles 
released are immature until the protease p11 cleaves Gag and Gag-Pol into the appropriate 
structural proteins. Once maturation is complete the new viral particles are fully infectious 
and ready to start a new replicative cycle (Appendix 3) (Freed, 2015). 
 
iv. Pathogenesis and transmission 
a) Course of HIV Infection 
Infection with HIV-1 is characterised by three clinical stages: primary/acute, asymptomatic 
and AIDS (Figure 3). The HIV-1 acute phase of infection lasts for between 3 to 6 weeks and is 
associated with an expansion of viral replication and reduction in the number of CD4+ T 
lymphocytes. At the end of the primo-infection, the immune system recovers partially with 
an increase in CD4+ T cells counts and a decrease in viral load. The following asymptomatic 
phase can typically last for 6 to 11 years in the absence of antiretroviral treatment (ART) and 
is characterised by the control of viral load by the immune system. However, residual 
replication leads to chronic inflammation and a progressive decline in CD4+ T cell number. 
When CD4+ T cells go below 200 cells/L, the immune system is unable to sufficiently control 
opportunistic infections and the patient is declared immunocompromised, termed AIDS and 
which subsequently leads to death (Modrow et al., 2013; Maartens, Celum and Lewin, 2014).  
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Figure 3 : Course of HIV-1 infection 
Adapted from (Alizon and Magnus, 2012)  
Relationship between plasma HIV-1 load increase and CD4+ T-cell loss over the course of infection in untreated 
patients. 
b) Primary Infection 
Infection with HIV-1 occurs when virus particles reach the bloodstream via injury, blood 
transfusion, mother-to-child transmission during pregnancy, delivery or lactation, or via 
mucous membranes as encountered during sexual intercourse (conjunctiva, rectum and 
genital mucosa). The first target cells for HIV-1 are likely DCs and macrophages present at 
the site of infection and which also includes Langerhans cells (LCs) (Appendix 4). DCs and 
macrophages are permissive for HIV-1 R5 infection by expression of CD4 and the CCR5 
receptors, where for LC entry of the virus is mediated by endocytosis. Consequently, DCs and 
macrophages play a crucial role in the initial phase of infection and represent viral reservoirs 
(Lawn, Butera and Folks, 2001; Wu, 2008; Modrow et al., 2013; Maartens, Celum and Lewin, 
2014). Individuals homozygous for a 32bp deletion in the CCR5 gene (CCR5-Δ32) have been 
described to have CD4+ lymphocytes refractory for infection with CCR5 using viruses, 
rendering them naturally resistant to infection (Huang et al., 1996; Paxton et al., 1996; Wu 
et al., 1997; Hütter et al., 2009). HIV-1 CXCR4 tropic viruses are found later in infection and 
evolve from viruses using CCR5 and can be found in 50% of infected individuals later in their 
disease course (Schuitemaker et al., 1992). However, positive selection of HIV-1 (R5) and 
restriction of HIV-1 (X4)  viruses during transmission represents a key mechanism for virus 
propagation as CXCR4 using viruses are associated with rapid loss of CD4+ T cells due to their 
strong cytopathogenic effect (Turville et al., 2004).  
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Infected cells activate the immune response recruiting new target cells (DCs and 
macrophages) to important anatomical sites via production of chemokines and subsequent 
migration to lymph nodes. There, the virus proliferates by infection of monocytes, 
macrophages and T lymphocytes, inducing the generation of adaptive immune responses, 
both cellular and humoral. Because of the physical contact between antigen-presenting cells 
(APCs) or infected cells and T cells through virological synapses, the virus can be transmitted 
from cell to cell. This mechanism can occur between infected macrophages or CD4+ T cells 
and uninfected lymphocytes, or between DCs and CD4+ T cells (Lawn, Butera and Folks, 2001; 
Wu, 2008; Modrow et al., 2013; Maartens, Celum and Lewin, 2014). In the case of DCs, the 
capture of infectious virions transmitted to uninfected T cells, occurs by attachment of the 
glycoprotein Env via mannose receptor or C-type lectin receptor. This mechanism is called 
trans-infection (Sallusto et al., 1995; Gummuluru, KewalRamani and Emerman, 2002; 
McDonald et al., 2003; Turville et al., 2003; Garcia et al., 2005; Wu, 2008).  
During primary infection, HIV-1 replication occurs initially within lymph nodes (first week of 
infection) and is then disseminated in plasma (resulting in peak replication during the second 
week of infection). HIV-1 replication subsequently declines to a stable level (typically after 4 
weeks of infection) and relates to the establishment of effective innate and adaptive immune 
response that can control viral replication (Lawn, Butera and Folks, 2001; Wu, 2008; Modrow 
et al., 2013; Maartens, Celum and Lewin, 2014).  
c) Anti-viral response and chronic infection  
As mentioned above, the immune response against HIV-1 is initiated by infected cells via the 
recognition of pathogen-associated molecular patterns (PAMPs) from viral elements by 
pathogen-recognition receptors (PRRs) expressed by immune cells. PRRs are receptors that 
mediate immunity including Toll-like receptors (TLRs) (present on the cell surface or in 
endosomes) or cGAS and IFI16 (present in the cytosol). Endosomal TLR7 and TLR8 recognise 
HIV-1 ssRNA, while cGAS and IFI16 will recognise the viral dsDNA generated from the RT step 
in the replication cycle. The activation of those signalling pathways activate the expression 
of various transcription factors leading to production of type I IFNs, cytokines (IL-1β, IL-6 and 
TNF-α) and chemokines for recruitment of immune cells such as macrophages, DCs, NK, T 
and B cells to the site of infection (Mogensen et al., 2010; Altfeld and Gale, 2015; Lahaye and 
Manel, 2015). IFN responses are crucial for anti-viral activity through promoting expression 
of anti-viral proteins such as tetherin, that blocks budding and release of viral particle (Neil, 
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Zang and Bieniasz, 2008; Perez-Caballero et al., 2009) or APOBEC-3G and SAMHD1, that 
inhibit reverse transcription (Okeoma et al., 2010; Goldstone et al., 2011; Laguette et al., 
2011; Wang et al., 2011; Harris and Dudley, 2015). Additionally, some chemokines produced 
are the natural ligands for the appropriate HIV-1 chemokine co-receptors, and consequently 
can block HIV-1 entry. It is the case for SDF-1, natural ligand of CXCR4 (Bleul et al., 1996), as 
well as MIP-1α, MIP-1β and RANTES the natural ligands of CCR5 (Cocchi et al., 1995).  
The host antiviral immune responses mounted include the induction of cytotoxic T cells (CTL) 
responses characterised by the proliferation of CD8+ T cells, whereas induced CD4+ T-helper 
responses are weaker. The environment of pro-inflammatory cytokines produced by the 
immune response during infection can positively modulate HIV-1 replication (Kedzierska and 
Crowe, 2001). TNF-α is described to enhance HIV-1 replication in macrophages and T 
lymphocytes via NF-κB pathway (Folks et al., 1989; Okamoto et al., 1989; Foli et al., 1997; 
Muñoz-Fernández et al., 1997) as well as IL-1 (Granowitz et al., 1995) and IL-6 (Foli et al., 
1997). 
HIV-1 has developed several strategies to escape the effects of the immune response. The 
viral accessory proteins Nef, Vpu, Vpr and Vif are determinants in modulating viral 
pathogenesis and disease progression. The Nef protein has been described to decrease 
expression of CD4 and MHC-I on the cell surface, thereby modulating infection. Depletion in 
CD4 at the surface of the cell can prevent superinfection and enhance release of new viral 
particle, whereas MHC-I down-regulation can inhibit recognition of the infected cells by 
cytotoxic T cells (Pereira and DaSilva, 2016). Vpu is a viroporin protein that can induce a 
reduction in CD4 expression at the cell surface and enhance the released of virions by 
promoting reorganisation of raft structures and budding (González, 2015). Vpr contributes 
to HIV-1 pathogenesis through an array of mechanisms, notably promoting early T cell 
activation facilitating productive HIV-1 infection of non-activated T cells and secretion of TNF-
α, IL-6 or IL-8 (González, 2017). Vif is required for HIV-1 replication and can induce 
degradation of APOBEC proteins, a cellular RNA editing enzyme restricting HIV-1 reverse 
transcription as mentioned above (Goila-Gaur and Strebel, 2008).  
Mutations frequently occur in MHC class-I CTL epitopes found in many of the viral proteins 
described above and this therefore limits the efficacy of CTL responses in controlling HIV-1 
infection (J. Kim et al., 2018). The progression of HIV-1 disease is related to the balance 
between viral replication and the cellular immune response mediated through CD8+ CTL and 
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the exhaustion of infected CD4+ T cells, thereby reducing virus production and replication. 
During chronic asymptomatic HIV-1 infection, persistent viral replication and production, 
leads to the loss of CD4+ T lymphocytes associated with constant systemic immune activation.  
d) Extracellular vesicles and HIV-1 infection 
Extracellular vesicles (EVs or exosomes), are small  vesicles ranging in size between 150 to 
1,000nm and are secreted from the plasma membrane (PM) by direct budding or by fusion 
of internal multivesicular compartments (MVB) with the PM (Figure 4).  
 
Figure 4 : EVs production from different intracellular origins 
Adapted from (Colombo, Raposo and Théry, 2014) 
Schematic representation of the different types of membrane vesicles released by eukaryotic cells, either by 
direct budding from the plasma membrane (PM) or by fusion of internal multivesicular compartments (MVB) with 
the PM.  
EVs can be produced by different cell types into the extracellular environment and can be 
detected in various biological fluids such as blood, urine, saliva, amniotic fluid, ascites, 
bronchoalveolar lavage, synovial fluid, semen and breast milk (Gould and Raposo, 2013; 
Raposo and Stoorvogel, 2013; Colombo, Raposo and Théry, 2014; Iraci et al., 2016).  
HIV-1 and EVs are generated by similar pathways (Fang et al., 2007; Usami et al., 2009) 
leading to incorporation of HIV-1 products into EVs such as Nef, Env, Gag, HIV-1 nucleic acids 
and microRNA, facilitating virus replication and pathogenicity (Kadiu et al., 2012; Arenaccio, 
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Chiozzini, Columba-Cabezas, Manfredi, Affabris, et al., 2014; Madison and Okeoma, 2015; 
Hildreth, 2017).  
As mentioned previously, the viral protein Nef can promote HIV-1 infection. When the 
protein is incorporated into EVs, it has been described to be able to activate HIV-1 replication 
and modulate inflammation (Arenaccio, Chiozzini, Columba-Cabezas, Manfredi and Federico, 
2014b; Lee et al., 2016). Additionally, EVs produced from infected cells can induce activation 
of latent HIV-1 genomes in CD4+ T cells and macrophages via TNF-α through ADAM17 
incorporated in EVs (Arenaccio et al., 2015). Recently, Tang et al. demonstrated the ability of 
exosomal Tat to activate latent HIV-1 in CD4+ T lymphocytes (Tang et al., 2018). Furthermore, 
EVs can modulate the inflammatory environment during infection through generating 
favourable conditions for viral replication. Sampey et al. revealed in 2015, a role of exosomal 
TAR RNA in modulating inflammation where EVs from HIV-1 infected cells induced secretion 
of IL-6 and TNF-β in macrophages, suggesting activation of the TLR pathway by EVs (Sampey 
et al., 2015). EVs can also modulate HIV-1 entry via cell to cell contact by influencing the 
expression or availability of membrane receptors. This is the case for the CCR5 and CXCR4 
co-receptors that can be transferred via EVs making cells more susceptible to HIV-1 infection 
(Mack et al., 2000; Rozmyslowicz et al., 2003). Additionally, the surface molecules CD45, 
CD86 and MHC-II can be released via EVs from HIV-1 infected cells influencing the evasion of 
the immune system (Esser et al., 2001). 
Some EVs can have a protective and negative impact on HIV-1 infection. As viral proteins, 
cellular components with anti-viral activity can be incorporated in EVs. APOBEC-3G has been 
described to be transferred from cell to cell via EVs thereby protecting cells against HIV-1 
infection (Khatua et al., 2009; Okeoma et al., 2010). Additionally, cytokines can be 
transferred in EVs including IL-4, IL-13 and TNF-α which can block HIV-1 infection by reducing 
expression of co-receptors needed for viral entry (Lane et al., 1999; Bailer, Lee and Montaner, 
2000; Creery et al., 2006; Li et al., 2013). It has been described that EVs secreted by T 
lymphocytes can incorporate the CD molecule into the vesicles and thereby block HIV-1 
infection (de Carvalho et al., 2014), as well as EVs form CD8+ T cells that can inhibit HIV-1 
transcription in infected cells (Tumne et al., 2009). Also, Näslund et al. showed in 2014 that 
EVs isolated from breast milk can inhibit DC mediated HIV-1 trans-infection by binding to DC-
SIGN (Näslund et al., 2014). However, because of the cytolytic replication of HIV-1, the 




ART consists of a combination of antiretroviral drugs to inhibit viral replication and prevent 
disease progression. Antiviral drugs (ARD) are classified according to the specific phase of the 
viral life-cycle they target (Appendix 1). 
a) Entry inhibitors 
Maraviroc is a CCR5 antagonist that binds to the CCR5 receptor inhibiting interaction with 
HIV-1 gp120 (Dorr et al., 2005). Resistance to this molecule can occur due to the hyper-
variability within the V3 loop (Yuan et al., 2011). Enfuvirtide (T20) is fusion peptide (fusion 
inhibitors FI) blocking gp41 folding and HIV-1 entry. However, rapid accumulation of 
mutations in gp41 can thwart its action (Carmona et al., 2005). 
b) Reverse transcriptase inhibitors 
The reverse transcription step in the viral life-cycle (ssRNA to dsDNA synthesis) has been 
heavily targeted in the development of ARDs. There are two main categories of drugs 
targeting reverse transcription: nucleoside and non-nucleoside reverse transcription 
inhibitors (NRTIs and NNRTIs respectively). NRTIs are analogues of the cellular nucleotides 
lacking a 3’OH group on the deoxyribose. The incorporation of NRTI instead the natural 
substrate, leads to premature stops in the formation of DNA chain during reverse 
transcription. NNRTIs are non-competitive inhibitors to reverse transcription. They bind to 
RT inducing conformational changes leading to the loss of the enzymes affinity for 
nucleotides (De Clercq, 2013). 
c) Integration inhibitors 
To inhibit integration of viral dsDNA, ARTs target the integrase IN protein. The integrase 
strand transfer inhibitors (INSTIs) bind to the active site of the integrase, blocking binding to 
the enzyme on its catalytic site essential for promoting integration (Métifiot, Marchand and 
Pommier, 2013). 
d) Assembly inhibitors 
These drugs interfere with the generation of functional proteins and the virus assembly 
process by inhibiting p11 protease activity. PIs are competitive inhibitors that prevent 
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cleavage of Gag and Gag-Pol precursor by interacting with the active site of p11. These 
inhibitors are commonly used in multi-therapy approaches even if its bioavailability is not 
optimum (De Clercq, 2013). 
e) Limitations of ART 
The introduction of ART has increased the duration of the asymptomatic period and the life 
expectancy of infected people. Commonly, ART consists of a combination of two NRTIs with 
either INSTI, PI or NNRTI. However, ART only controls disease and does not cure it. Indeed, 
upon treatment interruption a virus rebound is observed which associates with a drop in 
CD4+ T lymphocyte numbers due to reactivation of virus from latently infected reservoirs. 
Subsequent activation of latent viruses from CD4+ T lymphocytes and 
monocytes/macrophages lineages in the absence of treatment represents a major obstacle 
for virus eradication and total recovery for patients (Le Douce et al., 2012).   
 
vi. HIV-1 and co-infections 
The immunodeficiency caused by HIV-1 infection increases the risk of co-infection leading to 
higher risk of morbidity and mortality for infected individuals. Additionally, despite 
administration of ART in co-infection situations, the restoration of the immune response to 
normal level is not always achieved. Historically, HIV-1 was identified because of the increase 
in Pneumocystis carinii pneumonia and Kaposi’s sarcomas opportunistic diseases. Today, 
many other pathogens have been associated with significant detrimental effects for co-
infected individuals, through loss of immunity, and these include infection with Cryptococcus, 
Hepatitis B virus (HBV), Hepatitis C virus (HCV), Plasmodium and Mycobacterium tuberculosis 
(Mtb) (Chang et al., 2013). In this Thesis, we focused on studying the in vitro effects of Mtb 
on HIV-1 infection. 
 
II. Mycobacterium tuberculosis Infection 
The Mtb bacillus responsible for tuberculosis (TB) disease appeared 70,000 years ago. During 
the industrial revolution, TB became epidemic but its incidence decreased though the 20th 
century in developed countries. The introduction of the Bacillus Calmette-Guérin (BCG) 
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vaccine in 1921 along with associated antimicrobial drugs reduced considerably the 
incidence of disease. However, the incidence of TB has increased since the 1980’s due to a 
number of factors, including deterioration of health conditions, the generation of antibiotic 
resistant strains and the emergence of the HIV-1 pandemic  (Bates and Stead, 1993; Daniel, 
2006; Bañuls et al., 2015). 
 
i. Mtb composition 
Mtb is a bacillus measuring 2-4 µm characterised by a slow generation time of 12-24h under 
optimal conditions. The Mtb H37Rv genome, a standard pathogenic strain of TB, consists of 
4.4x106 bp containing approximately 4,000 genes classified according to function (Smith, 
2003). The bacteria cell wall confers to Mtb a strong impermeable barrier to toxic compounds 
and drugs and plays a major role in Mtb pathogenesis. The mycobacterial cell envelope is 
divided into three sections: the plasma membrane, the cell wall core and the capsule (Figure 
5).  
The mycobacterial cell envelope is complex and composed of a plasma membrane 
surrounded by a cell wall skeleton constituting 60% of its dry mass composed of diverse lipids 
presented within an outer capsule. The cell wall core consists of peptidoglycans (PG) in 
covalent attachment with arabinogalactan (AG) linked to mycolic acids (MA) by esterification. 
Free lipids associated with MA together form the mycobacterial outer membrane. It is 
composed of various and complex lipids such as glycolipids, trehalose dimycolate (TDM), 
phthiocerol dimycocerosate (PDIM/DIM), sulfolipids (SLs), phosphatidylinositol mannosides 
(PIM), lipomannan (LM) and lipoarabinomannan (LAM) (Hoffmann et al., 2008; Zuber et al., 
2008; Angala et al., 2014; Bansal-Mutalik and Nikaido, 2014; Grzegorzewicz et al., 2016; Singh 
et al., 2018). 
Importantly, the nature and the quantity of mycobacterial cell wall components can vary 
between Mtb isolates and can significantly impact on bacterial host interactions (Cywes et 
al., 1997; Ehlers and Daffé, 1998; Torrelles and Schlesinger, 2010). 
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Figure 5 : Structure of the Mtb cell envelope 
Adapted from (Singh et al., 2018)  
The mycobacterial cell envelope is mainly composed of three different covalently linked layers composed of 
plasma membrane, periplasmic space, cell wall core, outer membrane and capsule. PG (Peptidoglycan), AG 
(Arabinogalactan) and mycolic acids form the cell wall core. The outer membrane of the cell envelope contains 
various free acyl lipids DAT (Diacyltrehalose), TAT (Triacyltrehalose), PAT (Polyacyltrehalose), TDM (Trehalose 
6,6’-dimycolate), SL-1 (Sulfolipid-1), PDIM (Phthiocerol dimycocerosate), PGL (Phenolic glycolipid), etc. that are 
intercalated with the mycolic acids. The outer layer called the capsule, mainly contains polysaccharides and 
surface proteins. LAM (Lipoarabinomannan) is shown both in the outer membrane and plasma membrane. PIM 
(Phosphatidylinositol mannoside) is shown to be associated with plasma membrane and PG.  
 
ii. Pathogenesis 
Mtb infection starts when bacteria dispersed in the air, from an individual with active 
pulmonary TB, reaches the alveoli of the host. The bacteria are rapidly phagocytised by 
macrophages, typically resulting in the bacillus being destroyed. However, Mtb can survive 
and start to replicate in infected cells and to spread to other organs through the lymph 
system and the peripheral blood. After initiation of the adaptive immune response, migration 
of immune cells (including neutrophil and lymphocytes) to site of primary infection occurs 
and can form a cellular infiltrate, termed granuloma, in order to contain the spread of the 
bacteria. Granulomas are considered lesions which benefit both the host and Mtb (Smith, 
2003; Philips and Ernst, 2012; Delogu, Sali and Fadda, 2013). 
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The initial stage of TB infections starts 3 to 8 weeks after Mtb ingestion when the pathogen 
is disseminated within the lymphatic circulation to lymph nodes in the lung forming Ghon 
complexes (granuloma). The second stage of disease is characterised by bacterial spread to 
other organs, including other regions of the lungs through blood circulation and can typically 
last for three months. Once the bacteria reach the pleural space, severe chest pain appears 
and can last for up to two years. The resolution of Ghon complexes can take up to three years 
if the disease doesn’t progress (Smith, 2003). 
a) Mtb entry 
Mtb is rapidly phagocytised by alveolar macrophages (resident cells) as well as neutrophils, 
monocytes derived macrophages (MDM) and DCs. The bacteria is recognised by immune cells 
via interactions with different cellular receptors: Mannose receptor (Kang et al., 2005), C-
type lectin (DC-SIGN, Dectin-1), scavenger receptors (Class A and B), complement receptors 
(CR1, CR3), inducing opsonisation or phagocytose of Mtb (Smith, 2003; Philips and Ernst, 
2012). Mannose-capped LAM (ManLAM), from the mycobacteria envelope, is recognised by 
mannose receptors (expressed my macrophages) (Schlesinger, Hull and Kaufman, 1994; 
Ehlers and Daffé, 1998) and DC-SIGN (major receptor involved in Mtb recognition by DCs) 
(Geijtenbeek et al., 2003; Tailleux et al., 2003). PIM6 can also interact with DC-SIGN (Driessen 
et al., 2009) while TDM interacts with macrophage inducible C-type lectin (Mincle) (Ishikawa 
et al., 2009). The origin of the receptors involved in bacteria uptake determines the 
intracellular outcome of the bacteria (Smith, 2003; Philips and Ernst, 2012; Stanley and Cox, 
2013).  
b) Intracellular trafficking 
Most of the time the maturation of the phagosome with phagosome-lysosome fusion occurs 
leading to the bacteria being destroyed as the bacillus is subject to a hostile environment, 
characterised by acid pH, reactive oxygen intermediates and lysosomal enzymes (Figure 6, 
route e). However, in some case, the bacteria interfere with the phagosome maturation 
process and replicates. Various studies support the theory that Mtb inhibits phagosome 
maturation by interacting with host molecules which reside in a compartment similar to an 
early endosome (Figure 6, routes a and f) (Philips, 2008). The mycobacterial phagosome can 
interfere with Rab5 activity blocking Rab7 bound on phagosome membranes and the 
production of phosphatidylinositol 3-phosphate (PI3P) (Philips and Ernst, 2012; Stanley and 
Cox, 2013). Mycobacterial lipids TDM and ManLAM have been described to play a role in the 
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perturbation of phagosome maturation (Fratti et al., 2003; Indrigo, Hunter and Actor, 2003). 
However, studies support that Mtb can replicate in the cytoplasm by phagosomal escape 
(Leake, Myrvik and Wright, 1984; McDonough, Kress and Bloom, 1993) via membrane 
damage caused by the Esx-1 secretion system (Figure 6 routes b and c) (van der Wel et al., 
2007; Houben et al., 2012). Depending on the bacteria route, Mtb grows either inside the un-
maturated phagosome or in the cytosol. 
 
 
Figure 6 : Mycobacterium routes after phagocytose 
Adapted from (Philips and Ernst, 2012) 
a. Mtb can prevent phagosome maturation and grow in an early endosome–like compartment by inhibiting 
phosphatidylinositol 3-phosphate (PI3P) generation on the phagosome and impairing the recruitment of active, 
GTP-bound Rab7 while retaining Rab5. b. The Esx-1 system permeabilises the phagosomal membrane, allowing 
direct cytosolic access. c. In some cases, this process may result in the escape of the bacteria into the cytosol. The 
extent of cytosolic growth may depend upon cell type. d. the cytosolic bacteria are recognised by the host 
ubiquitin system and are sequestered in a membrane-bound compartment. e. Some ingested bacteria fail to 
prevent phagosome maturation, and they are delivered to the lysosome, where their replication is curtailed. f. In 
certain contexts, they may be able to grow in lysosomes. g. IFN-γ and vitamin D can overcome the early 
endosome–like arrest of Mtb, thereby promoting delivery of bacteria to autolysosomes, where growth is 
curtailed.  
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Infected macrophages can engage autophagy characterised by formation of autolysosomes 
containing the bacteria leading to the destruction of the bacteria (Figure 6 route g) or antigen 
presentation. Cytosolic bacteria can join this pathway by ubiquitination and sequestration 
via adaptor proteins (Figure 6 route d). Mtb is then released from infected macrophages by 
inducing cell apoptosis or necrosis (Philips and Ernst, 2012).   
c) Granuloma 
Activation of the immune response by Mtb results in macrophage recruitment to the site of 
infection, inducing aggregation and forming a granuloma. The Mtb released from early 
infected macrophages are rapidly ingested by surrounding macrophages contributing to 
early bacterial growth (Davis and Ramakrishnan, 2009). Various Mtb components have been 
described to be implicated in the initiation of granuloma formation such as LM, PIMs, TDM 
and LAMs (Puissegur et al., 2007). 
d) Immune Responses induced by Mtb components 
Mtb components (PAMPs) are recognised by different elements of the innate immune 
response that is essential for defence against progressive Mtb infection. The bacteria 
expresses multiple TLRs agonists with predominant TLR2 ligands such as LM (Quesniaux et 
al., 2004) and PIMs (Banaiee et al., 2006) and Mtb DNA that can be recognised by TLR9 (Bafica 
et al., 2005). Depending of the Mtb lineage, the bacteria will preferentially activate TLR2 or 
TLR4 pathways, resulting in the differential modulation of cytokine production. Compared to 
the H37Rv and HN878 strains, Mtb from the Beijing lineage activated macrophage via TLR4 
(Carmona et al., 2013). Activation of macrophages mediated by TLR2 enhanced vitamin D 
receptor and hyrdolaxylase, promoting antimicrobial responses (Liu et al., 2006) and 
activation of TNF-α production (Underhill et al., 1999). Additionally, TLRs mediate the 
interaction of Mtb induced activation/maturation of DCs and production of numerous 
cytokines including TNF-α, IL-6, IL-10, and IL- 12 in vitro (Hickman, Chan and Salgame, 2002; 
Jang et al., 2004). 
In parallel, mycobacterial PG can interact with the receptor NOD2 in the macrophage cytosol, 
inducing production of pro-inflammatory cytokines (Ferwerda et al., 2005; Divangahi et al., 
2008). The C-type lectin receptor Dectin-1 is a PRR expressed by macrophages, DCs, 
neutrophils and T cells recognising  α-glucan from Mtb (Dinadayala et al., 2004). Dectin-1 
mediated recognition induces Th1 and Th17 responses characterised by production of IL-17 
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(van de Veerdonk et al., 2010), DC responses via IL-12p40 production (Rothfuchs et al., 2007) 
and macrophage responses with TNF-α, RANTES, IL-6 and G-CSF production (Yadav and 
Schorey, 2006). Additionally, DC-SIGN can promote maturation of phagosomes and 
production of IL-10 leading to the induction of an anti-inflammatory response (Gringhuis et 
al., 2007; Tanne et al., 2009). 
The interactions of Mtb PAMPs with host PRRs induce cell activation and secretion of 
cytokines crucial for immune cell recruitment and clearance of the bacteria. TNF-α plays a 
crucial role in TB protection (Flynn et al., 1995) by containing latent TB (Mohan et al., 2001) 
and inhibiting bacterial growth and macrophage death (Clay, Volkman and Ramakrishnan, 
2008). IFN-γ induced by IL-12 and IL-18 production, promotes CD4+ T cell recruitment and 
CTL mediated bacteria killing. Additionally, the cytokines IL-1, IL-6 and IL-23 are important 
for promoting the pro-inflammatory response (Hossain and Norazmi, 2013). However, Mtb 
infection can induce upregulation of IL-4 and IL-10 cytokines, increasing disease progression 
and down-regulating macrophage and DC activity. The role of type I IFNs remains unclear as 
it could induce anti-inflammatory responses. The balance between pro- and anti-
inflammatory responses will in all likelihood determine TB progression (Philips and Ernst, 
2012; Hossain and Norazmi, 2013). 
e) Extracellular-vesicles and Mtb infection  
EVs from Mtb infection originate from the cytoplasmic membrane origin, proteomic analyses 
revealed that EVs are principally composed of proteins involved in host-pathogen interaction 
(Lee et al., 2015). Mtb EVs can participate in immune stimulations, indeed, EVs produced 
from infected macrophages can promote immune responses by activation of uninfected 
macrophages via induction of pro-inflammatory cytokines (Bhatnagar et al., 2007) or T cell 
activation (Giri and Schorey, 2008). Also, EVs derived from infected APCs can present 
processed antigen to T cells (Ramachandra et al., 2010) or DCs (Jurkoshek et al., 2016). 
However, several studies support that Mtb have utilised EV trafficking to export lipoglycan 
and lipoproteins that impair host immune response (Athman et al., 2015, 2017). Additionally, 
EVs can impair bacterial survival, Alvarez-Jimenez et al. described recently that EVs released 




The current treatment for Mtb infections include a cocktail of rifampicin (RIF), isoniazid (INH), 
pyrazinamide (PZA), and ethambutol (EMB), resulting in clearance of the bacteria after 6-9 
months. The high prevalence of Mtb disease is explained by the lack of availability of 
medications and the growing problem of MDR-TB. Treatment for MDR-TB towards two years 
is associated with toxic effects of the drugs. Furthermore, the development of treatment 
against MDR-TB induced development of extensively drug-resistant tuberculosis (XDR-TB). 
The development of novel chemotherapeutic options is crucial to treat MDR-TB (Hoagland 
et al., 2016). 
 
III. Mycobacterium tuberculosis and HIV-1 co-infection 
HIV-TB co-infection results in a rapid loss of numerous immunological functions and 
ultimately leads to death when not treated. WHO estimated in 2015 that 13 million people 
were infected by both pathogens. Mtb and HIV-1 can induce profound changes in the host 
immune system resulting in an increase of Mtb infections to active disease or the 
exacerbation of HIV infection. 
 
i. TB reactivation by HIV 
TB/HIV-1 co-infected patients are 21-34 times more likely to develop active TB disease than 
those only infected with Mtb. Furthermore, people living with HIV-1 are facing emerging 
threats with increase in prevalence of drug-resistant TB and where multi-drug resistant 
(MDR-TB) and extensively drug resistant TB (XDR-TB) strains over the last years (WHO). HIV-
1 infection increases the risk of acquiring primary Mtb infection by 2.2 to 5.5 fold (Chang et 
al., 2013) and facilitate via different mechanisms Mtb growth/dissemination (Pathak, 
Wentzel-Larsen and Åsjö, 2010) and activation of latent TB (Diedrich and Flynn, 2011). HIV-1 
infection induces a global dysfunction of the immune responses. A strong depletion of CD4+ 
T cells is observed in the context of co-infection (Law et al., 1996; Kalsdorf et al., 2009; 
Geldmacher et al., 2010) decreasing the ability to contain Mtb infection. This phenomenon 
is illustrated by disruption in IFN-γ, TNF and IL-2 production (Kalsdorf et al., 2009). HIV-1 
infection enhances the expression of receptors involved in Mtb entry such as CD14 (Rosas-
Taraco et al., 2006) or impairment with DCs antigen presentation (Singh et al., 2016). 
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Additionally, bacterial survival is improved with inhibition of macrophage phagocytosis and 
apoptotic responses with notable interactions of the viral protein Nef with adaptor proteins 
required for phagocytose (Mazzolini et al., 2010), and with the autophagy regulator beclin 1 
(Patel et al., 2007, 2009; Kyei et al., 2009). Because of the depletion of CD4+ cells, the 
granuloma formation can be disturbed leading to a systemic disease in co-infected patients, 
where extrapulmonary TB has been described only in patients with HIV-1 infection (Naing et 
al., 2013). 
 
ii. Exacerbation of HIV infection by Mtb infection 
a) HIV replication at sites of Mtb infection 
Various studies described the influence of Mtb infection on HIV-1 replication. In co-infected 
patients, enhancement of HIV replication were found on sites of Mtb infection in the lung 
(Nakata et al., 1997) and pleural space (Lawn et al., 2001). Additionally, in HIV-1-infected 
patients with pulmonary TB, HIV-1 viral load is higher compared to non-TB symptomatic HIV-
1-infected patients (Toossi et al., 2001). In vitro, Mtb have been described to activate virus 
replication in monocyte lineages or primary macrophages (Shattock, Friedland and Griffin, 
1993; Goletti et al., 1996; Toossi et al., 2001) by activation of LTR transcription (Zhang, 
Nakata, et al., 1995). 
b) Immune responses induced by Mtb components  
A large range of molecular components from Mtb (or PAMPs) are engaged in PRRs 
recognition by macrophages. Several studies described the involvement of Mtb PAMPs in 
activation of PRRs signalling pathways leading to modification/translocation of transcription 
factors resulting in enhancement of HIV-1 LTR activity (summarised Appendix 5). Indeed, the 
engagement by Mtb components of the TLR4, TLR2 and TLR9, induce a signal transduction 
MyD88-dependent and MyD88-independent cascade activating the MAPK and NF-κB (Falvo 
et al., 2011; Philips and Ernst, 2012; Hussein et al., 2014; Kawasaki and Kawai, 2014), resulting 
in activation of HIV-1 replication (Bafica et al., 2003; Equils et al., 2003; Hernández et al., 
2012; Rodriguez et al., 2013). Additionally, the engagement of the C-type lectins family with 
Mtb ligands receptors, such as DC-SIGN, can induce NF-κB pathways (Tailleux et al., 2003; 
Geijtenbeek et al., 2003; Koppel et al., 2004; Neyrolles, Gicquel and Quintana-Murci, 2006; 
Driessen et al., 2009; Gringhuis et al., 2009; Ehlers, 2010; Falvo et al., 2011; Lugo-Villarino et 
al., 2011; Philips and Ernst, 2012; Hussein et al., 2014). The observations of up-regulation of 
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HIV-LTR activity is correlated by reactivation of latent HIV-1 in T cells via TLR2 engagement 
in Mtb infection (Larson et al., 2017).  
c) Establishment of a favourable environment for HIV-1 infection 
As we described previously, the pro-inflammatory cytokine production induced by the 
immune response, can heighten HIV-1 replication by activation of the NF-κB pathway. In the 
context of Mtb co-infection, the immune response engaged against the bacillus, can increase 
HIV-1 replication, such as TNF and IL-6 (Ranjbar et al., 2009). In parallel, down-regulation of 
anti-inflammatory responses, such as IL-10 and TGF-β induced by co-infection lead to an 
exaggerated pro-inflammatory response, providing a benefit to the virus (Goletti et al., 1998; 
Chetty et al., 2014; Tomlinson et al., 2014). Additionally, HIV-1 entry is facilitated by an 
augmentation of co-receptor expression from cytokine production induced by Mtb infection 
(Hoshino et al., 2004; Rosas-Taraco et al., 2006; Kalsdorf et al., 2013; Wahid Ansari, 
Kamarulzaman and Schmidt, 2013) and associated with down-regulation of RANTES (natural 
ligand of CCR5 receptor, inhibiting HIV-1 entry) (Rosas-Taraco et al., 2006). Mtb can enhance 
HIV cell-to-cell transmission. For instance, the bacillus can increase the efficacy of virus 
transmission from infected MDM to T cells (Mancino et al., 1997). Additionally, because of 
the recruitment and association in granuloma of with immune cells (caused by Mtb), the 
propagation of virus can be facilitated (Bell and Noursadeghi, 2018). HIV-1 trans-infection 
mediated by DCs is enhanced in the presence of Mtb, the bacillus infection inducing 
perturbation in virus antigen presentation by the cell (Reuter et al., 2010).  
Overall, Mtb creates a favourable environment for HIV-1 replication, as Mtb infection leads 
to the activation and induction of immune responses, including activation of 
macrophages/DCs, recruitment of lymphocytes, co-receptor expression and production of 




Figure 7 : Mtb increasing HIV-1 replication and propagation 
Adapted from (Bell and Noursadeghi, 2018) 
Innate immune signalling pathways in macrophages can increase HIV-1 transcription through activation of the 
transcription factors. a. The host cell response to innate immune activation by Mtb leads to the production of a 
range of pro-inflammatory cytokines and chemokines inducing b. local recruitment of T cells. c. The accumulation 
of activated T cells provides a population of cells permissive to HIV-1 and allows for rapid virus propagation by 
direct cell–cell spread. d. The pro-inflammatory cytokines also promote transactivation of virus replication 
through the action of the transcription factors. e. HIV-1 attenuation of IL-10 responses to Mtb favours the virus 
by reducing IL-10-mediated inhibition of HIV-1 transcription by promoting pro-inflammatory responses. f. Mtb 
induces type 1 interferon responses in macrophages, which would be expected to promote an antiviral state, any 
autocrine or paracrine inhibition of HIV-1 replication is transient. g. Mtb can cause macrophage polyploidy 
through activation of the cell cycle coupled to cytokinesis failure. 
 
iii. Impact on treatments 
ART treatment improves the immune response, reducing primary TB and latent TB 
reactivation (Suthar et al., 2012). However, under anti-TB treatment and ART, immune 
reconstitution inflammatory syndrome (IRIS) can develop in some co-infected patients 
(Lawn, Bekker and Miller, 2005; Müller et al., 2010) which is associated with extrapulmonary 
TB in most cases (Meintjes et al., 2008). The risk of TB in patients is associated with early HIV-
1 infection before the initiation of ART. BCG vaccination administrated in infants with a high 
prevalence of tuberculosis is not recommended by the WHO in HIV-infected patients due to 
its opportunistic potential. The development of new TB vaccines would be of benefit in cases 
of HIV-1 co-infected infants. Finally, a better understanding of the immunological disorders 
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observed in HIV-1/TB co-infected individuals would lead to the development of appropriate 
immunomodulatory therapy. 
 
IV. Aims of the project 
In 2015, the WHO has estimated 390,000 deaths related to TB in HIV-infected individuals. 
Because of the complexity of the immune response there are multiple ways that Mtb can 
modulate HIV-1 infection and vice versa. The better of understanding of interactions 
between the host with HIV-1 and Mtb simultaneously is crucial when considering developing 
improved treatments. This thesis project follows this perspective by aiming to characterise 
the impact Mtb glycolipids have on modulating HIV-1 infection and to identify Mtb strains 
that differentially modulate HIV-1 infection and immune cell innate signalling. 
For this purpose, a technique allowing us to best mimic lipid distribution and antigen 
presentation on the mycobacterial cell wall was developed. Total lipid extracts from various 
mycobacterial strains BCG, M. smegmatis and Mtb from diverse origins (H37Rv, HN878, 
CDC1551 and EU127) were associated in liposomes. The composition and physical properties 
of generated liposomes were characterised by Thin-layer chromatography (TLC) and 
NanoSight technology to be used in in vitro assays. To understand the impact of Mtb 
glycolipids on the immune responses that can potentially influence HIV-1 infection 
(indirectly), the effect of Mtb liposomes on macrophages, DCs and CD4+ T cells activations 
were analysed in vitro by measuring cytokine production and cellular expression markers 
(Chapter 2). 
The direct impact of Mtb glycolipids associated in liposomes on HIV-1 infection was analysed. 
We investigated liposome effects on HIV-1 cis-infection (Chapter 3) and trans-infection 
mediated by DCs involved in HIV-1 transmission (Chapter 4). In both cases, two different 
approaches were used. In order to analyse interferences from Mtb glycolipids with HIV-1 cell 
attachment and cell entry via co-receptors CCR5 or CXCR4, a pseudo-typed viral particle 
system was developed. HIV-1 pseudo-typed viruses (either CCR5 or CXCR4 using tropic) 
produced by co-transfection of 293T cells were used to infect TZM-bl cells expressing 
reporter proteins to enable monitoring HIV-1 infectivity. To characterised DC-SIGN mediated 
HIV-1 capture/transfer, the Raji-DC-SIGN cell line was used, in parallel to immature and 
mature DCs from healthy donors, on TZM-bl trans-infection assays. The second approach 
 25 
developed, used fully replicative competent HIV-1 where infections were performed on CD4+ 
T lymphocytes from healthy donors in vitro and monitored for virus replication by measuring 
p24 production, HIV-1 DNA quantification and cytokine production. For trans-infection 
analysis using the replicative system viral capture/transfer was mediated by immature DCs 
to CD4+ T cells. Additionally, an in vitro system was tested where immature DCs and CD4+ T 
lymphocytes were co-cultured simultaneously, more resembling in vivo physiological 
conditions (Chapter 4). 
Finally, in the perspective of better understanding the role of EVs on influencing HIV-1 
infectivity in the context of TB co-infection, we developed and compared different 
techniques for generating EVs from plasma, namely utilising Ultra-centrifugation (UC) and 
gel filtration (Chapter 5).   
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Chapter 1: Material and Methods 
 
I. Liposomes generation and characterisation 
i. Mycobacterium total lipids extract  
a) Isolation of total lipid composition 
The isolation of total lipids from the all the Mycobacteria tested, have been performed in 
collaboration with Dr A. Bhatt, University of Birmingham. To isolate total lipids from 
Mycobacteria, standard procedures were performed as described Dobson et al., 1985. 
Bacterial cultures were pelleted in 8ml glass tubes with PTFE caps. 2ml of solvent 
CHCl3:MeOH:H20 was added to the pellet and kept at 50°C for 3h. The tube was then 
centrifuged at 3,000rpm and the supernatant transferred into a new tube. 1.75ml of 
chloroform and 750µl of water were then added to the supernatant, mixed and centrifuged 
again. The organic phase located at the bottom was then transferred to a new tube and 
washed 2x by addition of 2ml of CHCl3:MeOH:H20 3:47:48. After vortexing and centrifugation, 
the upper aqueous phase was discarded. After the final wash, the lower phase was 
transferred into a new tube to a heat block under air flow at 55°C. The amount of dried pellet 
was then calculated. 
b) H37Rv lipids fractionation 
This technique was performed in collaboration with Dr A. Bhatt (University of Birmingham). 
Total lipid extract from H37Rv bacteria (2mg) was fractioned using a silica column. The 
column was pre-washed with chloroform (3x void volume) before the sample was added. 
Once the input sample was added onto the column, 100ml of chloroform was added to start 
flow through collection. A mix of CHCl3:MeOH solvent was passed through the column with 
a progressive increase in the proportion of methanol as follows: 
- CHCl3:MeOH 99:1: collection tubes numbered 1-8 
- CHCl3:MeOH 98:2, collection tubes numbered 9-15 
- CHCl3:MeOH 97:3 collection tubes numbered 16-23  
- CHCl3:MeOH 95:5 collection tubes numbered 24-31 
- 93:7 collection tubes numbered 32-49  
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- 90:10 collection tubes numbered 50-57 
- 80:20 collection tubes numbered 57-63.  
c) Lipids used for liposome generation 
All dried lipid pellets were solubilised in CHCl3:MeOH 2:1 (Table 1.1), chloroform (CHCl3,Sigma 
Aldrich, UK) methanol (MeOH, Sigma Aldrich, UK). Phosphatidylcholine and cholesterol were 
solubilised in chloroform. 






HN878, Bejing strain donated by A. Bhatt (University of 
Birmingham) 
CDC155 donated by A. Bhatt (University of Birmingham) 
EU127 from clinical isolate donated by A. Koch and R. J. 
Wilkinson (University of Cape Town) 
EU111 from clinical isolate donated by A. Koch and R. J. 
Wilkinson (University of Cape Town) 
Ex30 from clinical isolate donated by A. Koch and R. J. 
and Wilkinson (University of Cape Town) 
H37Rv from W. Jacobs (Albert Einstein College of 
Medicine) 
H37Rv MA from C. Sassetti (University of 
Massachusetts) 
papA1Δ (H37Rv mutant ΔSL-1) donated by A. Bhatt 
(University of Birmingham) 
Mycobacterium 
chelonae 
donated by A. Bhatt (University of Birmingham) 
Mycobacterium 
marinum 
donated by A. Bhatt (University of Birmingham) 
Mycobacterium 
bovis 
BCG donated by A. Bhatt (University of Birmingham) 
Mycobacterium 
smegmatis 
MC2155 donated by A. Bhatt (University of Birmingham) 
Staphylococcus 
aureus 
Donated by A. Kadioglu (University of Liverpool) 
Corynebacterium 
glutamicum 
donated by A. Bhatt (University of Birmingham) 
Lipids 
solutions 
Phosphatidylcholine L-α-Phosphatidylcholine from egg yolk (Sigma Aldrich, 
UK) 
Cholesterol (Sigma Aldrich, UK) 
Sulpholipids-1 From H37Rv (BEI Resources) 
PDIM From H37Rv (BEI Resources) 
TDM From H37Rv (BEI Resources) 




ii. Liposomes generation 
“Liposome” is a generic term describing hydrated lipid dispersion which may be large or 
small, unilamellar or multilamellar vesicles (Mayer, Hope and Cullis, 1986). Here, small 
unilamellar vesicles (SUV) were produced by initially forming a thin dry lipid film that was 
hydrated in an aqueous medium. The lipid films were obtained by mixing different lipids in 
solution with organic solvent (CHCl3 or CHCl3:MeOH), and the solvents were then evaporated 
with the use of nitrogen gas. After the hydration step, multilamellar vesicles (MUV) were 
obtained by mechanical agitation. To reduce the size of produced SUV the preparations were 
finally sonicated (Figure 1.1). 
 
Figure 1.1 : Liposome preparation 
 
Liposomes were generated with phosphatidylcholine (PC) and cholesterol (Ch) in different 
proportions (Table 1.2). Lipids were mixed together (2mg in total) and then evaporated with 
nitrogen gas for 30min. Liposomes were hydrated by addition of Roswell Park Memorial 
Institute (RPMI-1640, ThermoFisher scientific, UK), Dulbecco Modified Eagle Medium 
(DMEM, ThermoFisher scientific, UK), Phosphate-Buffered Saline (PBS, ThermoFisher 
scientific, UK), or sterile water (for TLC analyses). Liposomes were then incubated at 55°C for 
30min with vortexing to achieve a final concentration of liposomes of 10mg/ml. The 
preparations were subsequently sonicated for 30min at 4°C. All liposomes were stored at 4°C 
for one month maximum. 
For NanoSight analyses of liposomes, 0.8PC:0.2Ch liposomes were filtered using the Avanti® 
Mini-Extruder system after sonication. Liposome solutions were filtered through a 100nm or 
200nm polycarbonate filter under 50°C temperature to produce 100nm and 200nm 
0.8PC:0.2Ch liposome diameters.  
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Table 1.2 : List of liposomes generated and composition 
Liposomes Composition and Proportion 
Phosphatidyl- 
choline 





PC 100% - - - - 
0.9PC:0.1Ch 90% 10% - - - 
0.8PC:0.2Ch 80% 20% - - - 
0.6PC:0.4Ch 60% 40% - - - 
Liposomes with lipids 
from Mycobacterium or 
others 






Fraction 1 (from H37Rv 1-9 collection tube) 
Fraction 2 (from H37Rv 10-13) 
Fraction 3 (from H37Rv 14-18) 
Fraction 4 (from H37Rv 19-27) 
Fraction 5 (from H37Rv 28-32) 
Fraction 6 (from H37Rv 33-36) 
Fraction 7 (from H37Rv 37-44) 
Fraction 8 (from H37Rv 45-63) 
Mtb H37Rv MA 
papA1Δ 
papA1Δ + SL1 60% 20% 19% 1% - 
PDIM 78% 20% - - 2% 
M. chelonae 60% 20% 20% - - 
M. marinum 
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Table 1.2 continued 
Liposomes Composition and Proportion 
Phosphatidyl- 
choline 
Cholesterol Total lipids extract SL-1 PDIM 
Liposomes with lipids 
from Mycobacterium or 
others 







iii. Thin-Layer Chromatography (TLC) 
Thin-Layer Chromatography (TLC) is a solid-liquid form of chromatography allowing for the 
separation of lipids depending of their polarity. The technique was used here to characterise 
the lipid composition of the H37Rv bacterial strain and its lipid fractionation; and the 
composition of the Mtb liposomes generated. As for the total lipids isolations and 
fractionations, this was performed in collaboration with Dr A. Bhatt, University of 
Birmingham. In both cases, 10µl of sample was spotted and dried on a silica gel 60 F254 plate 
(Sigma Aldrich, UK). Sample separation occurred in 60:16:2 CHCl3:MeOH:H2O solvent and was 
visualised by staining with molybdophosphoric acid (MPA) and charring. For H37Rv fractions 
analyses, fractions (1-9) were pooled as fraction 1, (10-13) pooled as Fraction 2, (14-18) 
pooled as Fraction 3, (19-27) pooled as Fraction 4, (28-32) pooled as Fraction 5, (33-36) 
pooled as Fraction 6, (37-44) pooled as Fraction 7, and (45-63) pooled as fraction 8 from TLC 
separations and used for further analyses. 
 
iv. Nanosight 
Visualisation, particle concentration and the size distribution of the generated liposomes 
were evaluated using the NanoSight NS300 instrument (Malvern, UK) and using Nanoparticle 
Tracking Analysis (NTA) software. The liposomes in suspension were placed into a chamber 
where a laser beam passed through. In this way, the particles could be visualised by the 
camera and the Brownian motion of the particles indicating the particle size diameter using 
the Stokes Einstein equation, calculated by the NTA software. Videos were recording at 
camera level 13. The post-acquisition settings were with a minimum detection threshold 7, 
automatic blur and automatic minimum expected particle size. Liposome preparations were 




i. PBMCs isolation 
Venous blood samples from healthy donors collected in either EDTA or heparin collection 
tubes were processed by density gradient centrifugation using Histopaque®-1077 (Sigma 
Aldrich, UK) to allow for PBMC isolation. Blood was diluted 1:1 in PBS and layered over Ficoll 
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in 50ml tubes (20ml of diluted blood onto 15ml of Histopaque®-1077). Tubes were placed 
into centrifuge buckets, avoiding any disruption of the layer, to be spun at 1000g for 20min 
at 18-20°C (acceleration 1, brake 0).  After centrifugation, the following layers were visible 
from the top to bottom of the tube: plasma and PBS, PBMC, Ficoll and red blood cells. The 
PBMC layer was carefully collected using a sterile plastic Pasteur pipette and transferred to 
50ml tubes. PBS (Thermofisher, UK) was added up to 50ml and cells were washed by 8min 
centrifugation at 500g, 18-20°C (acceleration and brake 4). After the first wash, supernatant 
was discarded and the cell pellet was re-suspended in PBS; 10µl of cell suspension was taken 
for the cell count and the remaining cells were washed as described above. For cell count, 
90µl of trypan blue 0.4% (Thermofisher, UK) was added to the cell suspension to allow for 
visualisation of dead cells. 10µl of the cell-trypan blue suspension was applied to a 
haemocytometer slide chamber. By using a microscope with a 10X objective alive (clear) and 
dead (blue) cells could be discriminated and live cells on one set of 4 corner squares counted. 
The total number of cells was then calculated with percentage viability determined. 
 
ii. Monocytes derived macrophage (MDMs) isolation and culture 
a) MDMs isolation and culture 
Monocyte derived macrophages (MDMs) were isolated from fresh PBMCs by MACS® 
Separation (Miltenyi Biotech, UK) with positive selection of the CD14+ cell population. PBMCs 
were washed in PBS and finally re-suspended in MACS buffer (80µl of buffer per 107 PBMCs) 
containing PBS with 0.5% bovine serum albumin (BSA, Sigma Aldrich, UK) and 2mM EDTA 
(ThermoFisher scientific, UK). Human magnetic CD14 MicroBeads (Miltenyi Biotech, UK) 
were added to the cells in suspension (10µl of beads per 107 total cells) and incubated for 
15min at 4°C. During the incubation, LS MACS Columns (Miltenyi Biotech, UK) were placed 
on the magnetic separator and activated by passing through MACS buffer. Following 
incubation with the CD14 MicroBeads, the cells were pelleted and re-suspended in MACS 
buffer (500µl of buffer per 108 total PBMCs) and applied onto the column. Unbound cells 
(CD14- population) passed through the column and were collected in a 50ml tube for CD4+ T 
cell isolation (Chapter 1 Part II. Section iv.). The LS column was washed with 1ml of MACS 
buffer (3x) before removing the column from the magnetic rack to elute the CD14+ 
population with 5ml of MACS buffer and collected in a 15ml tube containing 1ml of buffer. 
10µl of cell suspension was taken for determining cell counts and viability (as described in 
Chapter 1 Part II. Section i) and the remaining cells were pelleted by 8min centrifugation at 
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500g, 18-20°C (acceleration and brake 4). One aliquot of each population (CD14+ and CD14-) 
containing 1-0.5x106 cells (upon cell availability) was used for flow cytometry analysis 
(Chapter 1 Part II. Section vi.a)). The CD14+ cell population was re-suspended at 1x106 
cells/ml in RPMI-1640 containing L-glutamine, 10% AB+ serum, 100U/ml penicillin and 
100mg/ml streptomycin (Fisher Scientific, UK). The cells were then seeded in 6 well plates at 
3ml per well, and incubated for 6-7 days at 37°C, 5% CO2 to allow them to undergo 
differentiation. 
b) MDMs incubated with liposomes 
MDMs generated from 7 days of culture as described above were harvested and re-
suspended in fresh media consisting of RPMI-1640 with L-glutamine, 10% AB+ serum, 
100U/ml penicillin and 100mg/ml streptomycin at 106 cells/ml. In a 96-well plate, 200µl of 
the cell suspension were seeded per well, then, 40µg of liposome suspension in RPMI-1640 
was added per well with a total of 4 wells per condition. Liposomes tested: BCG, M. 
smegmatis, H37Rv, HN878, CDC1551 and EU127. 0.8PC:0.2Ch was used as a negative control 
and LPS (100ng/ml, Sigma Aldrich, UK) used as a positive control. After 18h of incubation at 
37°C 5% CO2, MDM were harvested and centrifuged for 5min at 1,400rpm, 18-20°C 
(acceleration and brake 4). The supernatant from 4 wells from the same condition were 
pooled and stored at -80°C before performing Lumniex® assays (Chapter 1 Part II. Section 
vii.). 
 
iii. Monocytes derived dendritic cells (DCs) isolation, culture and 
maturation 
a) iDCs isolation and culture 
Immature monocytes derived dendritic cells (iDCs) were isolated from fresh PBMCs by 
MACS® Separation (Miltenyi Biotech, UK) with the positive selection of the CD14+ cell 
population as described above for MDM (Chapter 1 Part II. Section ii.a)). The CD14+ cells 
obtained after isolation were re-suspended at a density of 1x106 cells/ml in RPMI-1640 
containing L-glutamine supplemented with 10% foetal bovine serum (FBS, Sigma Aldrich, UK), 
100U/ml penicillin, 100mg/ml streptomycin, 70ng/ml human IL-4 (Fisher Scientific, UK) and 
50ng/ml human GM-CSF (Fisher Scientific, UK). The cells were seeded in 6 well plates in 3ml 
media per well, and incubated at 37°C, 5% CO2 through differentiation. After 3 days the 
media was replaced with fresh media containing IL-4 and GM-CSF. The iDCs were harvested 
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after 3-4 days of incubation. One aliquot of cells at 1-0.5x106 cells/vial was used for flow 
cytometry analysis. 
b) iDCs maturation 
Mature monocyte derived dendritic cells (mDCs) were isolated from fresh iDCs. At day 5-6 
Poly(I:C) (20µg/ml, Sigma Aldrich, UK) or LPS (100ng/ml) were added to iDCs media. The 
mDCs cells were harvested after 18-24h of incubation at 37°C, 5% CO2. The cell phenotypes 
where confirmed by flow cytometry analysis (Chapter 1 Part II. Section vi.b)). 
c) iDCs maturation with liposomes 
For iDCs maturation in the presence of liposomes, iDCs generated from 5-6 days of culture 
were harvested and re-suspended in fresh media containing RPMI-1640 supplemented with 
L-glutamine, 10% FBS, 100U/ml penicillin, 100mg/ml streptomycin. The cells were seeded in 
6 well plates with 3ml per well at a density of 0.5x106 cells/ml. To each well 100µg of liposome 
suspension in RPMI-1640 was added per well with 2 wells per condition. Liposomes tested 
included: BCG, M. smegmatis, H37Rv, HN878, CDC1551 and EU127. Poly(I:C) and LPS were 
used as positive controls and in parallel iDCs without stimulation and 0.8PC:0.2Ch liposomes 
were included as negatives controls. After 18h of incubation at 37°C 5% CO2, iDCs were 
harvested and analysed by flow cytometry, additionally, the supernatants from each 
condition were kept and stored at -80°C for Luminex® assays.  
 
iv. CD4+ T lymphocyte isolation and culture 
CD4+ T lymphocytes were isolated from fresh PBMCs using MACS® Separation (Miltenyi 
Biotech, UK). Frist, the CD14- cell population was isolated by negative selection as described 
above for MDM (Chapter 1 Part II. Section ii.a)). Secondly, after 4 days of activation and 
expansion of the CD14- population to lymphocytes, CD4+ T lymphocytes were separated from 
CD8+ T lymphocytes by negative selection using Dynabeads® CD8 (ThermoFisher scientific, 
UK). The CD14- isolated fraction from MACS® Separation were re-suspended at a density of 
2x106 cells/ml in RPMI-1640 containing L-glutamine complemented with 10% FBS, 100U/ml 
penicillin, 100mg/ml streptomycin, 5µg/ml PHA-p (Sigma Aldrich, UK), 100U/ml human IL-2 
(Fisher Scientific, UK) and incubated at 37°C, 5% CO2. At day 2, the cells were re-suspended 
gently, counted and fresh IL-2 (100U/ml) was added to the media. At day 4 following cell 
activation and expansion the lymphocytes were harvested and pelleted by 8min 
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centrifugation at 500g, 18-20°C (acceleration and brake 4) to be re-suspended in isolation 
buffer (density of 107 lymphocytes/ml) containing PBS, with 0.1% BSA and 2mM EDTA. 
Dynabeads® CD8 were added to the cells in suspension (25µl of beads per 107 cells) and 
incubated for 30min at 4°C. The tube containing the cells incubated with the magnetic beads 
was then placed onto a magnetic rack to allow for the separation of CD4+ T lymphocytes from 
the magnetically retained CD8+ T lymphocytes. The CD4+ cells were harvested, pelleted and 
re-suspended in RPMI-1640 containing L-glutamine supplemented with 10% FBS, 100U/ml 
penicillin, 100mg/ml streptomycin and 100U/ml human IL-2. One aliquot of each population 
(CD4+ and CD4-) containing 5-10 x105 cells were used for flow cytometry analysis. The CD4+ 
T-lymphocytes were incubated at 37°C, 5% CO2 for 24-48h before being used in assays. 
 
v. CD4+T lymphocytes and iDCs co-culture 
a) CD4+T lymphocytes and iDCs co-culture 
The iDCs and CD4+ T lymphocytes were both isolated from the same blood donor with the 
methods described above. In a 96-well plate 2x104 iDCs were placed in culture with 2x105 
CD4+ T lymphocytes per well in 200µl of RPMI-1640 containing L-glutamine supplemented 
with 10% FBS, 100U/ml penicillin, 100mg/ml streptomycin and  100U/ml human IL-2. 
b) CD4+T lymphocytes and iDCs with liposomes 
40µg of liposome suspensions in RPMI-1640 were added per well to iDCs and CD4+ T 
lymphocyte co-culture, with a total of 4 wells per condition. Liposomes tested: BCG, M. 
smegmatis, H37Rv, HN878, CDC1551 and EU127. 0.8PC:0.2Ch is used as a negative control 
and LPS (100ng/ml, Sigma Aldrich, UK) as a positive control. After 7 days of incubation at 37°C 
5% CO2, the supernatant from 4 wells from the same condition were pooled and stored at -
80°C before being processed for Lumniex® analysis. 
 
vi. Flow cytometry 
Flow cytometric analysis was performed to confirm each cellular fraction’s phenotype by 
measuring expression of specific cellular markers relevant to the cell-type being assayed. 
Events were acquired using the BD Accuri™ C6 or BD FACSCelesta™ flow cytometers and the 
analysis was performed by using BD Accuri™ C6 Plus or FlowJo software, respectively.  
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a) CD14+/CD14- PBMC population isolation 
To confirm MACS® Separation of CD14+ from the CD14- PBMC population, flow cytometry 
was performed for the detection of CD14 markers. Following isolation of the two 
population’s, aliquots of 0.5x106 cells were pelleted by 1min centrifugation at 7,000rpm at 
room temperature (RT) and re-suspended in 40µl of MACS buffer. Cell suspensions were 
stained with the relevant antibody (Table 1.3) diluted following the manufacturer’s 
recommendations (Biolegend, UK). After 30min incubation at 4°C, cells were washed 2x in 
PBS and centrifuged at 7,000rpm at RT for 1min. After the final wash cells were re-suspended 
in 100µl of 2% PFA solution (Sigma Aldrich, UK) and incubated for 30-45min at 4°C. Finally, 
the cells were re-suspended in PBS before undergoing analysis. Flow cytometry analysis was 
performed using the BD Accuri™ C6 and 10,000 events were recorded for each sample. Data 
analysis was performed using the BD Accuri™ C6 Plus software. For each population, three 
conditions were tested: cells alone, cells with antibody and cells with isotype matched 
control antibody. 
b) iDCs maturation 
The mDCs phenotypes were confirmed via flow cytometry by measuring specific markers of 
differentiation of DCs which include: DC-SIGN, CD40, CD86, CD80, and HLA-II. DCs were 
stained following the same protocol described above for PBMCs. BD FACS Celesta™ was used 
to record 10,000 events for each sample and data analyses was performed using FlowJo 
software. 
c) CD4+ T lymphocytes isolation 
Flow cytometry was used to detect CD4+ cell markers to confirm the enrichment of CD4+ from 
CD14- cell populations using Dynabeads® CD8 depletion. Cells were stained following the 
same protocol described above for PBMCs and DCs. BD FACS Celesta™ was used to record 





Table 1.3 : List of antibodies used in flow cytometry assays 
Assays Target (fluorochrome) Company (Cat#) 
CD14+/CD14- PBMCs populations 
isolation 
CD14 (PE) BioLegend (325605) 
iDCs maturation DC-SIGN (PE) BioLegend (330106) 
CD40 (APC) BioLegend (334309) 
CD86 (PE) BioLegend (305405) 
CD80 (APC) BioLegend (305219) 
HLA-II (APC) BioLegend (307609) 
CD4+T lymphocytes isolation CD4 (PE) BioLegend (300508) 
 
d) HIV-1 infection 
For the development of in vitro assays to study HIV-1 infection, flow cytometry was used to 
measure expression of different florescent markers (depending on the conditions) to 
measure infections as described in Chapter 1 Part IV. Section iii.a) and Part V. Section iii.a). 
 
vii. Luminex® 
Supernatants from MDM, iDCs (Chapter 1 Part II. Sections ii.b) and iii.c), respectively) and 
HIV-1 cis-/trans-infection assays (Chapter 1 Part V. Sections iii.b) and iv.b), respectively) were 
assayed for a total of 27 soluble immune proteins quantified in four panels (listed Table 1.4) 
utilising the R&D Systems multiplex magnetic bead immunoassays and following 
manufacturer’s instructions. The Luminex® assays were performed in collaboration with Dr 
C. Herrera, Imperial College London. Briefly, samples were spun and diluted appropriately for 
each panel. For detection of TGF-β 1, 2 and 3, samples required acid activation with 1N HCl 
followed by 1.2 N NaOH/0.5M HEPES neutralisation. Serially diluted standards and samples 
were incubated with a magnetic microparticle cocktail for 2h at RT on a horizontal orbital 
microplate shaker. Plates were then washed with wash buffer three times with a handheld 
magnetic plate washer prior to incubation with a biotin antibody cocktail for 1h at RT on the 
orbital shaker. Streptavidin-PE was added to each well after three washes. Plates were 
incubated for 30min, washed and microparticles resuspended in wash buffer. Finally, plates 




Table 1.4 : List of cytokines studied and kits used in Luminex® assays 
Description Company (Cat#) 

























IL-12/23 p40 (BR67) 
Bio-Techne (LXSAHM-04) 






Human Mag Luminex Perf Assay Base Ki t, XL Cyt Disc 
Panel - LUXLM000 
IFN-α, XL 





III. Extra-vesicles (EVs) isolation and characterisation 
i. Plasma isolation 
In this thesis, extra-vesicles (EVs) were isolated from the plasma of healthy donors. In order 
to collect plasma, venous blood collected in EDTA or heparin tubes was centrifuged at 1,000g 
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for 20min at RT allowing separation of plasma from blood cells. The plasma (supernatant) 
was collected in 50ml tubes, aliquoted and stored at -80°C for. 
 
ii. Isolation of EVs by differential centrifugations 
a) Assay 1 
For this approach, 1ml of plasma from healthy donors was diluted in PBS 1:1 in 2ml 
microcentrifuge tubes. To eliminate cell debris the sample was first centrifuged 5min at full 
speed (7,000g) at 4°C. 2ml cleared plasma in microcentrifuge tubes was then centrifuged 
90min at full speed (7,000g) at 4°C. The supernatant was transferred to a new tube and 
stored at -80°C for subsequent analysis. The pellet containing the EV particles was re-
suspended in 500μl PBS and stored at -80°C prior to testing in the appropriate assays. 
b) Assay 2: Ultra-centrifugation 
For this approach, EV isolation was performed on a larger scale and utilised the ultra-
centrifugation protocol previously described (Théry et al., 2006). 10ml of plasma from 
healthy donors was diluted 1:1 in PBS and centrifuged 30min at 10,000g at 4°C to remove 
cell debris. Supernatant was transferred to 5.9ml polycarbonate Quick-Seal® tubes (Beckman 
Coulter, UK) and heat-sealed using the specified Beckman device. Cleared plasma was 
centrifuged 2h at 100,000g at 4°C in a Beckman SW41 swing-bucket rotor. After 
centrifugation the supernatant was collected using a syringe and kept at -80°C until 
subsequent analysis. The pellets containing the EVs were re-suspended in 1ml of PBS, 
transferred to a clean tube and incubated 30min at RT to dislodge and separate EV particles. 
25ml of PBS was added and the re-suspended pellet centrifuged for 2h 100,000g at 4°C as 
previously described. Following the wash step the second supernatant was collected and 
stored at -80°C for subsequent analysis. The pellet was re-suspended in 1ml PBS as described 
above and kept at -80°C for later analysis in the HIV-1 trans-infection assay (Chapter 1 Part 
IV. Section iv.d)). 
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iii. Isolation of EVs from Plasma by Gel Filtration (Size Exclusion 
Chromatography) 
a) Assay 1: Gel Filtration Sephadex paired with concentration 
For this approach, 1ml of plasma from healthy donor was diluted in PBS 1:1 in 2ml Eppendorf 
tubes. To eliminate cell debris the sample was centrifuged for 5min at full speed (7,000g) at 
4°C and aliquoted. 2ml of cleared plasma was applied to a Sephadex G-25 column in PD-10 
buffer (GE Healthcare, UK) to isolate the EVs from the plasma. The Sephadex G-25 column 
was first washed with 8ml of PBS. The cleared plasma was then eluted with PBS and collected. 
The eluate obtained was applied to an Amicon Ultra-15 30kDa filter (Merck Millipore, UK) 
and centrifuged 30min at 4,000g at 4°C to concentrate the EVs from plasma. The filtrate was 
removed and stored at -20°C to be subsequently utilised in HIV-1 trans-infection assays 
(Chapter 1 Part IV. Section iv.d)). The concentrate was washed once with 1ml PBS and 
centrifuged again for 30min at 4,000g at 4°C. After the wash step, the concentrate containing 
the EV particles was transferred to a clean Eppendorf tube and stored at -80°C before being 
analysed in HIV-1 trans-infection assays (Chapter 1 Part IV. Section iv.d)). 
b) Assay 2: Gel Filtration Sepharose  
For this approach EV isolation was performed following SEC as previously described (Böing 
et al., 2014). An SEC column was constructed using a 10ml syringe (Becton Dickinson BD) 
stacked with 10ml of Sepharose CL-2B (Sigma Aldrich, UK). Prior to adding Sepharose, the tip 
of the syringe was compacted with nylon stocking to avoid leaking. The column was washed 
with 50ml of PBS then 2ml of cleared plasma diluted 1:1 in PBS was applied to the column 
and eluted with PBS. Twenty-six fractions of 500μl were collected and stored at -80°C before 
subsequent characterisation (Chapter 1 Part III. Section iv.) and analysis in the HIV-1 infection 
assays (Chapter 1 Part IV. Sections iii.d) and iv.d)) . 
 
iv. Nanosight 
As explained above for liposome characterisation, the NanoSight NS300 was used to visualise 
the EV particles isolated from plasma in order to estimate the concentration and size 
distribution. Videos were recorded at camera level 13. The post-acquisition settings were 
with a minimum detection threshold 7, automatic blur and automatic minimum expected 
particle size. Fractions collected from SEC were diluted (between 1:5-1:100) in PBS and for 
each sample 3x 60sec videos were recorded and analysed. 
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v. Bradford 
The standard Bradford estimation method was used to quantify the amount of total protein 
present in the exosome preparations. The technique is based on an absorbance shift of the 
dye Coomassie Brilliant Blue G-250 in the presence of protein. Under acidic conditions the 
dye is predominantly red (Amax=470nm), but when the dye binds to protein it is converted to 
a blue colour (Amax=595nm). It is this blue protein-dye form that is detected at 595nm in the 
assay using a spectrophotometer. Quick Start™ Bradford Protein Assay Kit 1 (Bio-Rad, UK) 
was used with BSA (Bio-Rad) as a standard following the manufacturer’s instructions. The 
Quick Start™ Bradford 1x dye reagents were warmed to RT. Standards and samples from the 
SEC isolation were diluted in PBS. Because the protein concentrations of samples were 
unknown, two standards were produced in parallel comprising of different ranges in 
concentration: Standard A 2,000-125μg/ml BSA and Standard B 25-1.25μg/ml. For the 
Standard A assay, 5μl of standard or sample were mixed with 250μl of 1x dye reagent per 
well in a 96-well plate. For Standard B assay, 150μl of standard or sample were mixed with 
150μl of 1x dye reagent per well. Samples were quantified in duplicate. After 5-10min of 
incubation at RT the absorbance was read (595nm) using a spectrophotometer. 
 
vi. Western Blot 
To confirm isolation and characterise the EVs being isolated from plasma Western Blot 
analysis was used to detect the presence of specific EV proteins. This included testing for the 
TSG101 and CD63 markers with two different protocols using the Mini-PROTEAN®3 System 
(Bio-Rad, UK). 
a) Protocol 1 
Sample preparation 
Fractions 1-7 and fractions 8-13 (following SEC isolation Chapter 1 Part III. Section iii.) were 
separately pooled and concentrated using the Amicon Ultra-0.5 membrane Ultracel-10 
(Merk Millipore, UK) system. Samples were diluted in 1x RIPA Buffer (Sigma Aldrich, UK) and 
mixed 1:1 with 2x Laemilli buffer (Bio-Rad, UK) containing 5% β-mercaptoethanol (Bio-Rad, 
UK) and heated 10min at 100°C, after which 13μg of proteins (20μl) per well were loaded 




The following conditions were used for SDS-PAGE. 10% resolving gel composed of ProtoGel 
(GeneFlow, UK), ProtoGel Buffer (GeneFlow, UK), 10% ammonium persulfate (Sigma Aldrich, 
UK) and TEMED (Sigma Aldrich) and 4% stacking gel composed of stacking Buffer (0.5M Tris-
HCl, 0.4% SDS (Fisher Scientific, UK)), ProtoGel, 10% ammonium persulfate and TEMED were 
used. The gel was run with SDS-PAGE running Buffer composed of SDS-PAGE Tank Buffer 
(10x) and Tris-Glycine SDS (GeneFlow, UK) and at 100V for 1h30. 
Transfer 
Following SDS-PAGE electrophoresis proteins were transferred to a PVDF membrane cut to 
size (Merk Millipore, UK) and using the appropriate gel transfer apparatus. The transfer was 
performed with standard Buffer composed 1x Tris-glycine Buffer (GeneFlow, UK) and 20% 
methanol (Sigma Aldrich, UK) at 250mA for 90min. To determine that protein transfer 
occurred PVDF membranes were stained with Ponceau S solution (Sigma Aldrich, UK) with 
agitation for 5-10min. Once the transferred proteins were visible and identified the 
membranes were washed with 0.1% PBS-Tween solution and then blotted for 2h at RT under 
agitation with blotting Buffer composed of 0.1% PBS-Tween and 5% milk. 
Immuno-blotting 
Primary antibody recognising TSG111 (ab83, Abcam, UK) was diluted 1:1000 in blotting 
buffer. The antibody was incubated with the membrane O/N at 4°C and with shaking. The 
membrane was washed 3x with PBS-Tween for 15min. The secondary antibody, goat anti-
mouse (32430, ThermoFisher, UK) was diluted 1:100 and incubated with the membrane for 
90min at RT. As previously described, the membrane was washed 3x with PBS-Tween, then 
probed with Pierce™ ECL Western Blotting Substrate (ThermoFisher, UK) and exposed. 
b) Protocol 2 
Sample preparation 
The samples were prepared in reducing conditions as previously described and in non-
reducing conditions where the 2x Laemilli buffer lacked β-mercaptoethanol. 
SDS-PAGE 




The transfer was performed under the same conditions as in Protocol 1. 
Immuno-blotting 
Primary antibody recognising CD63 (ab193349, Abcam, UK) was used at 0.5μg/ml 
concentration and incubated overnight at 4°C. The same secondary antibody was used as in 
Protocol 1 using the same conditions. 
 
IV. Virological assays – Generation of pseudo-typed viral 
particles  
i. Viral production by transfection 
Single-round infectious virus particle stocks were routinely generated through transfection 
of 292T cells with a combination of plasmids (Figure 1.2).  
 
Figure 1.2 : Representation of pseudo-typed viral particle  production 
Adapted from (Ozaki et al., 2012) 
An expression plasmid containing the coding sequence for the HIV-1 envelope protein of 
either the following; JR-FL (utilising the CCR5 co-receptor, plasmid obtained from NIH AIDS 
Research and Reference Reagent Program), BAL (utilising the CCR5 co-receptor, plasmid 
obtained from NIH AIDS Research and Reference Reagent Program), LAI (utilising the CXCR4 
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co-receptor, plasmid obtained from NIH AIDS Research and Reference Reagent Program), or 
VSVg (a non-tropic envelope, plasmid obtained from NIH AIDS Research and Reference 
Reagent Program) was co-transfected along with pSG3Δenv, a plasmid coding for the 
proteins required for virus production (minus the intact envelope gene, Δenv from NIH AIDS). 
The transfected 293T cells thereby express the viral and envelope proteins required to 
generate a single-round infectious pseudo-typed virus particle, but since the incorporated 
viral genome of the produced viruses is Δenv the virus cannot generate new infectious virus 
particles following infection. 293T cells are human embryonic kidney cells, routinely 
maintained at 37°C 5% CO2 in DMEM supplemented with 10% FBS, L-glutamine, 100U/ml 
penicillin and 100mg/ml streptomycin.  One day prior to transfection 1.2x106 cells were 
seeded in a 10cm dish. After 24h, the cells were transfected using the Lipofectamine standard 
method where 2μg of HIV-1 envelope plasmid and 2μg of the backbone pSG3Δenv plasmid 
were mixed in 300μl of OptiMEM (Thermo Fisher scientific, UK). Separately, 24μl of 
Lipofectamine was mixed with 276μl of OptiMEM and 300μl of this was added to the DNA 
mix. After 30min incubation at RT, the Lipofectamine/DNA mixture was added dropwise to 
293T cells with 1ml of OptiMEM. After 6h, the media was replaced with fresh DMEM and the 
pseudo-typed virus stock (supernatant) was harvested after further 48h of incubation at 37°C 
5% CO2. Viruses were stored at -80°C and virus concentrations were quantified by measuring 
CA-p24 antigen levels as described below Section ii. 
 
ii. Virus quantification by p24 ELISA 
To measure HIV-1 viral stock concentrations, CA-p24 was quantified utilising a twin site 
sandwich HIV-1 p24 antigen ELISA (Aalto Bio Reagents, Ireland). The viral stock is lysed to 
release viral antigens and the p24 antigen is captured with a polyclonal antibody coated onto 
an ELISA plate. Bound p24 antigen is subsequently detected with an alkaline phosphatase 
conjugated anti-p24 monoclonal antibody and a luminescent detection system.  
To coat the ELISA plate, 100μl of 5μg/ml antibody (D7320, Aalto Bio Reagents, Ireland) was 
added per well and incubated overnight at RT. The following day the plates were washed 
once with 1x TBS buffer pH7.5 containing 4.21g NaCl (Sigma Aldrich, UK), 15.1g Tris-Trizma 
base (Sigma Aldrich, UK) and H2O. For blocking, 100μl of 2% milk-TBS is added per well and 
incubated for 1hr at RT. Coated plates could then be used or stored at -20°C for a maximum 
of 2 months. 
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To perform the ELISA, antigen coated plates were equilibrated at RT and washed once with 
1x TBS buffer. The standards and samples to be tested were diluted using 0.1% Empigen-TBS 
(Sigma Aldrich, UK). Additionally, samples were pre-treated with 1% Empigen-TBS, dilution 
1:1, prior to performing the dilutions to inactivate virus particles. 100μl per well of sample, 
standards, or controls were added in duplicate to the plate, and incubated for 3h at RT. 
Following incubation, plates were washed twice with 1x TBS buffer and tapped dry. Then, 
100μl of conjugate (BC 1071-AP, Aalto Bio Reagents, Ireland) diluted 1:5000 in 20% sheep 
serum (Sigma Aldrich, UK), 0.05% Tween and 1x TBS, was added per well. After 1hr incubation 
at RT, plates were washed 4x with 0.1% Tween-PBS, and 2x with ELISA Light assay buffer 
(Thermo Fisher scientific, UK). Finally, plates were tapped dry before adding 50μl of ELISA 
Light Substrate (CSPD with Sapphire Substrate, Thermo Fisher scientific, UK). After 30-45min 
incubation at RT, luminescence was measured with FLUOStar® Omega luminometer (BMG 
LabTech). 
 
iii. HIV-1 cis-infection 
a) Optimisation of HIV-1 pseudo-typed virus stocks on GHOST cell-lines 
GHOST cells (NIH AIDS) are derived from human osteosarcoma (HOS) cells and express GFP 
under control of Tat protein following HIV-1 infection. GHOST CXCR4+, CCR5+ and 
CXCR4+/CCR5+ cells were maintained at 37°C 5% CO2 in DMEM supplemented with 10% FBS, 
100U/ml penicillin, 100mg/ml streptomycin, 500μg/ml gentamycin G418 (Thermo Fisher 
scientific, UK), 100μg/ml hydromycin (Sigma Aldrich, UK) and 1μg/ml  pyromycin (Sigma 
Aldrich, UK). One day prior to infection, 3x104 cells per well were seeded in 96-well plates. 
After 24h the cells were infected with 2ng, 4ng or 8ng CA-p24 virus input within 50μl of total 
volume in supplemented DMEM as described above. Cells were infected with either pSG3-
JF-FL, pSG3-LAI, pSG3-VSVg or pSG3Δenv pseudo-typed virus. pSG3Δenv pseudo-typed virus 
was used as a negative control and pSG3-VSVg pseudo-typed virus was used as a positive 
control. After 2h of incubation at 37°C 5% CO2, 200μl of media was added. 48h post-infection 
at 37°C 5% CO2 the supernatants were removed and the cells washed with PBS before being 
detached with 1% trypsin (Thermo Fisher scientific, UK) and collected in microcentrifuge 
tubes. GHOST cells were washed a second time in PBS, pelleted by 1min centrifugation at 
7000rpm at RT and re-suspended in 100µl of 2% PFA solution. After 30-45min incubation at 
4°C, the cells were re-suspended in PBS. The infection of GHOST cells was quantified by 
measuring GFP production by flow cytometry. BD Accuri™ C6 was used to record 10,000 
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events for each sample and data analysis was performed using the BD Accuri™ C6 Plus 
software.  
b) TZM-bl cis-infection 
TZM-bl cells (NIH AIDS) are HeLa cells that have been transformed to express luciferase under 
control of the HIV-1 Tat protein, expressed following HIV-1 infection. The cells are lysed to 
liberate the luciferase and thereby provide luminescence in the presence of enzyme 
substrate, where luminescence intensity correlates with the level of infection. TZM-bl cells 
were maintained at 37°C 5% CO2 in DMEM complemented with 10% FBS, L-glutamine, 
100U/ml penicillin and 100mg/ml streptomycin. Cis-infections were performed as described 
for GHOST cells, with 8ng CA-p24 virus input. After 48h of infection the cells were washed 
with PBS, and 20μl of lysis Buffer (Promega) was added per well. Luciferase activity was 
determined using the Luciferase Assay kit (Promega) and FLUOStar Omega luminometer 
(BMG LabTech) following the manufacturer’s instructions. 
c) TZM-bl cis-infection in presence of liposomes 
To analyse the influence of liposome composition, varying in proportion of cholesterol, on 
HIV-1 cis-infection, two different assays were performed. In scenario one PC, 0.9PC:0.1Ch, 
0.8PC:0.2Ch or 0.6PC:0.4Ch liposome suspension in DMEM was added to the cells at the 
same time virus was added. 8ng CA-p24 of pSG3-JR-FL pseudo-typed virus stock was mixed 
with 100ng or 1ng of liposomes in 50μl total volume and added to the TZM-bl cells. After 2h 
incubation at 37°C 5% CO2, 200μl of media was added and the infection measured after 48h 
as described above. In the second scenario, liposome suspensions in DMEM were added to 
the cells prior to virus input. 50μl of 100ng or 1ng of liposome was added to the TZM-bl cells. 
After 30min incubation at 37°C and 5% CO2, 8ng CA-p24 of pSG3-JR-FL was added and 
incubated for 2h as described above. Following this incubation, 200μl of media was added to 
each well and incubated for 48h at which point cells were lysed and luciferase activity was 
measured.  
In parallel to the assays measuring the impact of liposome compositions on TZM-bl HIV-1 
infection, the impact of liposomes on cell viability was measured. In this case, PC and 
0.8PC:0.2Ch liposomes in suspension in DMEM were incubated on TZM-bl without virus. 
TZM-bl cells (3x104 per well) were seeded in 96-well plates and after 24h the cells were 
incubated with 1000ng, 100ng, 10ng and 1ng of liposome in 250μl total volume. After 48h 
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incubation at 37°C 5% CO2 the media was removed and the cells harvested via trypsin 
treatment and fixed in 2% PFA. After fixation, the cells were re-suspended in PBS and the 
viability was analysed by flow cytometry. BD Accuri™ C6 was used to record 10,000 events 
for each sample and data analysis was performed using the BD Accuri™ C6 Plus software.  
To analyse the influence of Mycobacterium liposomes on HIV-1 cis-infection the same assays 
were performed. 40μg of BCG, M. smegmatis, H37Rv, HN878, CDC1551, EU127 and 
0.8PC:0.2Ch liposome suspensions were tested with 8ng of pSG3-BAL and pSG3-LAI where in 
one case liposome was added at the same time as virus and in a second where liposomes 
were pre-incubated with the target cells prior to virus input. 
d) TZM-bl cis-infection in presence of EVs 
To study the influence of EVs isolated from plasma by SEC (Chapter 1 Part III. Section iii.) a 
similar approach was used as with the liposome assay. Fractions 9-13 from SEC were pooled 
together and tested using the TZM-bl HIV-1 cis-infection assay. As with liposomes, 50μl EVs 
were either pre-incubated for 30min with TZM-bl cells or added at the same time as virus. 
 
iv. HIV-1 trans-infection 
a) Optimisation of HIV-1 trans-infection 
For the optimisation of the HIV-1 trans-infection assay, the Raji and Raji-DC-SIGN cell-lines 
were utilised. Raji is an Epstein Barr Virus (EBV)-positive Burkitt’s lymphoma cell-line (ATCC), 
and Raji-DC-SIGN cells are Raji cells transduced to express the DC-SIGN receptor protein. HIV-
1 trans-infection is a mechanism whereby HIV-1 is captured by the DC-SIGN receptor and 
presented to target cells that it then infects via the classic CD4 and co-receptor cis-infection 
process. The routinely utilised trans-infection assay involves incubating HIV-1 with Raji 
(control) or Raji-DC-SIGN cells, washing and incubating with TZM-bl cells and measuring 
infection. Raji and Raji-DC-SIGN were cultured at 37°C 5% CO2 in RPMI-1640 containing L-
glutamine, supplemented with 10% FBS, 100U/ml penicillin and 100mg/ml streptomycin. 
One day prior to capture/transfer, 3x104 TZM-bl cells per well were seeded on 96-well plates 
and cultured overnight. For the capture assay, 0.5x106 Raji or Raji DC-SIGN cells were pelleted 
by 1min centrifugation at 7000rpm at RT, and mixed with 12.5ng CA-p24 pSG3Δenv, 25ng 
CA-p24 of pSG3-JR-FL and pSG3-BAL. After 2h incubation at 37°C 5% CO2, the cells were 
washed 4x with ice cold PBS. The first supernatant is collected and 15μl of the supernatant is 
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added as an input control on TZM-bl cells. Raji and Raji-DC-SIGN cells were re-suspended in 
45μl of DMEM containing 30ng/ml of Dextran and where 15μl of the suspension was used to 
infect TZM-bl cells. After 48h at 37°C 5% CO2, the TZM-bl cells were lysed and luciferase 
activity measured. 
b) HIV-1 trans-infection on TZM-bl in presence of liposomes 
To measure the influence of Mycobacterium liposomes on HIV-1 trans-infection, liposomes 
in RPMI-1640 suspension were added to Raji-DC-SIGN, iDCs or mDCs cells prior to capture of 
virus. Before capture, Raji-DC-SIGN, iDCs or mDCs cells were pre-incubated for 30min at 37°C 
5% CO2 with 100μg of liposome. Subsequently, 12.5ng CA-p24 pSG3Δenv, 12.5ng CA-p24 
pSG3-LAI and 25ng CA-p24 of pSG3-BAL were added to cells for 2hr and as described above 
the cells were washed in PBS and re-suspended RPMI-1640 media and added to TZM-bl cells. 
After 48h, the infectivity of the TZM-bl cells was measured via luciferase activity. 
c) HIV-1 trans-infection in the presence of Mannan 
Mannan, an antagonist of the DC-SIGN receptor and an array of other C-type lectins, was 
used to determine receptor involvement in HIV-1 trans-infection. 20μg/ml or 2mg/ml of 
mannan (Sigma Aldrich, UK) was pre-incubated with Raji-DC-SIGN, iDCS or mDCs cells for 
30min at 37°C 5% CO2 prior to HIV-1 capture and transfer. The same methods were then 
performed as described previously with pSG3-LAI virus. 
d) HIV-1 trans-infection in presence of EVs 
HIV-1 trans-infection mediated by Raji-DC-SIGN cells was tested in the presence of EVs 
isolated from plasma using a range of different techniques as described Part III.. 50μl of 
preparation (supernatant, pellet or EVs) undiluted or diluted in PBS were incubated with 
0.5x106 Raji-DC-SIGN cells for 30min prior the virus capture. Subsequently, the procedure 
was similar to that described in the liposome assay Chapter 1 Part IV. Section iv.c). 
 
V. Virological assays - Replicative System 
i. Viral production by transfection and viral growth 
As described for HIV-1 pseudo-typed viral production Chapter 1  Part IV. Section i., 293T cells 
were transfected with plasmids coding for full-length HIV-1. Two HIV-1 replication competent 
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viruses were produced: BAL-GFP virus recognising CCR5 and expressing GFP (Dorosko and 
Connor, 2010) and the LAI-YFP virus recognising CXCR4 and expressing YFP, donated by A. de 
Ronde (University of Amsterdam). The same transfection protocol was used as previously 
described for pseudo-typed virus production Chapter 1 Part IV. Section i.. Virus produced 
following 293T transfection were passaged and expanded on PM-1 cells, a T-lymphoid cell-
line permissive for growth of macrophage and T cell tropic virus strains (NIH AIDS). PM-1 cells 
were maintained at 37°C 5% CO2 in RPMI-1640 containing L-glutamine and supplemented 
with 10% FBS, 100U/ml penicillin and 100mg/ml streptomycin. At day 0, PM-1 cells (2.5x106) 
were inoculated with 1ml of virus supernatant from transfection of 293T cells in a 15ml tube 
and incubated at 37°C 5% CO2. After 18-24h (day 1), the supernatant was removed and fresh 
PM-1 cells (5x106) were added in a total of 5ml media and incubated in a T25 flask with fresh 
media added (day 4). Fresh PM-1 cells and media were added (day 5 and day 8) to allow for 
virus propagation and maintaining a cell density approximating 1x106 cells per ml. Viruses 
were harvested (day 11 and day 14), aliquoted and stored at -80°C. Each viral stock 
concentration was quantified by measuring CA-p24 antigen levels and by determining 
TCID50/ml values described Part V. Section ii.. Furthermore, aliquots of supernatant (days 4, 
8, 11 and 14) were stored at -80°C to monitor virus growth by quantifying HIV-1 CA-p24 
production. 
 
ii. Virus quantification by ELISA p24 and TCID50/ml 
To measure HIV-1 stock concentrations, CA-p24 was quantified using the antigen ELISA 
protocol 2 from Aalto Bio Reagents. In parallel, an estimation of TCID50/ml of virus stock 
corresponding to 50% tissue culture infectious dose (TCID) was performed. TCID50/ml values 
were determined utilising isolated CD4+ T-lymphocytes enriched as described previously Part 
II. Section iv.. The assay was performed in 96-well culture plates with a starting dilution of 
virus stock at 1:5 in RPMI-1640 media. A succession of 1:5 dilutions (7 fold) was performed 
with 4 replicates per dilution tested. The volume of virus dilution per well was 100μl with a 
cell density of 2x105 CD4+ T-lymphocytes per well. The media composition used for the assay 
was RPMI-1640 containing L-glutamine complemented with 10% FBS, 100U/ml penicillin, 
100mg/ml streptomycin and 100U/ml IL-2. The 96-well plate was prepared as follow: 
- Columns 1 and 12: 200μl PBS added per well 
- Columns 2 through 8: 100μl of cell suspension per well 
- Columns 9 through 11: 100μl of media. 
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The plate was incubated at 37°C 5% CO2 for 7 days. On day 7, samples were collected for p24 
estimation by ELISA: 120μl of each well were harvested and transferred to a new 96-well 
plate. Virus supernatant was then inactivated by adding 10μl of 2% Empigen-TBS (final 
concentration 0.1%) and incubated at 56°C for 30min. A CA-p24 ELISA was then performed 
as described Part IV. Section ii., to determinate the number of positive wells positive for CA-
p24 (value above 3x standard deviation of control wells). The number of positive wells was 
multiplied by 2 and using the Muench formula the TCID50/ml value was determined.  
 
iii. HIV-1 cis-infection 
a) Optimisation of HIV-1 cis-infection on CD4+T-lymphocytes 
At day 0 in a 96-well tissue culture plate CD4+ enriched T-lymphocytes (2x105/well) were 
mixed with 40, 200, 1000 or 3000 TCID50/ml LAI-YFP or 500, 1000, 3000 TCID50/ml BAL-GFP 
in 200μl total volume per well. Three plates with the same conditions were prepared (1 plate 
for 1 time point) with 3 replicates per condition per plate and incubated at 37°C 5% CO2. At 
day 4, 7 and 10 post-infection, 100μl of supernatant was collected for CA-p24 production 
determination and 100μl of fresh media RPMI-1640 containing L-glutamine complemented 
with 10% FBS, 100U/ml penicillin, 100mg/ml streptomycin and 100U/ml IL-2 was added. 
From condition triplicates, supernatants were pooled and HIV-1 CA-p24 production was 
determined for each time point by ELISA (Chapter 1 Part IV Section ii.). In parallel (day 7, 10 
and 14) CD4+ T lymphocytes were harvested to measure the percentage of infected cells by 
FACS analysis. The cells from each condition in triplicate were pooled together, washed in 
PBS and fixed in 2% PFA before being analysed. After being re-suspended in PBS the cells 
were acquired by flow cytometry using BD FACS Celesta™ with 10,000 events recorded for 
each sample and data analysis performed using standard FlowJo software. For LAI-YFP virus, 
YFP expression was measured to evaluate the percentage of cells infected and GFP 
expression for BAL-GFP virus. 
b) HIV-1 cis-infection in presence of Mycobacterium liposomes 
To measure the influence of Mycobacterium liposomes on HIV-1 cis-infection, liposomes in 
suspension in RPMI-1640 were added at day 0 of infection. At day 0, in 96-well culture plates 
CD4+ enriched T-lymphocytes (2x105/well) were mixed with 40μg of liposomes and 200 
TCID50/ml LAI-YFP or 500 TCID50/ml BAL-GFP in 200μl total volume per well. BCG, M. 
smegmatis, H37Rv, HN878, CDC1551, EU127 and 0.8PC:0.2Ch liposomes were tested with 
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LPS used as positive control with 100ng/ml concentration per well. All these conditions were 
performed in quadruplicate. At day 4, 100μl per well of supernatant was collected for CA-
p24 determination and replaced with 100μl of fresh media. At day 7, 50μl per well of 
supernatant was collected for CA-p24 quantification, then the supernatants left from 
quadruplicate wells were pooled. CD4+ T-lymphocytes were pelleted by 7min centrifugation 
at 1,400rpm at RT. Supernatant was collected and stored at -80°C before performing 
Lumniex® assays Part II. Section vii.. Cell pellets were frozen at -80°C for subsequent 
DNA/RNA extraction as described Part V. Section v.. 
 
iv. HIV-1 trans-infection 
a) Optimisation of HIV-1 trans-infection in CD4+ T lymphocytes via iDCs 
CD4+ T-lymphocytes and iDCs were both isolated from the same blood donor with the 
methods described Part II.. At day 0 of infection iDCs (6x104/well) were incubated 30min at 
37°C 5% CO2 with 40, 200, 1000, 3000 TCID50/ml LAI-YFP or 500, 1000, 3000 TCID50/ml BAL-
GFP virus. The cells were then washed 4x with PBS and re-suspended in 300μl of media. 100μl 
of suspension was inoculated with CD4+ T-lymphocytes (2x105/well) seeded in 100μl per well 
in a 96-well plate. The media used is the same as used for lymphocyte growth. Two plates 
with the same conditions were prepared in triplicate for each condition and incubated at 
37°C 5% CO2. At days 4, 7 and 10 post-infection, supernatants were collected in the same 
way as described for cis-infection optimisation for p24 quantification. At day 7 and 14 cells 
were harvested for FACS analysis (Part V. Section iii.a)). 
b) HIV-1 trans-infection in presence of Mycobacterium liposomes 
To measure the influence of Mycobacterium liposomes on HIV-1 trans-infection, liposomes 
in suspension in RPMI-1640 were added during capture and transfer of HIV-1. During virus 
capture iDCs (8x104) were incubated with 100μg of liposomes for 30min at 37°C 5% CO2. The 
cells were washed and then re-suspended in 400μl of media. 100μl of the suspension was 
then inoculated on CD4+ T-lymphocytes (2x105/well) seeded in 100μl per well in a 96-well 
plate. Finally, 40μg of liposomes were added per well. As for the study of the influence of 
liposomes on cis-infection, supernatants were collected at day 4 and 7 post-infection in a 
same way and the cells collected at day 7 for the same analysis. 
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v. HIV-1 DNA quantification 
a) DNA/RNA extraction 
For DNA and RNA extraction from HIV-1 infection assays, AllPrep DNA/RNA Mini Kit (Qiagen, 
UK) was used following the manufacturer’s instructions. Frozen cell pellets were quickly 
thawed, mixed with 350μl of lysis Buffer RLT Plus and then incubated at 56°C for 30min to 
inactivate virus. The cell lysate homogenates were transferred to an AllPrep DNA spin 
column. After 30sec of centrifugation at 8000g the column (containing DNA) was kept at 4°C 
during RNA purification. RNA from the eluate was precipitated with 70% ethanol and 
transferred to an RNeasy spin column. The ethanol was removed by 30sec centrifugation, 
and the RNA washed successively with Buffers RW1 and RPE. Finally, RNA was eluted from 
the column with 50μl of RNase-free water. For DNA isolation the column was washed with 
Buffer AW1 and AW2 before DNA elution with 70μl of Buffer EB. RNA and DNA samples were 
stored at -80°C. 
b) HIV-1 DNA quantification 
To proceed to HIV-1 DNA quantification, we used similar techniques previously described by 
van der Sluis et al. and Vandergeeten et al.  (van der Sluis et al., 2013; Vandergeeten et al., 
2014). Total HIV-1 DNA was quantified using primers targeting the LTR region of the virus 
genome and designed to amplify only fully reverse transcribed DNA. Similar primers were 
used to quantify 2-LTR circular DNA. Integrated HIV-1 DNA was quantified using primers for 
the LTR and two primers targeting human Alu sequences that are randomly dispersed across 
the human genome. All the primers and probes used for those assays are shown Table 1.7. 
Cell input was quantified using primers targeting the CD3 gene and with a help of a standard 
based on 293T cells of known concentrations. To distinguish HIV-1 DNA markers, pre-
amplifications were performed in 25µl reactions using reaction mixes and primers outlined 
Table 1.5 and 1.7. Pre-amplification products were then diluted in molecular grade water 
1:10 (5µl product with 45µl water) and used as input for qPCR. Quantifications were 
performed in 20µl reactions using Supermix-UDG (Invitrogen, UK) with the Qiagen Rotor 




Table 1.5: Reaction mix for pre-amplification 
 







Volume (µl) Final Concentration Volume (µl) Final Concentration 
Forward Primer 
10000nM 
0.3 120nM 0.75 300nM 
Reverse Primer  
10000nM 
0.3 120nM 0.75 300nM 
H2O 16.9 - 16 - 
10x PCR Buffer 2.5 1x 2.5 1x 
MgCl2  
50mM 
1.5 3mM 1.5 3mM 
Taq  
5U/µl 
0.25 0.05U/reaction 0.25 0.05U/reaction 
dNTP 
10nM 
0.75 0.3nM 0.75 0.3nM 
Total Master Mix: 22.5  22.5  




Volume (µl) Final Concentration Volume (µl) Final Concentration 
Forward Primer 
10000nM 
0.2 100nM 0.25 1250nM 
Reverse Primer  
10000nM 
0.3 100nM 0.25 1250nM 
Probe 
10000nM 
0.4 200nM 0.4 200nM 
2x Supermix UDG  10 1x 10 1x 
H2O 2.8 - 2.7 - 
Total Master Mix: 13.6  13.6  
Total Sample: 6.4  6.4  
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Table 1.7 : Primers and probes used for quantification assays 
 Assay Stage Name Function  Sequence 
Total HIV-1 Pre-
amplification 
5’PFP  Forward: Total HIV-1 TAACCCTCAGATGCTGCATAWAAGCAGCYGCT 
3’PRP  Reverse: Total AGCAAGCCGAGTCCTGCGTC 
qPCR 5’PF  Forward: Total HIV-1 GCCTCAATAAAGCTTGCCTTGA 
3’PR  Reverse: Total HIV-1 GGGCGCCACTGCTAGAGAT 
PPr  TaqMan Probe: Total HIV-1 5’-/56-FAM/CTGGTADCT/zen/AGAGATCCCTCAGA/3IABκFQ-3’ 
2-LTR  Pre-
amplification 
ULTRF1 Forward: 2-LTR ATGCCACGTAAGCGAAACTCCTCAATAAAGCTTGCCTTGA 
ULTRR1 Reverse: 2-LTR CTAACMAGAGAGACCCAGTAC 
qPCR ULTRR2 Reverse: 2-LTR GGTACTAGCTTGAAGCACCA 
Lambda T Forward: 2-LTR & Total ATGCCACGTAAGCGAAACT 
ULTR2 TaqMan TaqMan Probe: 2-LTR ACTCTGGTA/zen/ACTAGAGATCCCTCAGACC 
Integrate Pre-
amplification 
Alu1  TCCCAGCTACTGGGGAGGCTGAGG 
Alu2  GCCTCCCAAAGTGCTGGGATTACAG 
ULF1: 5’ Forward: Total ATGCCACGTAAGCGAAACTCTGGGTCTCTCTDGTTAGAC 
qPCR Lambda T Forward: 2-LTR & Total ATGCCACGTAAGCGAAACT 
UR2 Reverse: Total CTGAGGGATCTCTAGTTACC 
UHIV TaqMan TaqMan Probe: Total CACTCAAGG/zen/CAAGCTTTATTGAGGC 
CD3 Pre-
amplification 
HCD3 out 5’ Forward: CD3 ACTGACATGGAACAGGGGAAG 
HCD3 out 3’ Reverse: CD3 CCAGCTCTGAAGTAGGGAACATAT 
qPCR HCD3 in 5’ Forward: CD3 GGCTATCATTCTTCTTCAAGGT 
HCD3 in 3’ Reverse: CD3 CCTCTCTTCAGCCATTTAAGTA 
CD3 TaqMan TaqMan Probe: CD3 5’-/56-JOEN/ AGCAGAGAA/zen/CAGTTAAGAGCCTCCAT/3IABκFQ-3’ 
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VI. Statistical Analysis 
For all results, the statistical analyses were performed using GraphPad Prism 6.0 software. 
Unpaired sample comparisons were performed using the non-parametric rank test Mann 
Whitney and depict in Figures using the following: * for P value< 0.05, ** for P value< 0.01, 




Chapter 2: Impact of Mycobacterium 
liposomes on modulating immune responses 
 
I. Introduction 
In this Chapter, the research focus was on determining the influence of bacterial total lipid 
extracts from M. bovis BCG, M. smegmatis, Mtb H37Rv, HN878, CDC1551 and EU127 on 
modulating immune responses. An assay was developed where total lipid extracts from 
specific bacterial strains could be incorporated into liposomes, thereby mimicking lipid 
antigen as presented on the bacterial cell wall.  
The mycobacterial cell envelope is complex and composed of different lipids such as AG and 
MA linked to PG and free lipids TDM, PDIM, SL, PIM, LM and LAM described in the 
Introduction. Lipids from the mycobacterial cell wall play important roles in structural and 
biological functions. Importantly, because of their localisation and properties, those lipids 
can modulate the host immune response and specifically interact with various cell receptors 
influencing Mycobacterium pathogenicity.  
MA constitutes a natural barrier of the bacteria maintaining the shape and the integrity of 
the cell. The nature of its composition and oxygenation can modulate the cell wall viscosity 
and properties influencing Mtb pathogenicity (Barry et al., 1998; Dubnau et al., 2000). 
Oxygenated Mtb MA can modulate macrophage activation and differentiation (Vander Beken 
et al., 2011; Dkhar et al., 2014). Additionally, MA associated with PG and AG can be 
responsible for inflammatory activation of macrophage and DCs via TLR pathway signalling 
(Means et al., 1999). Interestingly, trans-cyclopropanation of MA on TDM can suppress 
inflammation and Mtb virulence (Rao et al., 2006). Additionally, MA can be recognised by 
specific T cells playing a protective role against Mtb infection (Zhao et al., 2015). 
The mycobacterial outer membrane contains various acyltrehaloses including TDM (also 
known as cord factor) and SL. TDM is a major contributor to inflammation (Ryll et al., 2001; 
Geisel et al., 2005; Linares et al., 2012; Welsh, Hunter and Actor, 2013) and it has been 
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described to modulate macrophage activation (Ryll et al., 2001; Indrigo, Hunter and Actor, 
2002; Ishikawa et al., 2009) and granuloma formation (Hamasaki et al., 2000; Sakamoto et 
al., 2013). Kan-Sutton et al., showed that TDM presence reduces expression of MCH-II, CD1d, 
CD40, CD80 and CD86 at the surface of macrophages. Additionally, they described that TDM 
can supress antigen presentation and T cell stimulation (Kan-Sutton, Jagannath and Hunter, 
2009). However, TDM properties are dependent on its composition/structure (Rao et al., 
2005, 2006) as well as the intracellular environment (Fischer et al., 2001). SLs are sulphated 
trehalose esters with SL1 representing the most abundant form produced by pathogenic 
mycobacteria. The direct role of SL1 in Mycobacterium pathogenicity remains unclear 
(Rousseau et al., 2003; Kumar et al., 2007). However, mmpL8 knock-out mutants of Mtb have 
been shown to attenuate bacterial virulence in mouse models (Converse et al., 2003; 
Domenech et al., 2004). Additionally, Mtb sft0 mutants showed a better survival than wild-
type Mtb strains in human macrophages but not in mice, suggesting that SL-1 negatively 
regulates the intracellular growth of Mtb (Gilmore et al., 2012). 
PDIMs are found in various Mycobacterium species and composed of mycocerosic fatty acids 
(Daffé and Laneelle, 1988; Daffé et al., 1988). PDIMs have been described to play a role in 
Mtb virulence (Goren, Brokl and Schaefer, 1974; Cox et al., 1999). Rousseau et al. have shown 
that a down regulation of PDIM induces production of high levels of TNF-α and IL-6 by 
macrophages and DCs in mice (Rousseau et al., 2004). Moreover, PDIMs are important for 
the maintenance of cell envelope permeability and architecture involved in Mtb virulence 
(Camacho et al., 2001). The presence of PDIMs at the bacterial surface can aide escape from 
macrophage recognition (Astarie-Dequeker et al., 2009; Quigley et al., 2017), mask PAMPs 
(Rousseau et al., 2004), and prevent macrophage recruitment (Cambier et al., 2014).  
PIMs are glycoconjugates and represent the major components of the mycobacterial cell 
envelope. They are precursors of LM, LAM and mannan capped lipoarabinomannan 
(ManLAM). Different forms of PIMs are described depending on the degree of the 
mannosylation and acylation (Boonyarattanakalin et al., 2008). PIMs play a crucial role in 
bacterial growth and survival (Haites et al., 2005; Fukuda et al., 2013; Yang et al., 2013). 
Interactions between mycobacteria PIM derivatives and the host result in delay of 
phagosome maturation (Fratti et al., 2001; Vergne, Chua and Deretic, 2003; Welin et al., 
2008) and modulation of the immune response. Mannoside caps associated to PIMs can be 
recognised by phagocytic receptors such as C-type lectins, including MR and DC-SIGN (Koppel 
et al., 2004; Pitarque et al., 2005; Driessen et al., 2009). Additionally, LM has been described 
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as a TLR2 and TLR4 ligands, modulating anti- and pro-inflammatory responses against the 
bacteria (Vignal et al., 2003; Quesniaux et al., 2004; Gilleron et al., 2006; Doz et al., 2007; 
Puissegur et al., 2007).  
The proportions of lipids present within the mycobacterial cell wall can vary between the 
Mycobacterium strains and with changed properties (Guenin-Macé, Siméone and Demangel, 
2009; Daffé, Crick and Jackson, 2014). However, variation in lipid compositions inside Mtb 
species can occur and impact on their pathogenicity. It has been shown that different clinical 
Mtb strains have been associated with important variations in immune response activation 
(Lin, Zhang and Barnes, 1998; Theus, Cave and Eisenach, 2005; Theus et al., 2007; Mvubu et 
al., 2018). In order to measure and compare the impact of total lipid extracts from different 
Mycobacterium and Mtb strains, we developed liposomes which contained Mycobacterium 
total lipid extracts. These liposomes are artificial vesicles composed of a mix of PC and 
cholesterol and used as the experimental foundation in our assays. In many cases, liposomes 
have been used as a carrier for various applications in pharmacology, including for diagnostic 
purposes, therapeutic treatments of cancer and use in vaccine technologies (Akbarzadeh et 
al., 2013). In the context of TB, the interest of using liposomes for vaccination strategies is 
important and well described in the literature (Sprott et al., 2004; Rosenkrands et al., 2005; 
Cardona, 2006; Homhuan et al., 2007; Kawasaki et al., 2014; Khademi et al., 2018). In our 
system, liposomes have been used as a carrier for total lipids from Mycobacterium without 
addition of any adjuvants allowing for the study the immunogenic properties of lipids extracts 
alone.  
The first section of Chapter 2 focusses on characterising the generated liposomes by 
analysing their compositions and physical properties by TLC and NanoSight technology, 
respectively (Part II. Section i.). The second part of the Chapter is dedicated to studying the 
impact Mycobacterium liposomes have on modulating immune responses by studying the 
influence of BCG, M. smegmatis, Mtb H37Rv, HN878, CDC1551 and EU127 liposomes on 
stimulating macrophages, DCs and CD4+ T cells in vitro (Part II. Section ii.) To characterise the 
activation and the immune responses induced by cells, Luminex® assays have been 
performed allowing for the simultaneous quantification of the cytokines listed below: 
- GM-CSF, M-CSF and G-CSF growth factors implicated in the innate immune response; 
- IL-1α, IL-1β, IL-6, IL-8, MIP-1α and MIP-2α implicated in the innate immune response 
and cell recruitment; 
- IL-15 implicated in T cells proliferation and survival; 
 59 
- IFN-α, IFN-β, IFN-γ, I-TAC, IP-10, MIG and RANTES involved in the adaptive immune 
response and T cell recruitment; 
- IL-12 23p40, IL-12p70, IL-18, IL-23 and TGF-β involved in the adaptive immune 
response and T cell activation;  
- IL-10, IL-27 and TGF-β involved in inducing anti-inflammatory responses. 
 
Furthermore, the study of the impact of liposomes on DCs has been complemented with flow 
cytometry analyses to measure expression of cellular markers.  
 
II. Results 
i. Liposome generation and characterisation 
Unilamellar liposomes were generated as described in Chapter 1 Part I. Section ii.. Briefly, 
total lipid extracts from Mycobacterium strains (listed in Chapter 1 Part I. Section i.c)) were 
mixed together with PC and cholesterol following the ratio 0.6PC:0.2Ch:0.2Mycobacterium. 
After evaporating solvents and obtaining a dry lipid film of the mix, liposomes were obtained 
by hydration and a sonication step. We characterised 0.8PC:0.2Ch, BCG and Mtb H37Rv 
liposomes generated by NanoSight technology (Figure 2.1 and Figure 2.2) and TLC (Figure 
2.3).  
We visualised liposome particles using NanoSight NS300 optics and software (Figure 2.1 and 
Figure 2.2). 0.8PC:0.2Ch, BCG and Mtb H37Rv liposomes were compared. Two batches of 
BCG liposomes were tested in order to validate the technique of liposome generation and its 
reproducibility. Additionally, three different preparations of 0.8PC:0.2Ch liposomes were 
generated and tested: 0.8PC:0.2Ch liposomes calibrate at 100nm with the Extruder system, 
0.8PC:0.2Ch liposomes calibrate at 200nm with the Extruder system and 0.8PC:0.2Ch 
obtained from a single sonication step. The calibrate 0.8PC:0.2Ch liposome preparations 
were used here as particle size controls.  
We observed that the mean size obtained for 0.8PC:0.2Ch 100nm liposomes (Figure 2.1 A.) 
was 140.8nm with a unique peak around 140nm from the distribution curve. For 0.8PC:0.2Ch 
liposomes calibrate at 200nm B., we observed a mean size higher at 182.9nm but with a 
presence of three peaks between 100 and 200nm from the distribution curve (Figure 2.1). 
The heterogenous populations of liposomes observed for 0.8PC:0.2Ch calibrating at 200nm 
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could be explained by the process of sonication that allows for the production of 100nm and 
200nm unilamellar liposomes. The additional extrusion step at 200nm after sonication 
doesn’t impact on the population distribution. From these controls, we validated the 
NanoSight analyses to characterise the size of Mycobacterium liposomes and allow for 
visualisation. 0.8PC:0.2Ch liposomes generated with a single step of sonication C. showed a 
mean size of 171.4nm with heterogenous populations. For the two batches of BCG D. and E., 
we obtained larger sizes at 221.3 and 229nm respectively. The two different preparations of 
BCG liposomes showed close size values and distributions, validating the reproducibility of 
the liposome generation technique. Similarly, H37Rv liposomes F. we observed a mean size 
of 201.7nm higher than the 0.8PC:0.2Ch preparation. However, the incorporation of 
Mycobacterium lipids into liposome BCG and H37Rv could explain why these particles 
appeared bigger than 0.8PC:0.2Ch liposomes.  
When comparing particle concentrations, we observed similar order values between 
liposome preparations included between 0.6-2x1012 particles per ml. Images of particle 






Figure 2.1 : NanoSight analyses of 0.8PC:Ch0.2, BCG and H37Rv liposomes 
2. 0.8PC:0.2Ch liposomes generated with Extruder system at 100nm size, B. 0.8PC:0.2Ch liposomes generated with Extruder system at 200nm size and C. 0.8PC:0.2Ch, D. BCG batch n°1, 
E. BCG batch n°2 and F. H37Rv liposomes made with by sonication without Extruder step, were analysed on NanoSight NS300. Liposome suspensions were diluted 1:1000-1:2000 in 
PBS, and three 60sec videos were recording at camera level 13. Post-acquisition were setting with a minimum threshold 7, automatic blur and automatic minimum expected particle 
size. The data shown are form one experiment 
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Figure 2.2 : Imaging of 0.8PC:Ch0.2, BCG and H37Rv liposomes from NanoSight analyses 
Imaging from NanoSight analyses of A. 0.8PC:0.2Ch liposomes generated with Extruder system at 100nm size, B. 0.8PC:0.2Ch liposomes generated with Extruder system at 200nm size and C. 
0.8PC:0.2Ch, D. BCG batch n°1, E. BCG batch n°2 and F. H37Rv liposomes made with by sonication without Extruder step. The data shown are from one experiment.
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After visualisation of Mycobacterium liposome particles, 0.8PC:0.2Ch, BCG (two batches) and 
H37Rv liposomes in solution were separated on a silica membrane with 60:16:2 
CHCl3:MeOH:H2O solvent in parallel of TDM, PDIM, SL and PIMs lipids solutions (Figure 2.3).  
 
Figure 2.3 : TLC analyses of 0.8PC:Ch0.2, BCG and H37Rv liposomes 
10µl of 0.8PC:0.2Ch, BCG batch n°1 (BCG 1), BCG batch n°2 (BCG 2) and H37Rv liposomes solution made in water 
were spotted and dried on a silica gel 60 F254 plate, in parallel of TDM, PDIM, SL and PIMs solutions. Samples 
separation occurred in 60:16:2 CHCl3:MeOH:H2O solvent and visualised by staining with molybdophosphoric acid 
(MPA) and charring. The data shown are from one experiment performed by Dr A. Bhatt, University of 
Birmingham. 
We observed that the three types of liposomes tested showed specific TLC profiles. 
0.8PC:0.2Ch, BCG and H37Rv liposomes shared in common 5 lines that could correspond to 
the migration of PC and cholesterol present in all the liposome preparations. Also, the two 
BCG batches showed exactly the same lipid separation profiles. BCG batches presented 
differences from H37Rv liposome lipid separations. Comparing lipid separation of BCG and 
H37Rv liposomes with TDM, SL, PDIM and PIMs lipid solution migration, we observed the 
presence of SL, PDIM and PIMs lipids in these liposomes. However, between BCG and H37Rv 
we observed variation in the intensity of lipid bands suggesting that SL, PDIM and PIMs are 
present in higher proportion in H37Rv than BCG liposomes. Unfortunately, we were not able 
to visual TDM in this assay.  
From the TLC analyses we were able to conclude that the integration of specific 
Mycobacterium lipids into the liposomes compared to 0.8PC:0.2Ch control and the 
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homogeneity between preparations strongly validated the technique of liposome generation 
used in these studies. 
From TLC and NanoSight analyses we validated the Mtb liposome generation technique to 
be utilised in the in vitro assays. 
 
ii. Influence of Mycobacterium liposomes on activating immune cells and 
cytokine production 
a) Activation of macrophages in presence of Mycobacterium Liposomes 
In order to measure the impact of glycolipids from Mycobacterium strains on the immune 
response, we investigated the influence of BCG, M. smegmatis, Mtb H37Rv, HN878, CDC1551 
and EU127 liposomes on stimulating MDM immune responses. Mycobacterium liposomes 
were incubated for 18h with macrophages isolated from healthy donors and the 
supernatants collected to be analysed by Luminex® technology (Figure 2.4). LPS was used as 
a positive control and 0.8PC:0.2Ch liposomes as a negative control. 
We observed that BCG, M. smegmatis and Mtb H37Rv liposomes, activated the production 
of the pro-inflammatory cytokines IL-6, IL-8, IL-23, IL-10, IP-10 and TNF-α compared to MDM 
which did not receive any stimuli. Additionally, EU127 liposomes trended to activate IL-23 
and TNF-α production in supernatant, but at a lower degree compared to BCG, M. smegmatis 
and H37Rv. Interestingly, all the Mtb liposomes demonstrated a trend towards up-regulating 
production of IL-15, RANTES and IL-12p40. Conversely, HN878 liposomes showed a trend 
towards down-regulating production of M-CSF and TGF-β3 as well as CDC1551 and EU127 
and production of the anti-inflammatory cytokine IL-10. The positive control LPS showed the 
capacity to strongly activate production of a large number of the pro-inflammatory cytokines 
and chemokines, such as IL-6, IL-8, IL-23, MIP-1α, IL-10, IP-10, I-TAC, TNF-α, IL-15, RANTES 
and IL-12 23p40 and to down-regulate TGF-β1 and 2. MDM responses to LPS validated the 
assays as did the results with the negative control 0.8PC:0.2Ch liposomes which did not have 
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Figure 2.4 : Influence of Mycobacterium liposomes on MDM cytokine production 
Human blood monocytes were isolated from buffy coats by Ficoll gradient centrifugation and a subsequent CD14 
selection step using the MACS cell separation system. From CD14+ isolation, MDMs were generated from 7 days 
of culture. On day 7, 106 cells/ml were harvested in 96-well plate and incubated with 5mg/ml LPS or 40µg/ml of 
0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, CDC1551 and EU127 liposomes for 18h. The supernatant was 
harvested for Luminex® analyses. Luminex results are represented by Heat Map Clusters of the Log2 of liposomes 
treatment/MDM baseline ratio. An increase of cytokine production in the supernatant is represented in red, a 
diminution of cytokine production depict in green and no change shown as black. For the data shown, n=3 
replicates using cells isolated from one donor. 
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These observations suggest that Mycobacterium liposomes could differentially modulate 
macrophage immune responses. CDC1551, EU127 and HN878 lipids appeared not to be able 
to activate MDM response as much as BCG, M. smegmatis and Mtb H37Rv that induced a 
heightened response from macrophages. 
b) Activation of iDCs in presence of Mycobacterium liposomes 
To further investigate on the influence of Mycobacterium liposomes on inducing immune 
responses, we studied the impact of BCG, M. smegmatis, Mtb H37Rv, HN878, CDC1551 and 
EU127 liposomes on iDCs activation. For this purpose, Mycobacterium liposomes were 
incubated for 18h with iDCs. The expression of specific markers of DC activation CD86, CD80, 
CD40, DC-SIGN and HLA-II, were measured on the cell surface by flow cytometry (Figure 2.5 
and Appendixes 6, 7, 8). Additionally, Luminex® measurements were determined utilising the 
corresponding supernatants (Figure 2.6). LPS and Poly(I:C) were used as positive controls for 
iDCs activation and 0.8PC:0.2Ch as a negative control. 
When comparing the impact of Mtb liposomes on modulating the percentage of DCs 
expressing the CD86 marker (Figure 2.5 A), we observed that the presence of M. smegmatis, 
H37Rv and HN878 increased CD86 expression to 71.3, 61.7 and 92.1%, respectively 
compared to 51.7% in iDCs that did not receive any stimuli. Concerning the CD80 marker, we 
observed that M. smegmatis, H37Rv and HN878 liposomes induced iDC expression of CD80 
to 80.0, 76.5 and 97.4%, respectively compared to 72.7% in unstimulated cells. We did not 
observe any influence of 0.8PC:0.2Ch liposomes on CD86 and CD80 cell surface expression, 
suggesting that the impact of M. smegmatis, H37Rv and HN878 liposomes observed on DCs 
were due to Mycobacterium lipids integrated into liposomes. Also, we observed that the 
presence of BCG and CDC1551 liposomes did not impact on CD86 and CD80 expression. For 
CD40, DC-SIGN and HLA-II markers, we did not observe differences on percentage of 
expression in DC populations (Appendix 9), indicating that all the cells studied were 
expressing these markers. However, we were able to analyse the MFI for these conditions 
and determine differences in the proportion of each marker (Figure 2.5 B). We did not 
observe any significant influence of any Mycobacterium liposome on CD40 expression 
compared to LPS and Poly(I:C), which both increased MFI to 598 and 521, respectively, 
compared to 252 MFI for the unstimulated iDC population. Concerning DC-SIGN, the 
activation of iDCs resulted in a decrease of expression on the cell surface. We observed that 
HN878 liposomes strongly down regulated DC-SIGN expression to 392 MFI similar to LPS (384 
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MFI) and Poly(I:C) (456 MFI). Additionally, M. smegmatis, H37Rv and EU127 liposomes 
showed a trend towards decreasing DC-SIGN cell expression to 498, 501 and 510 MFI, 
respectively, compared to 577 MFI for iDCs. For the HLA-II marker, we observed that HN878 
liposomes induced expression to 492 MFI comparable to LPS and Poly(I:C) with 598 and 555 
MFI values, respectively. The presence of M. smegmatis demonstrated a trend towards 
increasing HLA-II expression to 230, compared to 122 MFI for iDCs alone. However, we 
observed that the presence of BCG and CDC1551 liposomes did not influence the expression 
of DC-SIGN and HLA-II significantly. The negative control 0.8PC:0.2Ch did not impact on the 
expression of CD40, DC-SIGN and HLA-II markers. From these observations we could 
conclude that the influence of M. smegmatis, H37RV, HN878 and EU127 on iDC activation 
were due to the presence of liposome glycolipids.  
In conclusion, lipids from HN878 activate the maturation of iDCs to mDCs as shown by 
inducing the expression of CD86, CD80 and HLA-II and the reduction of DC-SIGN expression. 
Also, M. smegmatis glycolipids present on liposomes, appeared to activate iDCs with a less 
powerful effect compared to HN878 liposomes. Similarly, Mtb H37RV and EU127 lipids 
demonstrated a trend towards activating iDCs with lower CD86 expression and down-
regulation of DC-SIGN receptor expression. However, glycolipids from BCG and CDC1551 did 




Figure 2.5: Activation of iDCs by Mycobacterium liposomes – FACS Analyses 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with antibodies against CD80, CD86, CD40, 
HLA-II and DC-SIGN receptors and A. percentage of expression or B. The median fluorescence Intensity are 
measured for each condition after cell fixation with PFA by FACS analyses. The data shown are representative of 


















































































































































































































































Concerning Luminex® analyses of supernatants (Figure 2.6), we observed that the two 
positive controls LPS and Poly(I:C) induced similar responses from iDCs via production of a 
large number of pro-inflammatory cytokines including IL-6, IL-8, IL-12 70p, IL-23, MIP-2α, G-
CSF, MIP-1α, IL-10, IP-10, TNF-α, IFN-β, IL-15, RANTES and IL-12 23p40. Interestingly, the 
presence of the Mtb HN878 liposomes demonstrated a trend towards activating iDCs in a 
similar way, with an increase in production of IL-6, IL-8, MIP-1α, IL-10, IP-10, TNF-α, IL-15, 
RANTES and IL-12 23p40, correlating with the flow cytometry analyses. With the negative 
control 0.2PC:0.8Ch we observed a general reduction in cytokines production, suggesting 
that the liposome composition of PC and cholesterol might have an impact on iDCs. BCG and 
M. smegmatis liposomes showed a trend towards mimicking 0.8PC:0.2Ch impact, indicating 
that BCG and M. smegmatis glycolipids did not influence iDCs maturation. However, for M. 
smegmatis these observations were not correlated with the flow cytometry analyses 
whereby M. smegmatis showed an induction in CD-86, CD80 and HLA-II expression. 
Interestingly, Mtb H37Rv, CDC1551 and EU127 liposomes showed less impact on the 
decrease of IL-1α, IL-27, IP-10, TNF-α, GM-CSF and IL-12 23p40, indicating a possible 
activation of these cytokines produced when compared to the negative control. For the 
H37Rv and EU127 liposomes this observation correlated with the flow cytometry analysis 
which suggests a partial activation of iDCs, but not observed with CDC1551. 
In conclusion, flow cytometry and Luminex® analysis indicated that Mycobacterium 
liposomes are able to activate iDCs differentially. Glycolipids from Mtb HN878 integrated into 
liposomes, are able to induce a strong pro-inflammatory response from DCs and activate 
them. Additionally, lipids from Mtb H37Rv and EU127 induced partial maturation of iDCs and 
inflammatory response. However, BCG, M. smegmatis and CDC1551 lipids presented in 
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Figure 2.6 : Influence of Mycobacterium liposomes on iDC cytokines production 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the supernatant from each condition were harvested for Luminex® 
analyses. Luminex results are represented by Heat Map Clusters of the Log2 of liposomes treatment/iDCs baseline 
ratio. An increase of cytokine production in the supernatant is represented in red, a diminution of cytokine 
production depict in green and no change shown as black. For the data shown, n=3 using cells isolated from one 
donor. 
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c) Activation of iDCs in presence of H37Rv liposome: role of SL1 
We then characterised the maturation of iDCs induced by Mtb H37Rv and the implication of 
SL1 as its role in Mtb pathogenesis is not well described. For this purpose an H37Rv mutant 
papA1Δ was utilised. Polyketide associated-protein-1 (papA1) is an acetyltransferase enzyme 
present on the cytoplasmic side of the plasma membrane of Mtb and is involved in biogenesis 
of SL1. papA1Δ mutants result in the absence of SL1 on the mycobacterial cell wall. Liposomes 
with total lipids from H37Rv papA1Δ have been generated and tested in parallel to liposomes 
containing papA1Δ lipids complemented with soluble SL1. As described above liposomes 
were incubated for 18h with iDCs and the expression of specifics markers of DC activations 
CD80, CD40, DC-SIGN and HLA-II were then measured on the cell surface by flow cytometry 
(Figure 2.7 and Appendixes 10, 11, 12). 0.8PC:0.2Ch liposomes were used as a negative 
control and LPS and Poly(I:C) as positive controls for iDC maturation. 
We observed that H37Rv liposomes induced expression of the CD80 marker on DCs to 58.0% 
compared to 33.6% for iDCs that had not been stimulated with liposomes (Figure 2.7 A). 
However, papA1Δ liposomes were shown to activate expression of CD80 to a lesser extent, 
with expression measured at 43.3%. Interestingly, liposomes containing papA1Δ total lipid 
complemented with soluble SL1 induced expression of CD80 at a similar level to H37Rv, with 
55.5% DCs expressing CD80. LPS and Poly(I:C) both increase expression of CD80 to 99.0% of 
cells expressing the marker whilst 0.8PC:0.2Ch liposomes did not influence CD80 expression 
(38.7%), as expected. Altogether these observations suggest that SL1 is involved in the 
activation of CD80 expression during iDC maturation, induced by Mtb H37Rv. As described 
previously, we were not able to measure differences on the percentage of expression in DC 
populations for the CD40, DC-SIGN or HLA-II markers (Appendix 13), but we analysed MFI to 
determine the difference in proportion of each marker within the expressing cell population 
(Figure 2.7 B). We observed that H37Rv, papA1Δ and papA1Δ + SL1 liposomes similarly 
activated CD40 expression on iDCs to 224, 237 and 209 MFI, respectively compared to 167 
for iDCs and 171 MFI for 0.8PC:0.2Ch liposomes. Also, LPS and Poly(I:C) strongly induced 
CD40 expression with 600 and 655 MFI measurements, respectively. These results suggest 
that SL1 is not involved in modulating CD40 expression during iDCs maturation induced by 
H37Rv. Concerning DC-SIGN, we observed that H37Rv and papA1Δ complemented with SL1 
showed comparable MFI values obtained at 696 and 684 MFI, respectively. However, the 
presence of papA1Δ liposomes did not induce reduction of DC-SIGN expression with 721 MFI 
compared to iDCs with a 732 MFI.  
 72 
The two positive controls significantly reduced DC-SIGN expression on DCs to 449 MFI for LPS 
and 468 MFI for Poly(I:C). However, the negative control liposome 0.8PC:0.2Ch also 
decreased DC-SIGN expression to 693 MFI, therefore we couldn’t conclude on the specific 
role of SL1 modulating DC-SIGN expression. Finally, for HLA-II we observed that H37Rv 
liposomes induced expression to 582 MFI compared to 437 MFI for iDCs with no stimulation. 
Interestingly, papA1Δ and papA1Δ + SL1 liposomes did not activate HLA-II expression. LPS 
and Poly(I:C), as expected, induced high expression of HLA-II with 1,024 and 964 MFI 
measured, respectively compared to 429 MFI for 0.8PC:0.2Ch. These results suggest that SL1 
is not involved in modulating HLA-II expression during iDCs maturation with H37Rv 
liposomes. 
In conclusion, H37Rv lipids integrated into liposomes could partially activate iDCs by inducing 
the expression of CD80, CD40 and HLA-II markers and SL1 is likely involved in iDCs maturation 





Figure 2.7 : Activation of iDCs by H37Rv - Role of SL1 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrigugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs are harvested and 
incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, H37Rv, papA1Δ, papA1Δ+SL1 liposomes 
for 18h. Then the cells stained with antibodies against CD80, CD40, HLA-II and DC-SIGN receptors and A. 
percentage of expression or B. the median fluorescence intensity are measured for each condition after cell 









































































































































































d) Co-culture of iDCs and CD4+T cells in presence of liposomes 
Finally, in order to characterise the influence of Mycobacterium liposomes on the induction 
of immune responses, we analysed the cytokine production in iDCs and CD4+ T lymphocytes 
co-cultures in vitro in the absence and presence of liposomes. iDCs and CD4+ T cells were 
incubated for 7 days with Mycobacterium liposomes and the supernatants were collected for 
Luminex® analyses (Figure 2.8). LPS was used as a positive control, however, 0.8PC:0.2Ch 
couldn’t be used as a negative control in this assay as the liposomes were found to be toxic 
to CD4+ T cells (Appendix 14).  
In the context of iDCs and CD4+ T cell co-culture, the presence of LPS induced a global 
activation in production of several pro-inflammatory cytokines, including IL-6, IL-8, IFN-γ, IL-
1α, IL-23, MIP-1α, IL-10, IP-10, TNF-α and IL-1β. Compared to the positive control, only Mtb 
H37Rv liposomes demonstrated a trend towards activating production of IL-8, MIP-1α and 
IL-15. Indeed, for all the other liposomes, BCG, HN878, CDC1551 and EU127, we observed 
that their presence in the context of iDCs/CD4+ T cell co-cultures showed a trend towards 
decreasing production of a number of pro-inflammatory cytokines including MIP-1α. 
Additionally, H37Rv induces a decrease in IL-10, GM-CSF and M-CSF production. Interestingly, 
all the studied Mtb strains demonstrated a trend towards decreasing production of IP-10 and 
MIG. 
In conclusion, H37Rv liposomes demonstrated a trend towards stimulating expression of pro-
inflammatory cytokines from co-cultured iDCs and CD4+ T cells. Conversely, EU127, CDC1551 
and HN878 liposomes showed a trend towards decreasing pro-inflammatory responses 
whilst BCG did not induce any specific responses. From this observation we can conclude that 
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Figure 2.8 : Influence of Mycobacterium liposomes on CD4+T and iDCs co-culture cytokine 
production 
In a 96-well plate 2x104 iDCs were placed in culture with 2x105 CD4+ T lymphocytes per well and incubated with 
5mg/ml LPS or 40µg of BCG, H37Rv, HN878, CDC1551 and EU127 liposomes. At day 4, the supernatant from each 
condition were harvested for Luminex® analyses. Luminex results are represented by Heat Map Clusters of the 
Log2 of liposomes treatment/cells baseline ratio. An increase of cytokine production in the supernatant is 
represented in red, a diminution of cytokine production depict in green and no change shown as black. For the 
data shown, n=3 using cells isolated from one donor. 
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III. Conclusion 
From the characterisation and analyses of liposomes performed by TLC and NanoSight 
technologies, we validated our technique of liposome generation. Indeed, liposomes 
produced with BCG total lipids, showed consistency in sizes, concentrations (Figure 2.1 and 
2.2) and composition from two preparation batches. Additionally, liposomes showed specific 
compositions depending on the origin of the Mycobacterium lipids as we were able to 
visualise the presence of PDIM, SL and PIMs integrated into BCG and H37Rv liposomes at 
different proportions (Figure 2.3). However, theses analyses need to be followed up and 
confirmed by mass spectrometry which will inform the exact chemical composition of the 
generated liposomes. This will enable for the identification of the specific lipid compositions 
of each studied Mycobacterium strain and provide for quantification of lipid incorporation 
into liposomes. 
From analysing the influence of Mycobacterium liposomes on modulating immune 
responses, the results demonstrate various impacts depending on the origin of the Mtb strain 
being studied and also on the immune cells utilised (summarised Table 2.1). For 
macrophages, we showed that BCG, M. smegmatis and Mtb H37Rv were able to activate 
macrophage by inducing production of pro-inflammatory cytokines (Figure 2.4). These 
results suggest that BCG, M. smegmatis and H37Rv liposomes can induce innate immune 
responses within MDM via TNF-α production through activating IL-6, IL-8, MIP-1α, IL-10 and 
IL-12 expression and where Mtb EU127 showed the capacity to induce partial activation of 
MDM. Interestingly, in our in vitro assays all the liposomes induced production of IL-15, 
RANTES and IL-12p40. Concerning iDCs maturation, we observed that HN878 liposomes 
activated differentiation of iDCs by expression of CD80, CD86 and HLA-II surfaces markers 
and by induction of expression of a large number of pro-inflammatory cytokines including IL-
12 and chemokines (Figures 2.5 and 2.6). Additionally, H37Rv and EU127 liposomes showed 
the capacity to activate iDCs but to a lower extent compared to HN878. Conversely, BCG, M. 
smegmatis and CDC1551 liposomes did not exhibit any impact on iDC maturation.  
H37Rv liposomes are able to induce immune responses from MDM and iDCs, where in both 
assays H37Rv liposomes induced production of different cytokines and where the MDM 
response is stronger than seen with iDCs (no clear induction of cytokines production in this 
case). These results suggest that H37Rv lipids are able to activate immune responses from 
MDM and partially from iDCs, potentially through engaging different receptors expressed on 
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the different cell types. From H37Rv total lipids, LAM, LM and PIM showed the capacity to 
induce IL-8 expression in macrophages, which are involved in neutrophil recruitment (Zhang, 
Broser, et al., 1995; Riedel and Kaufmann, 1997; Ameixa and Friedland, 2002; Krupa et al., 
2015). The induction of IL-8 in our in vitro assays could be due to the presence of LAM, LM 
or PIMs integrated within H37Rv liposomes. IL-23 has been described to be produced during 
Mtb infection and to be involved in T cell proliferation and differentiation (Khader et al., 
2005). Our results suggest that glycolipids integrated into H37Rv liposomes are implicated in 
IL-23 production from MDM. Additionally, isolated PIM and ManLAM from the H37Rv strain 
were associated with induction of iDC maturation in the presence of LPS in vitro (Mazurek et 
al., 2012), suggesting that PIM and ManLAM present on liposomes could be involved in the 
maturation of iDCs. Also, our assays suggest a role of SL-1 expressed by H37Rv in DC 
activation where SL1 induced CD80 expression during iDCs maturation (Figure 2.7). Mtb 
EU127 is a clinical strain where the lipids have shown the capacity to induce partial 
maturation of MDM and iDCs, similar to H37Rv liposomes. This result suggests that lipids 
expressed by EU127, as similarly found in H37Rv, can activate MDM and iDCs. 
Interestingly, comparing the impact of BCG, M. smegmatis, HN878 and CDC1551 liposomes 
on MDM and iDCs assays, we observed different profiles of activation. BCG and M. 
smegmatis liposomes clearly induced activation of MDM similar to H37Rv. However, none of 
them were able to activate differentiation of iDCs. For HN878 liposomes, the opposite 
phenomenon was observed where HN878 strongly activated iDCs but not macrophages. This 
was similar for EU127 liposomes which showed a lower degree of MDM and iDCs activation 
comparable to H37Rv. The observed differences between the two experiments could be 
explained by the presence of cell types showing variant degrees of activation. The response 
of macrophages and iDCs is depending on the stimuli which can generate differences in the 
metabolism within the cells, therefore effecting the induced immune responses measured 
(Kelly and O’Neill, 2015). 
Concerning the ability of BCG liposomes to induce iDCs maturation, Sprott et al. described in 
2004 induction of pro-inflammatory cytokines from iDCs incubated with liposomes 
containing total polar lipids from BCG where mannose and/or palmitoylated-mannose are 
involved in TNF production, PIMs and LAM in IL-12 production and IL-6 in mice (Sprott et al., 
2004). Compared to our in vitro assays, Sprott et al. used liposomes containing ovalbumin on 
immunised mice and this could explain why we were not able to visualise maturation of iDCs 
with BCG liposomes in our system. Also the proportion of total lipids from BCG incorporated 
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within the liposomes could be too low to observe activation of the cells. However, lipids 
associated with liposomes from BCG and M. smegmatis were able to activate macrophages, 
similarly to H37Rv, suggesting that the same lipids present in BCG, M. smegmatis and H37Rv 
could be involved in MDM activation. In accordance with these results,  M. smegmatis total 
lipids incorporated into liposomes, similar to our assays, have been associated with 
immunogenic properties in mice creating cross reactions against Mtb antigens and making 
M. smegmatis liposomes a good candidate for TB vaccination (de los Angeles García et al., 
2013).  
For CDC1551 liposomes, we observe a trend towards activation of MDM with production of 
IL-15, RANTES and IL-12, but we did not observe any impact on iDC maturation. These results 
suggest that lipids from CDC1551 were partially able to activate of MDM but not DCs. 
However, the CDC1551 Mtb strain has been described to induce production in vitro and in 
vivo of pro-inflammatory cytokines. In infected animals, the production of cytokines was 
associated with a long term survival of the bacteria (Manca et al., 1999). Our in vitro system 
might need to be optimised to observe similar results as already described. Indeed, higher 
concentrations of liposomes or different liposome compositions should be tested in order to 
reproduce these observations. A more indepth analysis and quantification of lipid 
incorporation within liposomes may shed light on the lack of observed stimulations.  
Concerning HN878 liposomes, lipids from Mtb HN878 showed a strong capacity to activate 
iDCs compared to the other Mtb strains studied, but not MDM. HN878 is a virulent Mtb strain 
described to be able to reduce TH1 immune responses at the early stage of infection by 
production of type I IFNs (Manca et al., 2001; Ordway et al., 2007). However, in our in vitro 
system even if we observed a down regulation of pro-inflammatory cytokine production from 
MDM in the presence of HN878 liposomes, we were not able to visualise any augmentation 
in production of IFN-α/β as well as for iDCs despite a strong activation of cells.  
From the analyses on MDN and DC activation we observed variations between Mtb strains 
in their ability to induce immune responses (Figures 2.4, 2.5 and 2.6). Additionally, with the 
in vitro assay on iDCs and CD4+ T lymphocytes co-cultures, we observed significant 
differences on cytokines production profiles from the cells in response to the Mtb lipids 
integrated within liposomes (Figure 2.8). 
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Concerning Mtb H37Rv liposomes, we observed a pro-inflammatory response from iDCs 
(suggested by production of chemokines MIP-1α, IL-8 and production of cytokines IL-15) and 
CD4+ T lymphocytes. These results suggest that incubation with H37Rv lipids promotes 
interactions between CD4+ T lymphocytes and DCs, stimulating adaptive immune responses 
that induce T cell proliferation and differentiation. Interestingly, we did not observe any 
decrease in IFN-γ. This observation could be explained by testing supernatants on day 7 post-
incubation with liposomes and not 18h as with MDM and iDCs and where the cytokine has 
been internalised and consumed by the cells. However, BCG, Mtb HN878, CDC1551 and 
EU127 demonstrated a trend towards down regulating pro-inflammatory cytokine 
production during co-culture. Because HN878 and EU127 showed the capacity to activate 
iDCs maturation, we can hypothesise that these results could be due to variations in the 
assays or because of the consumption of cytokines at day 7.  
In this Chapter we described the ability of lipids from Mtb to induce differential immune 
responses, suggesting Mtb lipids from variant strains can differentially stimulate and 
modulate the types of innate and adaptive immune responses mounted in infection. The 
variation observed with the studied glycolipids could explain the variation observed in Mtb 
pathogenicity (Lin, Zhang and Barnes, 1998; Theus, Cave and Eisenach, 2005; Theus et al., 
2007; Guenin-Macé, Siméone and Demangel, 2009; Daffé, Crick and Jackson, 2014; Mvubu 
et al., 2018). In the case of HIV-1 and Mtb co-infection, Mtb infection and recognition by the 
immune system can impact on HIV-1 infection where TB leads to the activation of immune 
responses, including activation of macrophages/DCs, recruitment of lymphocytes, co-
receptors expression and production of pro-inflammatory cytokines. The variation in 
immune responses induced by Mtb lipids as observed in this Chapter could then modulate 
HIV-1 infection and subsequent replication (Chapters 3 and 4). The results presented here 
could be expanded upon by measuring the effects of Mtb liposomes on whole PBMC cultures 
as well as other purified cell populations. Furthermore, variant compositions of liposomes 
could be tested containing different concentrations of incorporated total lipid extracts or 
fractionated lipids such as LAM, LM or PIM.  
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Table 2.1 : Results Summary 
Conditions BCG M. smegmatis H37Rv HN878 CDC1551 EU127 
MDM  
18h activation ↑ TNF-α 
↑ IL-6/IL-15 
↑ IL-12 23p40/IL-23 
↑ IL-10 
↑ MIP-1α /RANTES/IL-8 
 
↓TGF-β3 
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Chapter 3: Impact of Mycobacterium 
liposomes on HIV-1 cis-infection 
 
I. Introduction 
Infection with Mycobacterium tuberculosis (Mtb) creates a favourable environment for HIV-
1 infection and/or replication through activation and induction of immune responses. We 
described in Chapter 2, how Mtb lipids associated with liposomes can modulate immune 
responses and potentially influence HIV-1 infection. In this Chapter, we study specifically how 
Mtb antigens in the context of liposomes can impact directly on HIV-1 cis-infection.  
Immune cells including CD4+ T lymphocytes, monocytes/macrophages, and DCs are the main 
target cells of HIV-1. Virus enters target cells by initially binding to the CD4 receptor molecule 
mediated by the viral surface glycoprotein Env. Following conformational changes, the gp120 
sub-unit interacts with the co-receptor(s) CCR5 and/or CXCR4 to facilitate entry through 
membrane fusion and injection of the capsid into the cell. After entry, the capsid containing 
two copies of the HIV-1 genome is uncoated thereby releasing the viral RNA molecules into 
the cell cytoplasm. The process of reverse transcription results in viral RNA being copied into 
dsDNA. The dsDNA molecule is then translocated to the nucleus where it is integrated into 
the host genome. After integration, transcription regulatory factors including Sp, NF-κB, 
C/EBP, NFAT or AP-1 bind to the HIV-1 LTR-region to promote gene expression resulting in 
viral protein translation and viral assembly to generate new virions and completing the viral 
life-cycle (Lawn, Butera and Folks, 2001; Maartens, Celum and Lewin, 2014).  
It was previously discussed that recognition of Mtb components by various cell-types within 
the immune system can activate PRR as well as intracellular signalling pathways. TB thereby 
creates a favourable environment for infection and/or replication HIV-1 through the 
modification/translocation of transcription factors and the resultant enhancement of HIV-1 
LTR activity. In this context, Mtb has been described to increase HIV-1 replication in co-
infected macrophages in vitro (Zhang, Nakata, et al., 1995b; Goletti et al., 1996; Lawn et al., 
2001; Hoshino et al., 2002; Ranjbar et al., 2009). TLR2 and TLR4 expression within immune 
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cells in HIV-1 patients infected with Mtb is up-regulated in comparison to HIV-1 patients not 
co-infected (Hernández et al., 2012). TLR2 stimulation with soluble Mtb factors was shown 
to induce HIV-LTR transactivation, but also with TLR9 co-stimulation (Equils et al., 2003). PIM6 
in vitro induces HIV-1 replication minimally and depending on TLR2 signalling (Rodriguez et 
al., 2013). Bafica et. al. have demonstrated that there is a TLR2 dependant induction of HIV-
1 in an HIV-1-transgenic mouse model (Bafica et al., 2003). Moreover, Mtb-TLR engagement 
stimulates post-transcriptional modifications of C/EBP proteins, which in turn promotes 
C/EBP-dependent activation of the HIV-1 LTR. The Mtb proline-proline-glutamic acid (PPE) 
protein Rv1168c (PPE17) increases HIV-1 LTR transcription in monocyte/macrophage 
infected cells. The interaction between LRR motifs 11–15 of PPE17 and TLR2 leads to the 
downstream activation of NF-κB resulting in HIV-1 LTR transactivation (Bhat et al., 2012). Mtb 
cell wall components rich in carbohydrate-containing molecules, such as PIMs, LM, LAM, 
polysaccharides or glycoproteins (19 kDa, 45 kDa and 38 kDa antigens), can interact with C-
type lectin receptors expressed by DCs and macrophages and induce NF-κB pathways 
(Tailleux et al., 2003; Geijtenbeek et al., 2003; Koppel et al., 2004; Neyrolles, Gicquel and 
Quintana-Murci, 2006; Driessen et al., 2009; Geurtsen et al., 2009; Gringhuis et al., 2009; 
Ehlers, 2010; Falvo et al., 2011; Lugo-Villarino et al., 2011; Philips and Ernst, 2012). Mtb 
strains differ with regards to the cell wall composition which can differentially alter HIV-1 
replication and disease progression profiles in HIV-1/Mtb co-infected individuals. Indeed, in 
vitro infection of PBMC from healthy donors has shown that HIV-1 replication is increased in 
the presence of antigens from the CDC1551 Mtb strain relative to viral replication in the 
presence of antigens from the HN878 strain. This observation is associated with increased 
levels of transcription and nuclear translocation of the p65 subunit of the transcription factor 
NF-κB by CDC1551 compared to HN878 (Ranjbar et al., 2009). 
PRR activation by Mtb antigens induces production of cytokines and chemokines by immune 
cells which can regulate the immune responses induced against bacteria. These pro-
inflammatory cytokines lead to different mechanisms which influence HIV-1 infection. Mtb 
infection is able to induce expression of NF-κB/transcription factors, recruitment/activation 
of immune cells, expression of co-receptors CCR5 and CXCR4 as well as modulate cell 
contacts that enhance HIV-1 infection and replication. An increase of TNF-α, IL-6, and IFN-γ 
expression levels, found in vivo at the site of Mtb infection, can up-regulate HIV-1 expression 
patterns in vitro (Garrait et al., 1997; Canaday et al., 2009). The Mtb strains CDC155 and 
HN878, which can induce HIV-1 infection and replication, have been associated with 
increased levels of TNF and IL-6 expression patterns (Ranjbar et al., 2009). High levels of the 
 83 
MCP-1 protein were found in HIV-1/TB co-infected subject’s pleural fluid and its 
neutralisation resulted in inhibition of Mtb-induced HIV-1 gag/pol mRNA transcription 
(Mayanja-Kizza et al., 2009). Moreover, the balance between pro-inflammatory and anti-
inflammatory cytokines plays a role on Mtb-HIV-1 regulation. Indeed, the neutralisation of 
endogenous IL-10 and TGF-β (with a negative effect on HIV-1 infection) augmented the up-
regulation of Mtb-HIV-1 replication (Goletti et al., 1998; Chetty et al., 2014). The activation 
of signalling pathways by Mtb antigen can up-regulate the transcription of a wide range of 
host genes involved with cellular receptor expression patterns, improving HIV-1 entry and 
cell contacts. For example, the MCP-1 protein is an inflammatory CC chemokine permitting 
recruitment of CCR2+ monocytes/macrophages and CD4+ T lymphocytes. It is found at high 
levels in TB/HIV-1 co-infected patient’s pleural fluid, suggesting that MCP-1 recruits HIV-1 
permissive monocytes/macrophages and CD4+ T lymphocytes to the site of infection and 
thereby promotes new rounds of HIV-1 replication. Furthermore, MCP-1 can induce HIV-1 
co-receptor CXCR4 expression, CD4 helper T cell (Th0) polarisation in Th2 and IL-4 induction 
and CXCR4 expression on resting CD4+ T lymphocytes: all enhancing HIV-1 infection (Wahid 
Ansari, Kamarulzaman and Schmidt, 2013). Hoshino et. al. documented that TB induces 
CXCR4 expression in alveolar macrophages increasing HIV-1 entry (Hoshino et al., 2004). In 
2002, they demonstrated that cell contacts between alveolar macrophages and activated 
CD4+ T lymphocytes reduces inhibitory C/EBPβ expression and activates NF-κB thereby 
increasing HIV-1 replication (Hoshino et al., 2002). Additionally in 2007, Hoshino et. al. 
described similar observations concerning direct contact between activated 
polymorphonuclear neutrophils and macrophages. Indeed, contact between these cells, 
stimulates HIV-1 replication and LTR transcription, and down-regulates inhibitory C/EBPβ in 
alveolar macrophages during pulmonary TB (Hoshino et al., 2007). 
The direct influence of Mtb antigens on HIV-1 CD4+ T lymphocyte infection is less described 
and understood. In this Chapter, we studied the impact of Mtb liposomes on HIV-1 cis-
infection using two different in vitro approaches. The first describes (Part II. Section i.) the 
pseudo-typed viral particle system, where we aim to understand if any interaction or 
interference occurs on HIV-1 entry and infection via co-receptors CCR5 or CXCR4 in the 
presence of Mtb antigens associated into liposomes. Following this strategy, HIV-1 pseudo-
typed virus particles X4 or R5 produced by co-transfection of 293T were used to infect TZM-
bl or GHOST cell lines that expressed reporter proteins enabling to monitor for infectivity 
specific to HIV-1: GFP expression for GHOST and luciferase activity for TZM-bl cells. The 
second aim was to describe the impact on Mtb liposomes on HIV-1 replication in CD4+ T 
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lymphocytes (Part II. Section ii.). For that, fully replicative competent HIV-1 was utilised. 
Infections were performed on CD4+ T lymphocytes from healthy donors and monitored for 
replication by measuring p24 production, HIV-1 DNA quantification and cytokine production. 
 
II. Results 
i. Influence of Mycobacterium liposomes on HIV-1 cis-infection – Pseudo-
typed viral particle System 
a) Optimisation 
Before studying the impact of Mtb liposomes on HIV-1 cis-infection, an optimisation of the 
experimental system to be utilised was required. GHOST cell lines expressing co-receptors 
CXCR4 or CCR5 were used to determinate the optimum concentration of virus required to 
detect infection and to control for virus envelope (Env) expression of HIV-1 pseudo-typed 
virus particles by monitoring virus tropism. HIV-LAI (HIV-1 X4, recognising co-receptor CXCR4) 
were tested on GHOST CXCR4+ cells and HIV-JR-FL (HIV-1 R5, recognising co-receptor CCR5) 
on GHOST CCR5+ cells in parallel to HIV-VSVg that possesses a neutral tropism and can infect 
all cell lines studied (Figure 3.1. A).  
We observed that the percentage of infected GHOST CXCR4+ cells expressing GFP is higher 
for HIV-VSVg infection than HIV-1 X4: 20-45% infected cells for HIV-VSVg compared to 3-12% 
for HIV-1 X4 (Figure 3.1 A(1)). Similar results were observed for HIV-1 R5 virus where HIV-
VSVg infects 18-44% of GHOST CCR5+ and HIV-1 R5 3-12% (Figure 3.1 A(2)). Furthermore, 
HIV-VSVg presented closer values of percentages of infected GHOST CXCR4+/CCR5+ cells 
(Figure 3.1 A(3)). HIV-VSVg was used as a positive control to validate the infection conditions. 
The higher infectivity observed with HIV-VSVg can be explained by the broad tropism of the 
virus that doesn’t require specific co-receptor recognition as is the case for HIV-1 X4 and HIV-
1 R5 infection. Importantly, we observed higher numbers of infected cells with higher dose 
of virus input: for instance, the percentage of GHOST CXCR4+ cells expressing GFP is 3% with 
2ng of HIV-1 X4 increasing to 12% with 8ng of virus input. This result suggests that 8ng is 
necessary to obtain good detection of infection (Figure 3.1 A). However, the efficacy of 
infections on GHOST cells expressing both receptors CXCR4 and CCR5 is lower than GHOST 
cells expressing single co-receptors. Indeed, the percentage of infected cells obtained with 
8ng of HIV-1 X4 or HIV-1 R5 is around 5% corresponding to a decrease of more than 50% of 
infectivity compared to GHOST cells expressing single receptors where we observed 12% of 
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infection (Figure 3.1 A(3)). For these reasons a different cell line (TZM-bl,) was used for 
further analyses of liposomes. This cell line, like GHOST CXCR4+/CCR5+, expresses both co-
receptors and produces luciferase upon HIV-1 infection, providing a more sensitive method 
of detection. We can visualise TZM-bl infections with 8ng of HIV-1 X4, HIV-1 R5 or HIV-VSVg 
(Figure 3.1 B). HIV-VSVg provided 2x106 relative light units (RLU), reaching the maximum limit 
of detection of the luminescence reading and validated conditions of the assay. For HIV-1 X4 
and HIV-1 R5 we observed 1.5x106 and 0.5x106 RLU, respectively, and these values are 
sufficient to visualise HIV-1 infection. In conclusion, the infection conditions and virus 

























































































Figure 3.1 : Optimisation of HIV-1 cis-infection on GHOST and TZM-bl cell lines 
A. 3x104 GHOST cells and B. TZM-bl cells per well were seeded in 96-well plates. After 24h, the cells were infected with 2ng, 4ng 
or 8ng virus. Cells were infected with pSG3-LAI (HIV-1 X4), pSG3-JF-FL (HIV-1 R5), pSG3-VSVg (HIV-VSVg) or pSG3Δenv (ΔpSG3) 
virus. 48h after infection, A. cells were fixed in PFA to measure GFP expression by flow cytometry and B. cells were lysed to 
measure luciferase activity with RLU. For the data shown, n=2. 
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b) Influence of Mycobacterium liposomes on modulating pseudo-typed virus 
infection 
Before introducing total lipids from Mtb strains into liposomes and monitoring the effects on 
HIV-1 infection with pseudo-typed virus particles, it was important to control the influence 
of liposome composition on target cells and infection. The viability of TZM-bl cells were 
tested in the presence of liposomes composed of PC or a mix of PC and cholesterol 
(0.8PC:0.2Ch). TZM-bl cells were incubated with increasing quantities of liposomes and 
monitored for viability after 48 h. We observed for all different conditions that liposomes do 
not affect cell viability, which remains around 90% for all concentrations tested (Figure 3.2 ).  
 
To control for the influence of liposome composition on HIV-1 infection, TZM-bl cells were 
infected with HIV-JR-FL (HIV-1 R5) in the presence of liposomes generated with different 
proportions of cholesterol: PC, 0.9PC:0.1Ch, 0.8PC:0.2Ch, 0.6PC:0.2Ch (Figure 3.3). Two 
different conditions were tested: A. liposomes were added to cells at the same time as virus 
and B. liposomes were incubated with cells 30min prior to infection. In comparison to the 
cells infected with virus alone (used here as reference=1), co-incubation with liposomes 
demonstrated no effect on HIV-1 cis-infection. Indeed, infection with 1ng or 100ng of 
liposome did not affect the level of infection with either method. For 0.6PC:0.4Ch, we 
observed a slight increase in HIV-1 R5 infectivity with 100ng liposomes. In conclusion, 
liposome compositions were chosen at a 0.6PC:0.2Ch:0.2Mtb ratio to build liposomes 
incorporating Mtb total lipids. 
 
Figure 3.2 : Viability of 
TZM-bl with liposomes 
3x104 TZM-bl cells were seeded in 
96-well plates, and incubated after 
24h incubation with 1000, 100, 10 
and 1ng of PC or 0.8:0.2Ch 
liposomes. After 48h of incubation, 
the cells were washed and fixed in 
PFA to determine cell viability by 
flow cytometry. For the data 



































Figure 3.3 : Influence of liposomes without  Mycobacterium lipids on HIV-1 cis-infection 
3x104 TZM-bl cells per well were seeded in 96-well plates. After 24h, the cells were infected with 8ng of pSG3-JF-
FL (HIV-1 R5) and pSG3Δenv (ΔpSG3) where A. virus input with 1 or 100ng of liposomes at the same time or B. 1 
or 100ng of liposomes added to TZM-bl cells 30min prior to adding virus. Liposomes tested: PC, 0.9PC:0.1Ch, 
0.8PC:0.2Ch and 0.6PC:0.4Ch. 48h post-infection cells were lysed and luciferase activity measured (RLU). ΔpSG3 
is used as a negative control and the infectivity of the virus alone as reference. For the data shown, n=4. 
The impact of Mtb liposomes containing BCG, M. smegmatis, H37Rv, HN878, CDC1551 and 
EU127 glycolipids on TZM-bl HIV-LAI (HIV-1 X4) and HIV-BAL (HIV-1 R5) cis-infection were 
subsequently studied (Figure 3.4.). As described above, liposomes were either A. or C. added 
to cells at the same time as virus or B. and D. pre-incubated with TZM-bl before virus input. 
For both viruses, the reference used is the value of TZM-bl cis-infection in the presence of 
0.2PC:0.8Ch liposomes. For HIV-1 X4 and HIV-1 R5, under both conditions, we did not observe 




















































Figure 3.4 : Influence of Mycobacterium liposomes on HIV-1 cis-infection 
One day prior to infection, 3x104 TZM-bl cells per well were seeded in 96-well plates. After 24h, the cells were 
infected with 8ng of A. B. pSG3-LAI (HIV-1 X4), C. D. pSG3-BAL (HIV-1 R5) and pSG3Δenv (ΔpSG3) where A. and C. 
virus input with 100ng of liposomes at the same time or B. and D. 100ng of liposomes added to TZM-bl cells 30min 
prior to adding virus. Liposomes tested: 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, CDC1551 and EU127. 
48h after infection cells were lysed to measure luciferase activity (RLU). 0.8PC:0.2Ch is used here as a negative 
control and reference. For the data shown, n=3. 
 
ii. Influence of liposomes on HIV-1 cis-infection – Replicative System 
a) Optimisation 
We optimised cis-infection of CD4+ T lymphocytes utilising two HIV-1 replicative competent 
strains; LAI-YFP (HIV-1 X4) and BAL-GFP (HIV-1 R5) (Figure 3.5). Lymphocytes isolated from 
healthy donors were infected with variant concentrations of both viruses. Infections were 
monitored over 14 days by measuring HIV-1 capsid p24 production and analysing 
































































































































































Four different concentrations of HIV-1 X4 LAI-YFP virus were tested (Figure 3.5 ): 40, 200, 
1000, and 3000 TCID50/ml. (1) At day 7 post-infection, for all viral inputs, we observed a peak 
of infected cells expressing YFP at 0.9, 2.1, 3.8 and 5.0%, respectively. At day 10 and 14 
infection levels declined for 1000 and 3000 TCID50/ml to 3.4%. The proportion of cells 
expressing YFP increased for the 40 and 200 TCID50/ml input concentrations at day 10 to 2.5% 
and 3.0%, respectively. At day 14 a plateau was reached for 40 TCID50/ml and a decline in 
infected cells to 2.0% for 200 TCID50/ml was observed. Concerning p24 production Figure 3.5 
A(2), a progressive increase was observed over time. The 40 TCID50/ml condition provided a 
clear increase in p24 production where the values increased from 1.5ng/ml at day 4 to 
141.20ng/ml at day 10. For 200 TCID50/ml input, we observed a similar replication profile, 
p24 concentration at day 4 post-infection of 9.9ng/ml increasing to 165.5ng/ml and 
227.5ng/ml at day 7 and 10 respectively. For 1000 and 3000 TCID50/ml, a plateau was reached 
at day 7 post-infection with 232.89ng/ml and 366.24ng/ml p24 measured respectively. To 
measure the impact of liposomes on CD4+ T lymphocyte HIV-1 infection, we elected to use 
200 TCID50/ml input for HIV-1 X4 LAI-YFP virus and to monitor until day 7 post-infection. 
For HIV-1 R5 BAL-GFP (Figure 3.5 B) three concentrations of virus input were tested: 500, 
1000 and 3000 TCID50/ml. When we measured the proportion of infected cells expressing 
GFP overtime by flow cytometry analyses (1), a peak of 0.7% infected cells was observed at 
day 10 for all the conditions with a decline to 0.4% at day 14. For p24 production we observed 
an increase over time for all conditions tested (2). A peak was observed at day 7 post-
infection with p24 levels increasing from 40.96ng/ml at day 4 to 165.4ng/ml at day 7 for 500 
TCID50/ml; 26.57ng/ml to 167.21ng/ml for 1000 TCID50/ml; and 34.2ng/ml to 303.22 for 3000 
TCID50/ml. For all three concentrations of BAL-GFP tested the p24 levels decreased at day 10 
to 155.45, 135.90, and 132.01ng/ml, respectively. The low level of fluorescence measured 
for BAL-GFP virus indicated that p24 measurements would be a better indicator of 
replication. Based on the p24 analysis we chose to utilise 500 TCID50/ml as the standard 




Figure 3.5 : Optimisation of HIV-1 cis-infection on CD4+ T lymphocytes 
2x105 CD4+ enriched T lymphocytes per well were seeded and incubated with A. 40, 200, 1000 or 3000 TCID50/ml 
LAI-YFP (HIV-1 X4) or B. 500, 1000, 3000 TCID50/ml BAL-GFP (HIV-1 R5) in 96-well plate. At day 4, 7 and 10 HIV-1 
capsid p24 was determined in the supernatant by p24 ELISA (2) and at day 7, 10, and 14 the percentage of infected 
cells was measure by flow cytometry (1) (YFP expression for LAI and GFP expression for BAL). The data shown are 
from one experiment using cells isolated from one donor.  
 
b) Influence of Mycobacterium liposomes on HIV-1 cis-infection 
We studied the effects that liposomes expressing variant Mtb strain glycolipids had on 
influencing HIV-1 cis-infection of CD4+ T lymphocytes. Viral p24 production was determined 
at two time points following infection (day 4 and 7) and with different forms of HIV-1 DNA 
being quantified at day 7: total HIV-1 DNA, 2-LTR circular form HIV-1 DNA and integrated 










































































proviral HIV-1 DNA. Selected cytokine and chemokine levels were quantified on the 
corresponding culture supernatant at day 7 using the Luminex® assay. 
Viral p24 production and HIV-1 DNA quantification analyses from HIV-1 X4 CD4+ T lymphocyte 
cis-infections in the presence of Mtb liposomes were compared (Figure 3.6). In the 
supernatant A., at day 4 post-infection (1), we observed significant differences in p24 
production during HIV-1 X4 infection, increasing from 12.48ng/ml (virus alone) to 18.04ng/ml 
in the presence of HN878 liposomes (P value =0.0286, Mann Whitney test). For all other 
liposomes tested no significant differences were observed in p24 production at day 4. BCG 
and H37Rv liposomes trended to decrease p24 concentration to 7.56 and 7.16ng/ml, 
respectively compared to the virus alone. At day 7 post-infection there was no significant 
difference in the level of p24 production with any of the liposomes. However, BCG liposomes 
demonstrated a trend towards decreasing p24 production by 2.4 fold whilst CDC1551 
liposomes showed a trend towards activating p24 production by 1.9 fold (Figure 3.6 A(2)).  
When analysing HIV-1 DNA quantification levels (Figure 3.6 B), we observed an increase in 
total HIV-1 DNA content (1) in the presence of LPS and CDC1551 liposomes to 6.9 log10 
copies/106 cells compared to 6.74 with virus alone. Also, the presence of BCG liposomes 
demonstrated a decreasing trend in the number of total HIV-1 DNA copies to 6.45 log10 
copies/106 cells. For 2-LTR HIV-1 DNA (2), BCG and EU127 liposomes decreased the number 
of 2-LTR by 4.04 (P value =0.0411, Mann Whitney test) and 4.07 (P value =0.0022, Mann 
Whitney test) log10 copies/106 cells compared to 4.39 with virus alone. H37Rv liposomes 
demonstrated a trend towards decreasing 2-LTR HIV-1 DNA to 4.2 log10 copies/106 cells. 
When comparing the quantification of integrated HIV-1 DNA levels (3), we did not observe 
any significant differences. Nevertheless, we observed overall a similar trend of Mtb 
liposomes impacting on total HIV-1 DNA quantification. Indeed, from these analyses, we 
could conclude that LPS, HN878 and CDC1551 showed a trend towards increasing HIV-1 X4 
replication, and conversely BCG, H37Rv and EU127 liposomes showed a trend towards 
inhibiting virus replication. Those observations are partially correlated with p24 production 
at day 4 and day 7. Finally, no differences were observed in proportions between total HIV-
1 DNA, 2-LTR and integrated DNA quantity (Appendix 15) and no toxic effect of the 


































































































































































































Figure 3.6 : Influence of Mycobacterium 
liposomes on HIV-1 X4 CD4+ T lymphocytes 
infection 
2x105 CD4+ enriched T lymphocytes per well were seeded 
and infected with 200 TCID50/ml LAI-YFP (HIV-1 X4) in a 96-
well plate. Then, 40μg of Mycobacterium liposomes BCG, 
H37Rv, HN878, CDC1551, EU127, or 100ng/ml of LPS was 
added. A. At (1) day 4 (n=4) and (2) day 7 post-infection 
(n=2), HIV-1 capsid p24 was determined in supernatant by 
ELISA. B. represents log10 HIV-1 DNA quantification 
determinate by PCR relative to the total number of CD4+ 
cells day 7 post-infection with (1) total number of HIV-1 
DNA (n=3), (2) number of HIV-1 2-LTR (n=6) and (3) 
number of integrated HIV (n=2). The data shown are from 
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Figure 3.7 : Influence of Mycobacterium liposomes on HIV-1 X4 CD4+ T lymphocytes 
infection - Luminex® 
2x105 CD4+ enriched T lymphocytes per well were seeded and infected with 200 TCID50/ml LAI-YFP (HIV-1 X4) in a 
96-well plate. Then, 40μg of Mycobacterium liposomes BCG, H37Rv, HN878, CDC1551, EU127, or 100ng/ml of LPS 
was added. At day 7 post-infection, supernatants were collected for Luminex® analyses. Luminex results are 
represented by Heat Maps Cluster of the Log2 of liposomes treatment/cells baseline ratio. An increase of cytokine 
production in the supernatant is represented in red, a diminution of cytokine production depict in green and no 
change shown as black. For the data shown, n=3 using cells isolated from one donor. 
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When comparing the cytokine production during HIV-1 X4 CD4+ T cell infection in the 
presence of liposomes, we observed that the virus alone induced a specific response from 
the cells characterised by induction of TNF-α, IFN-β, IL-15, RANTES, IL-12 23p40, TGF-β3 and 
TGF-β1 production and a decrease of IL-8 and IL-10 (Figure 3.7). Interestingly, we observed 
similar cytokine profiles in presence of liposomes H37Rv but at higher concentration. These 
observations suggest that H37Rv liposomes increase the viral response from CD4+ cells. 
Additionally, H37Rv liposomes seemed to induce MIP-1α production compared to virus 
alone. For the remainder, LPS, BCG, HN878, CDC1551 and EU127, a global down-regulation 
of pro-inflammatory cytokine and chemokine production was observed indicating a decrease 
in the inflammatory response from infected cells. Only the presence on LPS during HIV-1 X4 
cis-infection demonstrated a trend towards inducing IL-6 production. When we compared 
these observations with analyses of HIV-1 X4 replication we observed that Mtb liposomes 
demonstrated a trend towards up-regulating HIV-1 X4 infection such as with LPS, HN878 and 
CDC1551 and which shared similar CD4+ T cells cytokine production profiles. However, BCG 
and EU127 that showed the same cytokine pattern as HN878 and CDC1551, presented a 
trend towards inhibiting HIV-1 replication. Also, H37Rv liposomes, which demonstrated a 
trend towards down-regulating HIV-1 X4 replication, we observed pro-inflammatory 
responses similar to the virus alone. All together, these observations suggest that different 
mechanisms are involved in the influence of Mtb liposomes on modulating HIV-1 X4 
replication. 
The influence of Mtb liposomes on HIV-1 R5 cis-infection of CD4+T lymphocytes on p24 
production and total HIV-1 DNA content is represented in Figure 3.8. For p24 production A., 
we observed at day 4 (1) that LPS and CDC1551 liposomes enhanced p24 production in 
supernatant by 2.3 (P value =0.0286, Mann Whitney test) and 3.0 (P value = 0.0286, Mann 
Whitney test) fold respectively. Also, we observed that EU127 liposomes demonstrated a 
trend towards activating p24 production by 1.9 fold. Conversely, the presence of H37Rv 
liposomes decreased p24 concentration by 2.2 fold (P value = 0.0286, Mann Whitney test). 
At day 7 post-infection we observed a trend towards an increase of p24 production in the 
presence of LPS, CDC1551 and EU127 liposomes by 2.6, 3.4 and 2.3 fold, respectively (Figure 
3.8 A(2)). Concerning the influence of liposomes on HIV-1 DNA quantification (Figure 3.8 B) 
we observed that only the H37Rv liposome showed a trend towards decreasing total HIV-1 
DNA (1) to 6.71 compared to 6.99 log10 copies/106 cells for HIV-1 R5 alone. On HIV-1 2-LTR 
circular HIV-1 DNA (2), LPS, HN878 and CDC1551 liposomes significantly increased the 
number of HIV-1 copies to 4.57 (P value =0.0411, Mann Whitney test), 4.53 (P value =0.0368, 
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Mann Whitney test) and 4.79 (P value =0.0022, Mann Whitney test) log10 copies/106 cells, 
respectively. We also observed that EU127 liposomes demonstrated a trend towards 
increasing the number of 2-LTR copies to 4.51 log10 copies/106 cells. For integrated HIV-1 
proviral DNA levels (3), no significant differences were observed, but we did observe a similar 
trend when we compared the 3 graphs together. LPS, H878, CDC1551 and EU127 liposomes 
appeared to activate HIV-1 R5 replication and H37Rv liposomes showed a trend towards 
blocking replication. These observations from the DNA quantification analyses were 
correlated with p24 production overtime. Finally, no differences were observed in the 
proportions between total HIV-1 DNA, 2-LTR and integrated DNA quantity (Appendix 15) and 
no toxic effect of the Mycobacterium liposomes tested were observed in this assay (Appendix 
16). 
The analyses of the cytokine production by CD4+ T cells during HIV-1 R5 infection in the 
presence of Mtb liposomes presented, as for X4 virus, a specific response from infected cells 
characterised by induction of MIP-1α, IP-10, TNF-α, IL-15, RANTES, IL-12 23p40, TGF-β3 and 
TGF-β2 and a decrease of IL-10 production (Figure 3.9). H37Rv liposomes followed the same 
pattern of cytokine production observed with virus alone but with higher concentrations. 
Also, the presence of H37Rv showed a trend towards up-regulating production of IL-8 and 
IFN-β. Conversely, the presence of LPS, BCG, HN878, CDC1551 and EU127 showed a decrease 
of CD4+ T cell inflammatory cytokine production with the exception of IP-10 that was up-
regulated. These observations indicate that these liposomes modulate CD4+ T cell responses 
during infection with HIV-1 R5 where a down-regulation of CD4+ T cell pro-inflammatory 
responses is associated with up-regulation of HIV-1 R5 replication and an increase of pro-








































































































































































































Figure 3.8 : Influence of Mycobacterium 
liposomes on HIV-1 R5 CD4+ lymphocytes 
infection 
2x105 CD4+ enriched T lymphocytes per well were seeded 
and infected with 500 TCID50/ml BAL-GFP (HIV-1 R5) in a 
96-well plate. Then 40μg of Mycobacterium liposomes 
BCG, H37Rv, HN878, CDC1551, EU127, or 100ng/ml of LPS 
was added. A. At Day 4 (n=4) (1) and 7 (n=2) (2) post-
infection, HIV-1 capsid p24 was determined in 
supernatant by ELISA. B. represents log10 HIV-1 DNA 
quantification determined by PCR relative to the total 
number of CD4+ cells at day 7 post-infection with (1) total 
number of HIV-1 DNA (n=3), (2) number of HIV-1 2-LTR 
(n=6) and (3) number of integrated HIV (n=2). The data 
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Figure 3.9 : Influence of Mycobacterium liposomes on HIV-1 R5 CD4+ lymphocytes infection 
2x105 CD4+ enriched T lymphocytes per well were seeded and infected with 500 TCID50/ml BAL-GFP (HIV-1 R5) in 
a 96-well plate. Then 40μg of Mycobacterium liposomes BCG, H37Rv, HN878, CDC1551, EU127, or 100ng/ml of 
LPS was added. At day 7 post-infection, supernatants were collected for Luminex® analyses. Luminex results are 
represented by Heat Maps Cluster the Log2 of liposomes treatment/cells baseline ratio. An increase of cytokine 
production in the supernatant is represented in red, a diminution of cytokine production depict in green and no 
change shown as black. The data shown are form one experiment with n=3 using cells isolated from one donor. 
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The pro-inflammatory responses from infected cells with HIV-1 X4 or R5 presented some 
similarities with the production of TNF-α, IL-15, RANTES, IL-12 23p40 and TGF-β3, suggesting 
activation of same anti-viral mechanisms. Additionally, when comparing the influence of Mtb 
liposomes on HIV-1 X4 and HIV-1 R5 replication, we observed some variations. For both 
viruses, Mtb H37Rv liposome appeared to block cis-infection of CD4+ T lymphocytes 
demonstrated a trend towards increasing the anti-viral response from infected CD4+ T cells. 
Additionally LPS, HN878 and CDC1551 showed a trend towards activating HIV-1 replication 
associated with a down-regulation of the pro-inflammatory response. However, BCG 
liposomes blocked replication of HIV-1 X4 but not HIV-1 R5 virus. Additionally, EU127 
liposomes demonstrated a trend towards lowering HIV-1 X4 replication and conversely 
showed a trend towards activating HIV-1 R5 cis-infection. BCG and EU127 showed in both 
virus infections a down regulation of pro-inflammatory responses from CD4+ T infected cells. 
In conclusion, we observed that liposomes representing variant Mtb strains were shown to 
induce differences in HIV-1 cis-infection of CD4+ T lymphocytes. This impact can also be 
variable depending on the tropism of the virus and is not solely influenced by the Mtb 
pathogenic strain being tested. 
III. Conclusion 
From the approach studying cis-infection of TZM-bl cells with HIV-1 pseudo-typed virus 
particles in the presence of Mtb liposomes we observed that none of the glycolipids from 
Mtb strains H37Rv, HN878, CDC1551 and EU127 and non-pathogenic strains BCG and M. 
smegmatis, influenced HIV-1 X4 or HIV-1 R5 infectivity (Figure 3.4). The bacterial glycolipid 
antigens presented on liposomes therefore did not interfere with HIV-1 entry to target cells 
via either the CCR5 or CXCR4 co-receptor. Interestingly, when studying HIV-1 replicative 
competent viruses large differences were observed when comparing both the Mtb strains 
being tested and the co-receptor usage profile of the virus strains (CCR5 or CXCR4) (Figures 
3.6 and 3.8), observable also when considering the cytokine profiles produced during 
infection (summarised in Table 3.1). 
Concerning the non-pathogenic BCG strain, liposomes blocked HIV-1 cis-infection on CD4+ T 
lymphocytes by reducing HIV-1 replication. Indeed, we observed a decrease in p24 
production at day 4 and day 7 post-infection with HIV-1 X4, correlating with a decrease in 
HIV-1 DNA copies at day 7 (both for total HIV-1 DNA and 2-LTR forms). Nevertheless, BCG 
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glycolipids did not demonstrate the same effect for HIV-1 R5 infectivity. However, for both 
viruses BCG glycolipids presented by liposomes reduced pro-inflammatory responses from 
infected CD4+ T lymphocytes. Additionally, EU127 (Mtb strain isolated from clinical samples) 
showed the opposite effect when comparing HIV-1 X4 and HIV-1 R5 infections. For X4 virus 
we described that EU127 liposomes demonstrated a trend towards lowering p24 production 
at day 7 post-infection, reducing HIV-1 replication. Conversely, we observed activation of 
HIV-1 R5 replication (both p24 and HIV-1 DNA levels). As observed for BCG liposomes, EU127 
decreased pro-inflammatory responses in CD4+ T cells with both virus infections. From this 
observation, EU127 Mtb strains may therefore have the potential to modulate viruses found 
early in infection, including during the acute stages of infection in patients and when viral 
loads are typically high. The differences observed between virus tropisms may be due to 
variation in cell types being infected as well as cell activation profiles.  
The pathogenic CDC1551 Mtb liposome demonstrated the induction of heightened HIV-1 
replication for both R5 and X4 viruses. For HN878, the observations were less clear but 
demonstrated a trend towards activating HIV-1 cis-infection with both virus strains. CDC1551 
and HN878 are both Mtb pathogenic strains and where CDC1551 induced a strong pro-
inflammatory response and where HN878 is deemed to be more lethal (Manca et al., 1999, 
2001; Ordway et al., 2007). Additionally, CDC1551 has been described to significantly 
increase IL-6 and TNF levels in context of HIV-1 X4 PBMC infection compared to HN878 
(Ranjbar et al., 2009). In our in vitro assays, our results showed the opposite effect where 
HN878 and CDC1551 demonstrated a trend towards decreasing pro-inflammatory responses 
in CD4+ T cells, with both X4 and R5 viruses. Additionally, up-regulation of HIV-1 replication 
was not correlated with high levels of TNF-α and IFN-γ as expected (Garrait et al., 1997; 
Canaday et al., 2009).  Ranjbar et al. used in their assays Mtb bacteria and PBMCs from PPD+ 
patient that could explain the variations observable. However, from these observations we 
could conclude that different mechanisms are involved in the modulation of HIV-1 replication 
in CD4+ T cells in the presence of HN878 and CDC1551 lipids in vitro. However, IP-10 is a 
chemokine described to up-regulate HIV-1 infection (Lane et al., 2003). In case of HN878, 




Table 3.1 : Luminex Results Summary 
Conditions BCG H37Rv HN878 CDC1551 EU127 
CD4+ T cells  
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Block virus replication Increase virus replication Block virus replication 
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↓ MIP-1α/RANTES/IL-8 
↓ TGF-β1/2/3 
- Block virus replication Increase virus replication 
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Concerning H37Rv liposomes, we demonstrated that H37Rv significantly reduces HIV-1 X4 
and R5 cis-infection. These observations suggest that H37Rv glycolipids block CD4+ T 
lymphocyte infection. The variation between the glycolipid components on each Mtb strain 
could explain the differences that we observed in our assays. Interestingly, H37Rv liposomes 
induce in both cases similar pro-inflammatory responses comparable to virus alone but to 
higher levels suggesting that H37Rv lipids up-regulate responses from infected cells. 
Furthermore, the chemokines MIP-1α and RANTES, known to inhibit viral entry of HIV-1 R5 
(Cocchi et al., 1995; Trkola et al., 1998), were produced at higher concentrations in the 
supernatant during HIV-1 X4 and R5 CD4+ T cell infection. This observation suggests that the 
H37Rv liposomes blocking effect on HIV-1 R5 replication could be due to an inhibition of virus 
entry as described by (Hoshino et al., 2004) on macrophages and mediated via the blocking 
of the CCR5 receptor by its natural ligands.  
To further investigate and better understand the impact of Mtb glycolipids on modulating 
HIV-1 infections, in vitro infections of HIV-1 X4 and R5 virus on macrophages, DCs and PBMC 
cultures could be realised in parallel in order to characterise sub-cellular population effects 
and interactions between cells. Additionally, transformed cell lines expressing specific 
markers of signalling pathways, such a TLRs, NF-κB could be used to identify mechanisms 
involved with liposomes modulating HIV-1 replication. Finally, liposomes containing lipids 
from Mtb strains only could be designed and used in order to characterise any specific roles 
towards affecting HIV-1 infections.  
From the work presented the direct role of Mtb glycolipids on modulating HIV-1 CD4+ T cells 
cis-infection remains un-clear but we demonstrate differential impacts of liposomes 
depending on Mtb strains as well as virus tropism. Several articles in the literature have 
described the modulation of HIV-1 replication by altering expression of several transcriptions 
factors differentially expressed following the activation of specific cell signalling pathways. 
However, the system of infection monitored here is different to those utilised in most studies 
cited in the literature. In the present Chapter we analysed the direct impact Mtb glycolipids 
exerted on HIV-1 cis-infection, in the next Chapter we focus on a second mechanism of HIV-
1 infection: trans-infection 
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Chapter 4: Impact of Mycobacterium 
liposomes on HIV-1 trans-infection 
 
I. Introduction 
Dendritic cells play a major role in controlling pathogen infections. Micro-organisms entering 
mucosal tissues are captured by DCs and their antigens processed for presentation to the 
immune system. The cells migrate to lymph nodes for presentation to naïve lymphocytes and 
activate a cascade of reactions driving the adaptive immune response. HIV-1 recognition by 
DCs induces strong CD4+ and CD8+ T lymphocyte responses (Cameron, Forsum, et al., 1992; 
Larsson et al., 2002; Zhao et al., 2002; Frank et al., 2003; Jones, McDonald and Canaday, 
2007). However, DCs have also been shown to capture virus and subsequently present 
infectious virus particles to target CD4+ T lymphocytes, thereby enhancing infection through 
the classic CD4 and co-receptor mediated pathway (Cameron, Freudenthal, et al., 1992; 
Cameron et al., 1994; Dong et al., 2007; J. T. Kim et al., 2018). The mechanism of trans-
infection occurs in the infectious synapse where high concentration of HIV-1 from DCs are in 
contact with CD4+ T lymphocytes enriched in co-receptor expression (Sallusto et al., 1995; 
Gummuluru, KewalRamani and Emerman, 2002; McDonald et al., 2003; Turville et al., 2004; 
Garcia et al., 2005). Different receptors have been described to be involved with trans-
infection, such as the mannose receptor (Sallusto et al., 1995; Turville et al., 2002) and the 
C-type lectin receptor DC-SIGN (Geijtenbeek et al., 2000; Turville et al., 2003; Moris et al., 
2006; van Montfort et al., 2007), which both capture virus by interaction with the HIV-1 
gp120 envelope protein. Siglec, expressed mainly on mature DCs (mDCs), can capture HIV-1 
via interactions with ganglioside GM3 localised on the virus membrane and allow for trans-
infection (Bobardt et al., 2003; de Witte et al., 2007; Puryear et al., 2012; Izquierdo-Useros 
et al., 2014; Akiyama et al., 2015). Immature DCs (iDCs) and mature DCs (mDCs) are both able 
to facilitate HIV-1 trans-infection. Unlike iDC, mDC are not infectable with HIV-1 but are more 
efficient at supporting virus trans-infection  (Granelli-Piperno et al., 1998; Sanders et al., 
2002; Izquierdo-Useros et al., 2014). 
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Different parameters can alter the mechanism of HIV-1 trans-infection. Naarding et al. 
described that Lewis X containing molecules, present in human milk, can inhibit HIV-1 
transfer to CD4+T lymphocytes specific to DC-SIGN by binding the receptor and blocking viral 
interactions (Naarding et al., 2005). They further demonstrated that bile salt-stimulated 
lipase (BSSL), a Lewis X containing glycoprotein present in human milk, can alter HIV-1 
capture-transfer via DC-SIGN (Naarding et al., 2006; Stax et al., 2011). It was also identified 
that molecular polymorphisms in BSSL could associate with the strength of inhibition and 
was further shown that these could also associate with parameters associated with HIV-1 
disease progression. Mucin 6 (MUC6) present in seminal plasma has also been identified to 
inhibit DC-SIGN mediated trans-infection (Stax et al., 2009). Collectively, these findings 
indicate that host proteins within bodily secretions and plasma have the potential to bind 
DC-SIGN and block HIV-1 trans-infection, thereby interfering with either viral transmission 
and/or subsequent disease progression.  
As explained in the Introduction, Chapter 2 and Chapter 3, Mtb components such as PIMs, 
LM, LAM, polysaccharides and glycoproteins can interact with C-type lectin receptors and 
potentially interfere with HIV-1 capture and transfer. In this Chapter, the aim was to study 
the influence of Mtb glycolipids associated with liposomes on HIV-1 trans-infection. 
As described in Chapter 3, we utilised the pseudo-typed virus particle system in parallel with 
the HIV-1 replicative system to study the effects of Mtb carrying liposomes in modulating 
HIV-1 trans-infection. Trans-infection experiments were performed using different cell-types 
including Raji-DC-SIGN cells as well as iDCs and mDCs from healthy donors. The Raji-DC-SIGN 
cell line cannot be infected with HIV-1, but can support capture-transfer of the virus due to 
expression of DC-SIGN. Both iDCs and mDCs transfer HIV-1 as explained. The TZM-bl cell line, 
expressing CD4 and the CCR5 and CXCR4 co-receptors were used as the target cell for the 
pseudo-typed virus system (Part II. Sections i. and ii.) and CD4+ T lymphocytes for the 




i. Influence of liposomes on HIV-1 trans-infection – Pseudo-typed virus 
particle System 
a) HIV-1 trans-infection on TZM-bl via Raji-DC-SIGN 
To be able to study the impact of liposomes on HIV-1 trans-infection the system was 
optimised. First, we selected an HIV-1 R5 virus strain that demonstrated sufficient capture 
and transfer of virus to TZM-bl via Raji-DC-SIGN cells (Figure 4.1). We compared trans-
infection of two HIV-1 R5 strains from different origin: JR-FL and BAL. For HIV-1 R5 JR-FL we 
observed that the efficacy of trans-infection was lower when compared to BAL (Figure 4.1 
A), indeed BAL virus provided RLU values 10 times higher than for JR-FL pseudo-typed virus 
particles even with the two viruses showing similar infectivity of TZM-bl cells (Figure 4.1 B) 
with RLU values around 600,000 each. From this observation, HIV-1 R5 BAL virus was selected 
for use in further experiments.  
 
Figure 4.1 :  Optimisation of HIV-1 R5 pseudo-virus trans-infection on TZM-bl via Raji DC-
SIGN 
0.5x106 of Raji and Raji-DC-SIGN cells were incubated 2h with HIV-1 pseudo-typed virus: particles 20ng pSG3-JR-
FL (pink) or pSG3-BAL (green). A. After capture the cells were washed and co-cultured with TZM-bl cells. The 
luciferase activity (RLU) was read after 48h. B. After capture and before Raji and Raj-DC-SIGN cells were washed, 
the supernatant (15μL) was kept to infect directly the TZM-bl cells. After 48h incubation luciferase activity (RLU) 
was determined. For the data shown, n=2. 
To measure the influence of Mtb antigens on HIV-1 trans-infection via DC-SIGN, liposomes 
containing Mtb incorporated glycolipids were incubated with Raji-DC-SIGN before capture of 
HIV-1 (Figure 4.2). The results represent the influence liposomes have on HIV-1 X4 A. and R5 
































of trans-infection in the presence of liposomes 0.2PC:0.8Ch not containing incorporated Mtb 
glycolipids (negative control). The Mtb pathogenic strain, H37Rv, significantly blocked trans-
infection of HIV-1 X4 virus via DC-SIGN by 2.9 fold (P value< 0.0001, Mann Whitney test) 
(Figure 4.2A). Conversely, HN878 slightly increased efficacy of trans-infection by 1.16 fold (P 
value= 0.0012, Mann Whitney test) whilst CDC1551 did not affect HIV-1 X4 trans-infection. 
The Mtb clinical strains EU127, Ex30 and EU111 provided a different impact on trans-
infection. EU127 blocked capture and transfer of HIV-1 X4 to 0.74 relative efficacy of transfer 
(P value= 0.0001, Mann Whitney test) compared to the negative control 0.8PC:0.2Ch 
liposomes. On the contrary, Ex30 and EU111 liposomes did not influence HIV-1 trans-
infection.  
Concerning the non-pathogenic mycobacterial strains BCG and M. smegmatis, we observed 
a strong effect for BCG, which decreased 2.5 fold DC-SIGN mediated trans-infection (P value< 
0.0001, Mann Whitney test). C. glutamicum was tested here as it is a micro-organism 
described with a membrane composition comparable to Mycobacterium, but M. smegmatis 
and C. glutamicum did not impact HIV-1 capture-transfer. M. chelonae and M. marinum are 
both non-pathogenic mycobacterial strains that under specific conditions could both create 
opportunistic infections with strong damage to the infected host. Here, we observed that 
these two strains blocked the efficacy of HIV-1 X4 trans-infection via DC-SIGN by 1.4 fold (P 
value< 0.0001 and P value= 0.0004 respectively, Mann Whitney test). S. aureus which is a 
common co-infection observed in HIV-1 patients did not affect HIV-1 X4 capture-transfer. 
Interestingly, both viruses exhibited similar profiles to Mycobacterium liposomes (Figure 
4.2). Generally, we observed a similar trend for HIV-1 X4 A. and HIV-1 R5 B.. Mtb H37Rv, with 
Mtb EU127, BCG, M. chelonae and M. marinum liposomes significantly decreasing DC-SIGN 
mediated HIV-1 trans-infection with a decrease of 2.9 (P value< 0.0001, Mann Whitney test), 
1.4 (P value< 0.0001, Mann Whitney test), 2.1 (P value< 0.0001, Mann Whitney test), 1.4 (P 
value < 0.0001, Mann Whitney test) and 1.6 (P value< 0.0001, Mann Whitney test) 
respectively. Contrary to HIV-1 X4, CDC1551 increased virus capture-transfer by 1.2 fold (P 
value= 0.0313, Mann Whitney test) but which was not observed for HN878. We did observe 
the same phenomena with M. smegmatis, where HIV-1 R5 virus trans-infection was 
increased 1.4 fold (P value= 0.0034, Mann Whitney test). Concerning the clinical Mtb strains 
Ex30 and EU111, we observed that EU111 significantly reduced capture-transfer significantly 
by 1.1 fold (P value= 0.04, Mann Whitney test). Variations observed on HN878 and EU111 
liposomes impact on HIV-1 X4 and R5 trans-infection via DC-SIGN may be explained by 
experimental variation. Indeed, in the case of HIV-1 R5, even though HN878 liposomes did 
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not significantly affect trans-infection, there was a consistent trend towards heightened 
capture-transfer.  
 
Figure 4.2 : HIV-1 trans-infection on TZM-bl via Raji-DC-SIGN with Mycobacterium 
liposomes 
0.5x106 of Raji-DC-SIGN cells were pre-incubated for 30min with 100μg of liposomes or 50µl of media. Then the 
cells were incubated 2h with HIV-1 pseudo-typed virus: A. 12.5ng pSG3-LAI (HIV-1 X4) or B. 20ng pSG3-BAL (HIV-
1 R5). After capture the cells were washed and co-cultured with TZM-bl cells. The luciferase activity (RLU) was 
read after 48h. 0.8PC:0.2Ch liposome was used here as a negative control and reference. Data are represented in 
boxplot where the box extends from the 25th and 75th percentiles, the median is plotted at the line in the middle 
of the box, the whiskers represents the minimum and maximum value and where n≥3. 
The Mycobacterium glycolipid liposomes including H37Rv, EU127, BCG, M. chelonae and M. 
marinum could potentially recognise DC-SIGN thereby blocking HIV-1 trans-infection to 
target cells. Importantly, we have observed an array of impacts Mycobacterium glycolipids 
can have on trans-infection, dependent on the strain being tested. Additionally, similar 










































































































































































different Mtb strains possess the ability to differentially effect DC-SIGN mediated capture-
transfer. 
b) HIV-1 trans-infection via DCs on TZM-bl 
We next tested the impact of Mycobacterium liposomes on trans-infection of HIV-1 via DCs, 
the physiological relevant cell-types mediating HIV-1 capture-transfer. As described above 
with Raji-DC-SIGN, DCs were pre-incubated with liposomes before capture-transfer of virus. 
HIV-1 X4 and R5 trans-infection were tested mediated by DCs at different stages of 
maturation: iDCs (Figure 4.3) and mDCs (Figure 4.4).  
Interestingly, Mtb H37Rv, EU127, Ex30 and EU111 liposomes reduced HIV-1 X4 trans-
infection via iDC by 1.9 (P value= 0.0003, Mann Whitney test), 1.8 (P value= 0.0003, Mann 
Whitney test), 2.9 (P value= 0.0008, Mann Whitney test) and 2.1 (P value= 0.0008, Mann 
Whitney test) fold, respectively (Figure 4.3 A) compared to the negative control. For Mtb 
HN878, we observed a trend towards increased trans-infection and Mtb CDC1551 
heightened trans-infection by 1.3 fold (P value= 0.0022). For non Mtb liposomes (BCG) we 
observed a decrease in HIV-1 R4 trans-infection via iDCs by 1.7 fold (P value= 0.0010, Mann 
Whitney test), but no significant changes were observed for M. smegmatis, C. glutamicum, 
M. chelonae and M. marinum. Conversely, S. aureus liposomes increased HIV-1 capture-
transfer by 1.4 fold (P value= 0.0238, Mann Whitney test) compared to the negative control 
(0.8PC:0.2Ch). 
Concerning the HIV-1 R5 strain, as observed with HIV-1 X4 the Mtb H37Rv and EU127 
liposomes decreased trans-infection by 2.0 (P value< 0.0001, Mann Whitney test) and 1.7 
fold (P value= 0.0009, Man Whitney test), respectively (Figure 4.3B). HN878 demonstrated 
again a trend towards increasing HIV-1 capture-transfer when compared to the negative 
control (0.8PC:0.2Ch), opposed to CDC1551 which increased the effect by 1.7 fold (P value= 
0.0139, Mann Whitney test). Ex30 and EU111 Mtb liposomes did not affect HIV-1 R5 trans-
infection via iDCs. Interestingly, BCG, C. glutamicum, M. chelonae and M. marinum liposomes 
decreased HIV-1 R5 capture-transfer via iDCs of 1.3 (P value= 0.0345, Mann Whitney test), 
1.6 (P value= 0.0408, Mann Whitney test), 1.6 (P value= 0.0087, Mann Whitney test) and 1.6 
(P value< 0.0001, Mann Whitney test) fold, respectively. Conversely, the M. smegmatis 
liposome blocked transfer by 1.7 fold (P value= 0.0090, Mann Whitney test). S. aureus, 
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contrary to what was observed with HIV-1 X4, did not impact on HIV-1 R5 trans-infection via 
iDCs when compared to the negative control. 
 
Figure 4.3 : HIV-1 trans-infection on TZM-bl cells via iDC with Mycobacterium liposomes 
Human blood monocytes were isolated from buffy coats using Ficoll gradient and a subsequent CD14 selection 
step using the MACS system. Purified monocytes were differentiated into iDCs in the presence of IL-4 and GM-
CSF, 70ng/ml and 50ng/ml respectively. On day 6, the phenotype of the cultured iDCs was confirmed by flow 
cytometry and 0.5x106 iDCs was pre-incubation for 30min with 100μg of liposomes or 50µl of media. The cells 
were then incubated 2h with HIV-1 pseudo-typed virus: A. 12.5ng pSG3-LAI (HIV-1 X4) or B. 20ng pSG3-BAL (HIV-
1 R5). After capture the cells were washed and co-cultured with TZM-bl cells. The luciferase activity (RLU) was 
read after 48h. 0.8PC:0.2Ch liposome was used here as a negative control and reference. Data are represented in 
boxplot where the box extends from the 25th and 75th percentiles, the median is plotted at the line in the middle 
of the box, the whiskers represents the minimum and maximum value and where n≥3. For the data shown, the 










































































































































































The observations from Figure 4.2 and Figure 4.3 are similar. Indeed, in both situations Mtb 
H37RV, Mtb EU127 and BCG liposomes significantly blocked both HIV-1 X4 and R5 trans-
infection. The similarity in results between HIV-1 trans-infection via DC-SIGN receptor and 
via iDCs indicates that the blocking effect of Mtb liposomes via iDCs is likely due to the 
interaction of glycolipids with the DC-SIGN receptor. Additionally, Mtb CDC1551, Mtb HN878 
and M. smegmatis trended to increase HIV-1 capture-transfer for both HIV-1 strains in both 
assays. In this case, glycolipids from those specific strains may signal through binding DC-
SIGN and activate expression of other receptors.  
The impact Mtb liposomes have on influencing HIV-1 trans-infection via mDCs is shown in 
Figure 4.4. Isolated iDCs were maturated with poly (I:C) for 18h before being pre-incubated 
with liposomes prior to performing virus capture-transfer assay. Variation between donors 
was observed, explaining for the high standard deviations observed, however trends were 
observed when comparing the different Mtb strains. None of the Mtb liposomes were shown 
to impact HIV-1 trans-infection, but for HN878, one mDCs donor did exhibit heightened 
transfer of HIV-1 X4 by 2.5 fold and which seemed to follow a trend of activation (Figure 4.4 
A). For non TB liposomes, BCG and C. glutamincum significantly blocked trans-infection by 
1.2 (P value= 0.0075, Mann Whitney test) and 1.7 (P value= 0.0075, Mann Whitney test) fold, 
respectively. As observed for the Mtb HN878 liposomes, M. smegmatis and M. marinum, 
trends were observed towards increased HIV-1 X4 capture-transfer via mDCs with one 
specific donor showing an increase of 1.5 and 2.9 fold, respectively. Interestingly, the same 
donor increased trans-infection of HIV-1 X4 via mDCs in the presence of HN878 and M. 
marinum liposomes, and another donor for M. smegmatis liposomes. Additionally, we 
observed that S. aureus increased trans-infection by 1.14 fold (P value= 0.0438, Mann 
Whitney test). 
The Mtb H37Rv liposome, opposed to HIV-1 X4 trans-infection via mDCs, was shown to 
significantly block HIV-1 R5 capture-transfer by 1.3 fold (P value= 0.0020, Mann Whitney test) 
(Figure 4.4 B). The same observation was found for Mtb CDC1551 which decreased transfer 
by 1.6 fold when compared to the negative control (P value= 0.0002, Mann Whitney test). 
Concerning non-TB liposomes, BCG, C. glutamicum, M. chelonae and S. aureus, were shown 
to significantly decrease HIV-1 R5 trans-infection via mDCs by 1.5 (P value= 0.0019; Mann 
Whitney test), 2.05 (P value= 0.0002, Mann Whitney test), 2.6 (P value< 0.0001, Mann 
Whitney test) and 1.5 fold (P value= 0.0033, Mann Whitney test), respectively. 
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Figure 4.4 : HIV-1 trans-infection on TZM-bl cells via mDC with Mycobacterium liposomes 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient and a subsequent CD14 selection 
step using the MACS system. Purified monocytes were differentiated into iDCs in the presence of IL-4 and GM-
CSF, 70ng/ml and 50ng/ml respectively. On day 6, iDC are differentiated in the presence of 20µg/ml Poly(I:C), On 
day 7, the phenotype of the cultured mDCs were confirmed by flow cytometry and 0.5x106 mDCs was pre-
incubation during 30min with 100μg of liposomes or 50µl of media. Then the cells were incubated 2h with HIV-1 
pseudo-typed virus: A. 12.5ng pSG3-LAI (HIV-1 X4) or B. 20ng pSG3-BAL (HIV-1 R5). After capture the cells were 
washed and co-cultured with TZM-bl cells. The luciferase activity was read after 48h. 0.8PC:0.2Ch liposome was 
used as a negative control and reference. Data are represented in boxplot where the box extends from the 25th 
and 75th percentiles, the median is plotted at the line in the middle of the box, the whiskers represents the 
minimum and maximum value and where n≥3. For the data shown, the experiment has been performed using 



























































































































































Generally we observed variations on the impact of Mtb liposomes on HIV-1 X4 and R5 trans-
infection via mDCs compared to iDCs. Indeed, for iDCs mediated virus capture-transfer we 
observed a clear impact of liposomes on transfer with no variation between blood donors 
and when compared to mDCs. Additionally, we observed some variations of liposomes when 
comparing the X4 and R5 strains of HIV-1. These observations suggest that receptors other 
than DC-SIGN are likely involved when considering mDCs HIV-1 trans-infection compared to 
iDCs. 
We further investigated the involvement of the DC-SIGN receptor on influencing HIV-1 trans-
infection via iDC and mDCs (Figure 4.5). For this purpose mannan was included in our 
experiments as a DC-SIGN receptor antagonist. As described for the Mtb liposome assays 
Raji-DC-SIGN, iDCs and mDCs were pre-incubated with mannan prior to HIV-1 capture-
transfer to TZM-bl with two concentrations tested. 
 
 
We observed that Raji-DC-SIGN HIV-1 X4 trans-infection of TZM-bl cells is strongly inhibited 
with both concentrations of mannan tested. Indeed the efficacy of transfer decreased to 0.16 
with 20µg/ml and was totally inhibited with 2mg/ml of mannan compared to virus alone. For 
iDCs, capture-transfer was found to be partially blocked by mannan in a dose dependant way: 
where with 20µg/ml the efficacy was reduced by 1.5 fold and to 2.0 fold with 2mg/ml. 
Blocking DC-SIGN receptor with mannan on iDCs seems not to fully inhibit HIV-1 trans-
infection. Concerning capture-transfer via mDCs, we did not observe any inhibition to HIV-1 
































Figure 4.5 : HIV-1 trans-infection 
on TZM-bl cells in presence of 
mannan 
0.5x106 Raji-DC-SIGN, iDCs and mDCs were 
pre-incubation for 30min with 20μg/ml, 
2mg/ml of mannan or 50µl of media. The 
cells were then incubated for 2h with 
12.5ng pSG3-LAI HIV-1 X4 pseudo-typed 
viral particles. After capture the cells were 
washed and co-cultured with TZM-bl cells. 
The luciferase activity was read after 48h. 
RLU from condition of capture-transfer 
without mannan is used here as a reference 
for each cell types. The data shown are 
representative of one experiment using 
cells isolated from one donor with n=3. 
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It can be concluded that DC-SIGN recognition from antagonists such as mannan can decrease 
HIV-1 trans-infection via iDCs (Figure 4.5). Conversely, on mDCs the DC-SIGN antagonist could 
even be seen to increase HIV-1 trans-infection at the higher concentration. Those 
observations confirm our hypothesis that glycolipids from Mtb H37Rv, Mtb EU127 and BCG 
strains can recognise the DC-SIGN receptor on iDCs and block HIV-1 trans-infection.  
 
ii. Characterisation of H37Rv lipids involved on HIV-1 trans-infection 
modulation – Pseudo-typed virus particles System 
As described previously, we observed that Mtb H37Rv glycolipids integrated within 
liposomes can interact with the DC-SIGN receptor and block HIV-1 trans-infection via iDC. In 
this section, we characterised specifically the Mtb H37Rv impact on HIV-1 trans-infection via 
the DC-SIGN receptor.  
We compared the influence of Mtb H37Rv liposomes with variant H37Rv strains from 
different origins to better understand the biology behind the effects observed (Figure 4.6). 
The main H37Rv strain that was used in all assays is from William Jacobs (Albert Einstein 
College of Medicine). We compared this H37Rv strain with H37Rv MA originally from Chris 
Sassetti (University of Massachusetts) on HIV-1 trans-infection via Raji-DC-SIGN and iDCs. As 
described previously, Raji-DC-SIGN and iDCs were pre-incubated with liposomes prior to 
capture-transfer of virus to TZM-bl cells. Interestingly, Mtb H37Rv MA did not block Raji-DC-
SIGN HIV-1 trans-infection compared to H37Rv (Figure 4.6 A). Indeed, for both viruses HIV-1 
X4 and R5, the efficacy of capture-transfer in the presence of H37Rv MA liposomes was at 
1.09 and 0.98, respectively compared to 0.35 (P value= 0.0004, Mann Whitney test) and 0.22 
(P value= 0.0004, Mann Whitney test) in the presence of H37Rv. For HIV-1 X4 virus we 
observed that H37Rv MA blocked trans-infection via iDCs by 2.6 fold compared to HIV-1 R5 
where H37Rv MA did not show any impact (Figure 4.6 B). From this observation, we conclude 
that H37Rv and H37Rv MA have different effects on HIV-1 trans-infection via DC-SIGN. This 
discrepancy is most likely due to differences in the glycolipid composition of the liposomes 




We therefore aimed to identify and characterise glycolipids from H37Rv that influence 
specifically HIV-1 trans-infection via DC-SIGN interactions (Figures 4.7 and 4.8). H37Rv total 
lipid extract was fractionated as described in Chapter 1 Part I. Section i.b). The H37Rv lipid 
fractionation was visualised by TLC allowing a partial identification of some components as 
PDIM, SL, TDM, TMM, PL and PIMs present on fractions (Figure 4.7).  
The H37Rv fractions obtained were then associated into liposomes and analysed to 
characterise the impact on HIV-1 X4 A. and R5 B. trans-infection via DC-SIGN. On HIV-1 X4 
trans-infection (Figure 4.8 A), we observed that Fractions 2 and 4 strongly inhibited capture-
transfer by 6.3 and 4.9 fold, respectively. For Fraction 1 and 5, we observed some weaker 
inhibition, Fraction 1 decreased the efficacy by 1.4 and Fraction 5 by 1.7 fold compared to 
the negative control (0.8PC:0.2Ch liposomes). Fraction 3 and 6, conversely, did not show any 
modulation of HIV-1 X4 trans-infection via DC-SIGN. Interestingly, for Fraction 7 and 8 we 

























































































































Figure 4.6 : Comparison 
between H37Rv and 
H37Rv MA 
0.5x106 A. Raji-DC-SIGN (n≥6) 
and B. iDCs (n=3, using cells 
isolated from one donor) were 
pre-incubated for 30min with 
100μg of 0.8PC:0.2Ch, H37Rv, 
H37Rv MA liposomes or 50µl of 
media. The cells were then 
incubated 2h with HIV-1 pseudo-
typed virus: (1) 12.5ng pSG3-LAI 
(HIV-1 X4) or (2) 20ng pSG3-BAL 
(HIV-1 R5). After capture the 
cells were washed and co-
cultured with TZM-bl cells. The 
luciferase activity was read after 
48h. 0.8PC:0.2Ch liposome is 
used here as a negative control 
and reference. Data are 
represented in boxplot where 
the box extends from the 25th 
and 75th percentiles, the median 
is plotted at the line in the 
middle of the box, the whiskers 
represents the minimum and 
maximum value. 
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observations were obtained for HIV-1 X4 (Figure 4.8 B). Indeed, Fractions 2 and 4 totally 
inhibited HIV-1 R5 transfer via the DC-SIGN receptor to 0.06 and 0.15, respectively, compared 
to 0.23 for H37Rv liposomes containing total lipids. Fraction 5 decreased capture-transfer by 
1.5 fold. For Fractions 1, 3 and 7 the impact of HIV-1 R5 is not clear due to high variations 
observed between values produced in triplicate, but these fractions demonstrated a trend 
towards not impacting on trans-infection via DC-SIGN, with relative values of 0.8, 0.79 and 
0.8 observed, respectively. Interestingly Fractions 6 and 8 showed a trend towards 
decreasing capture-transfer by 1.6 and 1.4 fold, respectively. 
PDIM and SL are both present in Fraction 2 (Figure 4.7) with the inhibition of Fraction 2 (for 
HIV-1 X4 and R5 trans-infection) via DC-SIGN suggesting interactions between PDIM and/or 
SL resulted in blocking virus capture (Figure 4.8). In addition, TDM is present within Fractions 
4 to 7, with a decrease in concentration through fractionation: TDM is present at higher 
concentrations in Fraction 4 compared to Fraction 7 (Figure 4.7). The inhibition of Fraction 4 
on capture-transfer of HIV-1 suggests that the presence of TDM could interact with DC-SIGN 
and block HIV-1 recognition(Figure 4.8). This conclusion is supported by the fact that Fraction 
5 can still inhibit DC-SIGN mediated trans-infection but the effect is lost when the 
concentration of TDM is lower in Fractions 6 and 7 (dose dependant effect). TMM, PL and 
PIM present in Fraction 5, 6, 7 and 8 (Figure 4.7), showed in our assays no clear impact on 
HIV-1 trans-infection via DC-SIGN with variations of impact of Fractions 7 and 8 based on HIV-







Figure 4.7 : TLC analyses of H37Rv Fractions 
TLC of H37Rv’s fractions occurred from H37Rv total lipid extract in 60:16:2 CHCl3:MeOH:H2O solvent and visualised by staining with MPA and charring. Fractions (1-9) were pooled as Fraction 1, 
(10-13) pooled as Fraction 2, (14-18) pooled as Fraction 3, (19-27) pooled as Fraction 4, (28-32) pooled as Fraction 5, (33-36) pooled as Fraction 6, (37-44) pooled as Fraction 7, and (45-63) 





Figure 4.8 : Impact of H37Rv Fractions on HIV-1 trans-infection 
H37Rv Fractions 1 to 8 have been integrated into liposomes following the ratio 0.6PC:0.2Ch:0.2Fraction. 0.5x106 Raji DC-SIGN were pre-incubated during 30min with 100μg liposomes or 50µl of 
media. The cells were then incubated for 2h with HIV-1 pseudo-typed virus B. 12.5ng pSG3-LAI (HIV-1 X4) C. 20ng pSG3-BAL (HIV-1 R5). After capture the cells were washed and co-cultured with 
TZM-bl cells. The luciferase activity was read after 48h. 0.8PC:0.2Ch liposome is used here as a negative control and reference. Data are represented in boxplot where the box extends from the 










































































































































We further investigated the potential role of PDIM and SL1 from Mtb H37Rv on affecting HIV-
1 trans-infection (Figure 4.9). For this purpose the H37Rv mutant papA1Δ was used. As 
described in Chapters 2 Part II. Section ii.c), liposomes with total lipids from H37Rv papA1Δ 
(missing SL1) were generated in parallel to liposomes with papA1Δ lipids complemented with 
soluble SL1. Additionally, liposomes containing soluble PDIM lipids were generated and 
tested. 
 
Figure 4.9 : Role of SL1 and PDIM lipids on HIV-1 trans-infection 
0.5x106 A. Raji-DC-SIGN (n≥3) and B. iDCs (n≥3 on cells isolated from two donors, excepted for the papA1Δ + SL1 
condition which utilised cells isolated form one donor) were pre-incubated for 30min with 100μg liposomes or 
50µl of media. The cells were then incubated for 2h with HIV-1 pseudo-typed virus: (1) 12.5ng pSG3-LAI (HIV-1 
X4) or (2) 20ng pSG3-BAL (HIV-1 R5). After capture the cells were washed and co-cultured with TZM-bl cells. The 
luciferase activity was read after 48h. 0.8PC:0.2Ch liposome is used here as a negative control and reference. Data 
are represented in boxplot where the box extends from the 25th and 75th percentiles, the median is plotted at 

























































































































































We observed that papA1Δ liposomes decreased slightly HIV-1 X4 (1) and R5 (2) trans-
infection via DC-SIGN but with much lower effect when compared to H37Rv liposomes 
(Figure 4.9A). Indeed, in the presence of papA1Δ liposomes the efficacy of capture-transfer 
decreased to 0.8 (X4 P value= 0.0053, R5 P value= 0.0030, Mann Whitney test) compared to 
0.3 for H37Rv for both virus strains (X4 and R5 P value<0.0001, Mann Whitney test), 
respectively. Interestingly, liposomes composed of papA1Δ total lipids complemented with 
SL1 were shown to cause strong inhibition of 3.4 fold for HIV-1 X4 (P value< 0.0001, Mann 
Whitney test) and 4.1 for HIV-1 R5 (P value< 0.0001, Mann Whitney test) trans-infection, 
respectively. This result indicates that SL1 expressed on H37Rv binds the DC-SIGN receptor, 
blocking HIV-1 trans-infection via this C-type lectin. Concerning PDIM, the liposomes 
containing soluble PDIM did not significantly impact on either HIV-1 X4 or R5 virus trans-
infection via DC-SIGN.  
When further investigating the impact of SL1 and PDIM on HIV-1 trans-infection via iDCs 
(Figure 4.9B), a similar trend was observed as with Raji-DC-SIGN capture-transfer (Figure 
4.9A). For HIV-1 X4, papA1Δ did not impact on trans-infection compared to H37Rv which 
decreased the efficacy by 1.4 fold (P value =0.0176, Mann Whitney test). Liposomes 
complemented with SL1 did not show a significant influence on HIV-1 X4 trans-infection but 
showed a trend towards decreasing the effect by 1.2 fold. Regarding HIV-1 R5, we observed 
differences with papA1Δ on modifying virus capture-transfer, but which seemed to inhibit to 
a lesser extent compared to H37Rv: with papA1Δ decreasing transfer by 1.6 fold (P value= 
0.0279, Mann Whitney test) compared to 2 for H37Rv (P value< 0.0001, Mann Whitney test). 
When papA1Δ liposomes were complemented with SL1 we observed less variation and a 
decrease of HIV-1 R5 trans-infection via iDCs by 1.8 fold (P value= 0.0036, Mann Whitney 
test). From those observations we could conclude that SL1 from H37Rv can be recognised by 
the DC-SIGN receptor expressed on iDCs and thereby decreasing HIV-1 capture-transfer to 
TZM-bl cells. 
 
iii. Influence of liposomes on HIV-1 trans-infection - Replicative System 
a) Optimisation 
HIV-1 trans-infection via iDCs to CD4+ lymphocytes within a replicative system was optimised 
before studying the effects of Mtb liposomes on HIV-1 replication. As explained previously in 
Chapter 3 Part II. Section ii.a), two HIV-1 strains were tested; HIV-1 X4 LAI-YFP and HIV-1 R5 
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BAL-GFP, with infection being monitored over 14 days by measuring HIV-1 capsid p24 
production and analysing percentage of CD4+ infected cells expressing YFP (LAI) or GFP (BAL) 
by flow cytometry. The optimisation of the system for trans-infection using the replicative 
system is shown (Figure 4.10).  
 
Figure 4.10 : Optimisation of HIV-1 trans-infection using CD4+ T cells 
Human blood monocytes were isolated from buffy coats using Ficoll gradient and a subsequent CD14 selection 
step using the MACS system. Purified monocytes were differentiated into iDCs in the presence of IL-4 and GM-
CSF, 70ng/ml and 50ng/ml respectively. On day 6, the phenotype of the cultured iDCs cells was  confirmed by 
flow cytometry and 2x104 iDCs were incubated 30min with A. 40, 200, 1000, 3000 TCID50/ml LAI-YFP (HIV-1 X4) 
or B. 500, 1000, 3000 TCID50/ml BAL-GFP (HIV-1 R5) virus. After capture the cells were washed and co-cultured 
with 2x105 CD4+ enriched T-lymphocytes. At day 4, 7 and 10 HIV-1 capsid p24 was determined in the supernatant 
by ELISA, and at day 7, 10, and 14 the percentage of infected cells was measure by FACS (YFP expression for LAI, 













































































Four titres of HIV-1 X4 were tested: 40, 200, 1000 and 3000 TCID50/ml (Figure 4.10 A.). 
Regarding YFP expression by infected cells (1), we observed at day 7 a peak of infected cells 
for 1000 and 3000 TCID50/ml LAI-YFP concentrations with 5.8% and 8.09% cells expressing 
YFP, respectively. This number decreased overtime to 4.55 and 3.05%, respectively at day 14 
post-infection. For 40 and 200TCID50/ml titres, the peak of infected cells was obtained at day 
14 with 5.6 and 4.6% cells expressing YFP. Concerning p24 production in supernatant (2), for 
all four conditions we observed a gradual increase in p24 production overtime from day 4 to 
day 10 post-infection rising from 6.1 to 1551.9ng/ml for 40 TCID50/ml, 9.4 to 2058.6ng/ml for 
200 TCID50/ml, 57.3 to 3401.9ng/ml for 1000 TCID50/ml and 155.4 to 3583.6ng/ml for 3000 
TCID50/ml. As for the HIV-1 cis-infection assays (Chapter 3) we decided to use 200 TCID50/ml 
for HIV-1 X4 LAI-YFP titres and to stop the experiment at day 7 post-infection for the capture-
transfer assay. 
Next three concentrations of BAL-GFP 500, 1000 and 3000TCID50/ml were tested (Figure 4.10 
B). As observed Chapter 3 Part II. Section ii.a) for CD4+ T lymphocytes cis-infection, measuring 
the proportion of infected cells by flow cytometry with percentage cells expressing GFP was 
not a good read-out for our assays. Indeed (1), the percentage of infected cells reached only 
0.7% of infected cells at day 14 post-infection. Conversely, when reading p24 production in 
the supernatant (2) we observed a gradual rise in p24 overtime. The p24 concentration 
increased from 245.0 at day 4 to 4475.8ng/ml at day 10 for 500 TCID50/ml, 194.9 to 
4753.8ng/ml for 1000 TCID50/ml and 206.7 to 4345.9ng/ml for 3000 TCID50/ml. We therefore 
chose to use 500 TCID50/ml as a standard titre for HIV-1 R5 BAL-GFP infections and to 
complete trans-infection experiments at day 7 post-infection. 
b) Influence of Mycobacterium liposomes on HIV-1 trans-infection 
We studied the effects that Mtb glycolipid liposomes have on HIV-1 X4 and R5 trans-infection 
via iDCs to CD4+ T lymphocytes where Mtb liposomes were present during capture-transfer 
of virus. The p24 production was determined at day 4 and 7 post-infection, and HIV-1 DNA 
content was quantified at day 7 (total HIV-1 DNA, 2-LTR circular DNA and integrated DNA). 
Cytokine and chemokine expression levels were monitored in culture supernatant at day 7 
using the Luminex® assay.  
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The influence of Mtb liposomes present during virus capture-transfer on HIV-1 X4 trans-
infection via iDCs to CD4+ lymphocytes is shown (Figure 4.11 and 4.12). The condition of 
capture-transfer with virus alone was used as a reference.  
Monitoring p24 at day 4 post-infection LPS, BCG, H37Rv, HN878, CDC1551 and EU127 
demonstrated significant decreases in HIV-1 replication, by 1.3, 2.2, 2.4, 1.4, 1.7 and 2.2 fold 
(P values= 0.0286, Mann Whitney test), respectively (Figure 4.11 A(1)). The strongest effect 
was observed for BCG, H37Rv and EU127 liposomes. The same phenomenon was observed 
at day 7 post-infection (2) where BCG, HN878, CDC1551 and EU127 demonstrated a trend 
towards decreasing p24 production by between 1.2-1.3 fold for each. The presence of H37Rv 
liposomes did not have a significant impact on capture-transfer. We observed an increase 
(Figure 4.11 B) in total HIV-1 copy numbers (1) in the presence of LPS to 7.7 log10 copies per 
106 cells compared to 7.3 for virus alone. Mtb HN878 liposomes present during capture-
transfer of HIV-1 X4 showed a trend towards increasing HIV-1 replication with 7.5 log10 
copies per 106 cells measured. The 2-LTR circular DNA copy numbers (2) indicated that the 
presence of BCG and CDC1551 log10 copy numbers per cell were reduced by 4.9 compared 
to 5.1 for virus alone. In addition, LPS demonstrated a trend towards increasing HIV-1 2-LTR 
copy numbers to 5.2. Concerning the HIV-1 integrated DNA form (3), we did not observe any 
significant impact of liposomes on modulating copy numbers. When observing ratios 
between quantity of HIV-1 total DNA, 2-LTR and integrated forms, no differences where 
noticed (Appendix 19, right panels). Finally, no toxic effects of the liposomes tested were 
observed in this assay when comparing cell concentration for each condition (Appendix 20). 
It can be concluded, taking the results together, that Mtb HN878 and LPS showed a trend 
towards increasing HIV-1 X4 trans-infection when liposomes were present during capture-
transfer, thereby heightening virus replication. BCG, H37Rv, CDC1551 and EU127 liposomes, 
on the contrary, appear to exert no significantly impact on HIV-1 X4 trans-infection via iDCs 





























































































































































































Figure 4.11 : Influence of Mycobacterium 
liposomes on HIV-1 X4 trans-infection 
8x104 iDCs were pre-incubated with 100μg of 
Mycobacterium liposomes or 100ng/ml of LPS for 30min. 
The cells were incubated 30min with 200 TCID50/ml LAI-
YFP (HIV-1 X4), washed then co-cultured with CD4+ 
enriched T lymphocytes in 96-well plate. Finally 40μg of 
the same Mycobacterium liposomes or 100ng/ml of LPS 
was added per well. A. Concentration of total HIV-1 
capsid p24 was determined in the supernatant by ELISA 
at (1) day 4 (n=4) and (2) day 7 (n=4)post-infection. B. 
represents log10 HIV-1 DNA quantification determined by 
PCR relative to the total number of cells at day 7 post-
infection with (1) total HIV-1 DNA quantification (n=2), (2) 
number of HIV-1 2-LTR (n=2) and (3) number of integrated 
HIV (n=2). The data shown are representative of one 
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Figure 4.12 : Influence of Mycobacterium liposomes on HIV-1 X4 trans-infection – Luminex® 
8x104 iDCs were pre-incubated with 100μg of Mycobacterium liposomes or 100ng/ml of LPS for 30min. The cells 
were incubated 30min with 200 TCID50/ml LAI-YFP (HIV-1 X4), washed then co-cultured with CD4+ enriched T 
lymphocytes in 96-well plate. Finally 40μg of the same Mycobacterium liposomes or 100ng/ml of LPS was added 
per well. At day 7 post-infection, supernatants were collected for Luminex® analyses. Luminex results are 
represented by Heat Maps Cluster of the Log2 of liposomes treatment/MDM baseline ratio. An increase of 
cytokine production in the supernatant is represented in red, a diminution of cytokine production depict in green 
and no change shown as black. For the data shown, n=3 using cells isolated from one donor. 
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From Luminex® assays (Figure 4.12), Heat Map analyses revealed that HIV-1 X4 trans-
infection enhanced production of MIP-1α, TNF-α, IFN-γ, IFN-β, IL-15, RANTES, IL-12 23p40 
and TGF-β2 compared to the non-infected cells, and induced a reduction of IL-23, IL-10, IP-
10 and GM-CSF. The liposomes HN878 and CDC1551 followed globally the same pattern 
observed with virus alone, suggesting that they did not impact on the immune response 
induced within the infected cells. LPS showed the capacity to induce a strong production of 
numerous pro-inflammatory cytokines such as IL-6, IL-8, IL-1α, IL-23, G-CSF, IP-10, TNF-α, 
MIG and IL-1β compared to virus alone. However, the presence of BCG, H37Rv and EU127 
liposomes during trans-infection showed a different profile of cytokine production compared 
to the virus alone and LPS. Indeed, for these conditions we observed a decrease in IFN-γ, 
MIP-1α, TNF-α, MIG, IL-15, RANTES, IL-12 23p40, M-CSF and TGF-β3 cytokines. This result 
suggests that these liposomes influenced the infected cells immune response.  
Depending on the Mtb strains studied we observed different impacts on HIV-1 X4 trans-
infection and cytokine production. When comparing analyses from Figures 4.11 and 4.12, we 
could conclude that HN878 and LPS demonstrated a trend towards activating HIV-1 X4 trans-
infection via the different mechanisms that allow for activation of the immune response 
favourable for virus infection. Indeed, LPS showed a trend towards activating many pro-
inflammatory cytokines, whereas HN878 did not seem to change the immune response from 
the infected cells compared to trans-infection with virus alone. Conversely, liposomes 
showing influences on cytokine production from infected cells did not influence HIV-1 X4 
replication. 
The influence of Mtb liposomes on HIV-1 R5 capture-transfer is shown (Figures 4.13 and 
4.14). The trans-infection of virus alone, as above, was used as a reference. At day 4 post-
infection the presence of LPS and HN878 significantly increased p24 production in the 
supernatant by 1.6 and 1.2 respectively (P value= 0.02686, Mann Whitney test) (Figure 4.13 
A(1)). However, we additionally observed a trend towards increased replication with H37Rv 
(1.3 fold) and EU127 (1.2 fold). At day 7 post infection only EU127 stimulation showed a 
significant impact on p24 production with an increase of 1.3 fold (P value= 0.02686, Mann 





























































































































































































Figure 4.13 : Influence of Mycobacterium 
liposomes on HIV-1 R5 trans-infection 
8x104 iDCs were pre-incubated with 100μg of 
Mycobacterium liposomes for 30min or 100ng/ml of LPS. 
The cells were incubated 30min with 500 TCID50/ml BAL-
GFP (HIV-1 R5) and washed before co-culturing with CD4+ 
enriched T lymphocytes in 96-well plate. Finally 40μg of 
the same Mycobacterium liposomes or 100ng/ml of LPS 
was added per well. A. Concentration of total HIV-1 
capsid p24 was determinate in the supernatant by ELISA 
at (1) day 4 (n=4) and (2) day 7 (n=4) post-infection. B. 
represents log10 HIV-1 DNA quantification determined by 
PCR relative to the total number of CD4+ cells at day 7 
post-infection with (1) total HIV-1 DNA quantification 
(n=2), (2) number of HIV-1 2-LTR (n=2) and (3) number of 
integrated HIV (n=2). The data shown are representative 
of one experiment using cells isolated from one donor. 
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The observation concerning p24 production did not totally correlate with HIV-1 DNA 
quantification levels (Figures 4.13 B). Total HIV-1 DNA copy numbers (1) increased in the 
presence of LPS to 7.2 log10 copies per 106 cells from 7 for virus alone. However, BCG, H37Rv, 
HN878 and CDC1551 demonstrated a trend towards decreasing the copy number to 6.9 and 
6.8 log10 copies per 106 cells. Concerning HIV-1 2-LTR DNA forms (2), the presence of LPS 
showed a trend in increasing numbers to 4.9 log10 copies per 106 cells. As observed for total 
DNA quantifications BCG, H37Rv, HN878, CDC1551 and EU127 demonstrated a trend in 
decreasing the number of 2-LTR copies to 4.5, 4.6, 4.6, 4.5 and 4.6 log10 copies per 106 cells, 
respectively compared to 4.7 for virus alone. For integrated HIV-1 DNA copies (3) we 
observed a similar trend with LPS, where levels increased to 7.1 log10 copies per 106 cells 
compared to 6.8 for virus alone. However, the influence of BCG, H37Rv and HN878 liposomes 
were not clear due to a high degree of variation between duplicates. Interestingly, CDC1551 
and EU127 demonstrated a trend towards increasing the levels of integrated HIV-1 copies to 
7 copies. When observing ratios between quantity of HIV-1 total DNA, 2-LTR and integrated 
forms, no differences where noticed (Appendix 19, right panels). Finally, no toxic effect of 
the liposomes tested were observed in this assay (Appendix 20). 
In conclusion, LPS increased HIV-1 R5 trans-infection via iDCs to CD4+T lymphocytes and 
showed increased viral replication, however none of the Mtb liposomes demonstrated an 
impact on HIV-1 R5 trans-infection. 
Concerning the cytokines produced during HIV-1 R5 trans-infection (Figure 4.14), we 
observed that infection with virus alone induced specific production profiles compared to 
the uninfected cells. Indeed, HIV-1 R5 trans-infection induced a decrease in production of 
IFN-γ, MIP-1α, TNF-α, IL-15, RANTEs and IL-12 23p40. LPS presence influenced infected 
responses by inducing production of a large pro-inflammatory response. Interestingly, BCG, 
H37Rv and EU127 liposomes showed a trend similar for virus alone, however some variations 
can be observed. BCG liposomes induced stronger inhibition of MIP-1α, IL-15, RANTEs and 
IL-12 23p40 compared to virus alone. Additionally, BCG induced a decrease in IL-10, IFN-β, 
GM-CSF and M-CSF whereas H37Rv inhibited IL-6 and MIG. The presence of EU127 liposomes 
during R5 trans-infection seemed to induce production of IL-6, IL-8, IL-10, IP-10 and IL-1β. 
These results suggest that BCG, H37Rv and EU127 influenced immune responses within 
infected cells. For HN878 and CDC1551 there was a trend observed towards altering cytokine 
profiles within infected cultures. Indeed, for both liposomes we observed less impact on 
cytokine production compared to non-infected cells. HN878 liposomes provided an increase 
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Figure 4.14 : Influence of Mycobacterium liposomes on HIV-1 R5 trans-infection - Luminex® 
8x104 iDCs were pre-incubated with 100μg of Mycobacterium liposomes or 100ng/ml of LPS for 30min. The cells 
were incubated 30min with 500 TCID50/ml BAL-GFP (HIV-1 R5), washed then co-cultured with CD4+ enriched T 
lymphocytes in 96 well plate. Finally 40μg of the same Mycobacterium liposomes or 100ng/ml of LPS was added 
per well. At day 7 post-infection, supernatants were collected for Luminex® analyses. Luminex results are 
represented by Heat Maps Cluster of the Log2 of liposomes treatment/MDM baseline ratio. An increase of 
cytokine production in the supernatant is represented in red, a diminution of cytokine production depict in green 
and no change shown as black. For the data shown, n=3 using cells isolated from one donor. 
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When comparing the impact of liposomes on HIV-1 R5 trans-infection on replication (Figure 
4.13) and the cytokines production (Figure 4.14) analyses, we observed that the origin of Mtb 
strains influences differentially HIV-1 R5 trans-infection via iDCs to CD4+T lymphocytes. LPS, 
CDC1551 and EU127 showed a trend towards enhancing HIV-1 R5 replication. The 
mechanisms behind this observation might be different since variant cytokine production 
profiles were observed as with HIV-1 non-infected cultures. Additionally, from HIV-1 X4 and 
R5 trans-infection, we observed different impacts of liposomes, where HN878 up-regulates 
replication of HIV-1 X4 but no HIV-1 R5 or CDC1551 and EU127 up-regulates HIV-1 R5 but not 
HIV-1 X4. Also, the cytokines profiles obtained by both infections were slightly different 
where HIV-1 X4 showed a stronger capacity to induce pro-inflammatory cytokine production 
compared to HIV-1 R5. The presence of liposomes therefore induced some variations on the 
immune response from infected cells depending of the virus being tested.  
 
iv. Influence of Mycobacterium liposomes on co-culture – Replicative 
System 
To understand the impact of Mtb glycolipids on HIV-1 infection and pathogenicity, the 
strategy selected was to study cis- and trans-infection separately. Indeed, we tested in 
Chapter 3, the impact of Mtb liposomes on HIV-1 cis-infection and in this Chapter the focus 
is studying liposome influence on HIV-1 trans-infection. For both experimental systems we 
utilised two different systems: the pseudo-typed virus particle system and the replicative 
system. In this section we studied a more physiologically relevant system, ie addressing the 
impact Mtb liposomes have on HIV-1 infections where iDCs and CD4+ T lymphocytes are co-
cultured together. In this setting, HIV-1 cis- and trans-infection occur simultaneously. We 
studied the impact of liposomes on influencing HIV-1 X4 (Figures 4.15), and HIV-1 R5 (Figure 
4.17) replication. As previously described, infections were monitored by measuring p24 
production at day 4 and 7 post-infection as well as HIV-1 DNA quantifications (total HIV DNA, 




























































































































































































Figure 4.15 : Influence of Mycobacterium 
liposomes on HIV-1 X4 infections - co-culture 
iDC and CD4+T cells 
In a 96-well plate, 2x104 iDCs were placed in culture with 
2x105 CD4+ T lymphocytes and infected with 200 
TCID50/ml LAI-YFP (HIV-1 X4). 40μg of Mycobacterium 
liposomes or 100ng/ml of LPS was added. A. 
Concentration of total HIV-1 capsid p24 was determined 
in the supernatant by ELISA at (1) day 4 (n=4) and (2) day 
7 (n=4) post-infection. B. represents log10 HIV-1 DNA 
quantification determinate by PCR relative to the total 
number of CD4+ cells at day 7 post-infection with (1) total 
HIV-1 DNA quantification (n=3), (2) number of HIV-1 2-
LTR (n=3) and (3) number of integrated HIV (n=2). The 
data shown are from one experiment using cells isolated 
from one donor. 
 131 
When HN878 and CDC1551 liposomes were present during co-culture the p24 production 
with HIV-1 X4 significantly increased by 1.9 and 2.0 fold (P values= 0.0286, Mann-Whitney 
test), respectively (Figure 4.15 A(1)). None of the other conditions demonstrated any impact 
on infection. At day 7 post-infection H37Rv decreased p24 production by 2.0 fold (P value= 
0.0286, Mann-Whitney test) compared to virus alone (Figure 4.15 A(2)). Conversely, HN878 
increased p24 production by 1.7 fold (P value= 0.0286, Mann-Whitney test). Concerning HIV-
1 DNA quantification, we observed a clear profile of Mtb liposomes impacting on HIV-1 
replication (Figure 4.15 B.). For total HIV-1 DNA (1), LPS, BCG, HN878 and EU127 decreased 
the number of copies to 6.7, 6.5, 6.7 and 6.6 log10 copies per 106 cells compared to 6.9 copies 
for the virus alone. Conversely, H37Rv and CDC1551 increased HIV-1 DNA to 7.4 and 7 log10 
copies per 106 cells, respectively. A similar profile was observed for 2-LTR circular DNA levels 
(2), indeed, LPS, BCG, HN878 and EU127 decreased the number of copies to 4.9, 4.7, 4.9 and 
4.7 log10 copies per 106 compared to 5.2 for virus alone. Mtb H37Rv increased 2-LTR copies 
to 5.4, but CDC1551 decreased the levels to 5.1 copies. For integrated HIV-1 DNA levels (3), 
H37Rv increased HIV-1 copy numbers to 7.1 log10 copies per 106 cells from 6.6 for virus 
alone. However, CDC1551 decreased HIV-1 DNA integration to 6.2 copies. LPS and HN878 did 
not demonstrate any influence on HIV DNA-1 integration but BCG and EU127 showed a trend 
towards reducing levels to 6.3 log10 copies per 106 cells. When observing ratios between 
quantity of HIV-1 total DNA, 2-LTR and integrated forms, no differences where observed 
(Appendix 21). Finally, no toxic effect of the liposomes tested were observed in this assay 
(Appendix 22). Overall, we can conclude that BCG, HN878 and EU127 appear to reduce HIV-
1 X4 replication, whilst H37Rv and CDC1551 showed a trend towards activating virus 
production and replication on iDC/CD4+ T cell co-culture in vitro. 
From the Luminex® analyses on iDC/CD4+ T cell co-cultures infected with HIV-1 X4 (Figure 
4.16) we observed that virus alone induced production of TGF-β1 and 2, and decreased IL-10 
production. The presence of LPS induced production of a large number of pro-inflammatory 
cytokines. Additionally, H37Rv, HN878, CDC1551, EU127 similarly enhanced production of 
cytokines compared to virus alone. However, compared to LPS, different cytokines were 
expressed such as MIP-1α, IFN-β, GM-CSF, IL-15 for H37Rv and decreased MIG for H37Rv, 
HN878, CDC1551 and EU127. Additionally, the presence of BCG and EU127 during HIV-1 X4 
infection demonstrated a decrease in MIP-1α production. These results suggest that Mtb 
liposomes induced different responses in infected cell populations compared to infection 
without stimuli. These observations suggest that the mechanisms involved might be different 
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Figure 4.16 : Influence of Mycobacterium liposomes on HIV-1 X4 infections - co-culture iDC 
and CD4+T cells - Luminex® 
In a 96-well plate, 2x104 iDCs were placed in culture with 2x105 CD4+ T lymphocytes and infected with 200 
TCID50/ml LAI-YFP (HIV-1 X4). 40μg of Mycobacterium liposomes or 100ng/ml of LPS was added. At day 7 post-
infection, supernatants were collected for Luminex® analyses. Luminex results are represented by Heat Maps 
Cluster of the Log2 of liposomes treatment/MDM baseline ratio. An increase of cytokine production in the 
supernatant is represented in red, a diminution of cytokine production depict in green and no change shown as 
black. For the data shown, n=3 using cells isolated from one donor. 
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Interestingly, when we compared Luminex results with the impact of liposomes on 
modulating HIV-1 X4 replication we observed some variations. Indeed, BCG, HN878 and 
EU127 demonstrated a trend towards inhibiting HIV-1 X4 replication in iDC/CD4+ T cell co-
cultures. However, cytokine production induced by infected cells were found to differ for the 
three liposomes tested suggesting that BCG, HN878 and EU127 blocked HIV-1 X4 replication 
by different mechanisms which were modulated by immune responses induced in HIV-1 
infected cultures. Additionally, H37Rv and CDC1551 demonstrated a trend towards 
increasing HIV-1 X4 replication. This associated with heightened activation of pro-
inflammatory cytokine production compared to HN878 and EU127, similar to LPS. These 
results suggest that H37Rv and CDC1551 created a favourable environment for HIV-1 
replication, but conversely LPS showed a trend towards decreasing HIV-1 X4 replication. We 
can conclude that strong activation of the pro-inflammatory response with LPS can down-
modulate HIV-1 X4 replication. 
The impact of Mtb liposomes on modulating HIV-1 R5 infection when CD4+ T cells and iDCs 
are co-cultured are shown Figures 4.17. At day 4 post-infection LPS and H37Rv decreased 
p24 production to 10.5ng/ml and 10.3ng/ml (P values= 0.0286, Mann-Whitney test) 
compared to 28.9ng/ml for virus alone (Figures 4.17 A(1)). For the other liposomes no effects 
were observed. At day 7 post-infection BCG, H37RV, CDC1551 and EU127 decreased p24 
production to 61.2, 35.1, 51.9 and 60.2ng/m,l respectively (P values= 0.0286, Mann-Whitney 
test) compared to 109.3ng/ml for HIV-1 R5 alone (Figures 4.17 A(2)).  
When analysing total HIV-1 DNA quantification it was observed that for all liposomes an 
increase in copy numbers was observed (Figure 4.17 B(1)). Indeed, LPS increased total HIV-1 
DNA to 7.1 log10 copies per 106 cells, BCG 6.9 copies, H37Rv to 6.9 copies and EU127 to 7 
copies compared to 6.8 log10 copies per 106 cells with the control. The stronger effects were 
observed with HN878 and CDC1551 which increased HIV-1 DNA production to 7.4 and 7.5 
log10 copies per 106 cells, respectively. Interestingly, we observed that HN878 and CDC1551 
significantly increased the copy numbers of HIV-1 2-LTR (2) to 5.5 and 5.6 log10 copies per 
106 cells compared to 5.1 copies for virus alone. LPS, BCG, and EU127 did not show any 
influence on the 2-LTR copy number but H37Rv decreased the number of copies to 5 log10 
copies per 106 cells. Relating to virus integration (3), LPS and H37Rv increased integrated DNA 
levels to 6.9 log10 copies per 106 compared to 6.8 copies for virus alone. HN878 and CDC1551 
showed again the strongest effects with an increase to 7.3 copies. When observing ratios 
between quantity of HIV-1 total DNA, 2-LTR and integrated forms, no differences where 
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observed (Appendix 21). Finally, no toxic effect of the Mycobacterium liposomes tested were 
observed in this assay (Appendix 22). Taking the results together, we can conclude that 
HN878 and CDC1551 liposomes showed a strong trend towards increasing HIV-1 production 
and replication in our system. The action of BCG, H37Rv and EU127 liposomes showed lesser 
effects on modulating HIV-1 replication.  
We next compared cytokine production during HIV-1 R5 infection of iDC/CD4+ co-cultures 
(Figure 4.18) and compared infected and uninfected responses. HIV-1 R5 infection induced 
production of IFN-γ, IL-23, IL-10, IP-10, TNF-α, MIG, GM-CSF and IFN-α, and decreased TGF-
β3 in the absence of liposomes. Liposomes additionally induced production of IL-10, IP-10 
and TNF-α suggesting that production of these cytokines is associated with viral infection. 
Furthermore, we observed some variations where liposomes were able to induce differential 
cytokine production in infected populations, such as IL-8 and decrease M-CSF production. 
These observations suggest that Mtb liposomes were able to induce differential immune 
responses from infected cells compared to virus alone, depending on the M strain. LPS alone 
showed the capacity to induce a strong pro-inflammatory response with up-regulation of 
various cytokines and reduction of IL-8 production.  
When comparing HIV-1 R5 replication (Figure 4.17) and cytokine production (Figure 4.18), 
we can conclude that the up-regulation observed with HN878 and CDC1551 liposomes in 
association with HIV-1 R5 replication is due to the creation of a favourable environment for 
viral expansion. Indeed, HN878 and CD1551 induced different cytokine production profiles. 
Whereas with BCG, H37Rv and EU127 liposomes, the modulation of immune responses 
observed in the infected co-cultures had no impact on HIV-1 R5 replication. 
Differing cytokine/chemokine Luminex profiles were observed when comparing the effects 
of the variant liposomes on HIV-1 X4 and R5 virus replication in the iDCs/CD4+ T lymphocyte 
co-culture system. For HIV-1 X4, H37Rv clearly increased HIV-1 production and replication, 
whereas BCG, HN878 and EU127 demonstrated a trend towards decreasing infection. 
Conversely, HIV-1 R5 was shown to increase in the presence of HN878 and CDC1551 
liposomes. We have therefore observed variations in immune profiles induced in co-cultures 
infected with either an HIV-1 R5 or X4 strain and which can be influenced by exposure to Mtb 






























































































































































































Figure 4.17 : Influence of liposomes on HIV-1 
R5 infections - co-culture iDC and CD4+ T cells 
In a 96-well plate, 2x104 iDCs were placed in culture with 
2x105 CD4+ T lymphocytes and infected with 200 
TCID50/ml LAI-YFP (HIV-1 X4). 40μg of Mycobacterium 
liposomes or 100ng/ml of LPS was added. A. 
Concentration of total HIV-1 capsid p24 was determinate 
in the supernatant by ELISA at (1) day 4  (n=4) and (2) day 
7 (n=4) post-infection. B. represents log10 HIV-1 DNA 
quantification determinate by PCR relative to the total 
number of CD4+ cells at day 7 post-infection with (1) total 
number of HIV-1 DNA (n=3), (2) number of HIV-1 2-LTR 
(n=3) and (3) number of integrated HIV (n=2). The data 
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Figure 4.18 : Influence of liposomes on HIV-1 R5 infections - co-culture iDC and CD4+ T cells 
- Luminex® 
In a 96-well plate, 2x104 iDCs were placed in culture with 2x105 CD4+ T lymphocytes and infected with 500 
TCID50/ml BAL-GFP (HIV-1 R5). 40μg of Mycobacterium liposomes or 100ng/ml of LPS was added. At day 7 post-
infection, supernatants were collected for Luminex® analyses. Luminex results are represented by Heat Maps 
Cluster of the Log2 of liposomes treatment/MDM baseline ratio. An increase of cytokine production in the 
supernatant is represented in red, a diminution of cytokine production depict in green and no change shown as 
black. For the data shown, n=3 using cells isolated from one donor. 
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III. Conclusion  
The initial section to this Chapter focussed on studying the impact liposomes carrying Mtb 
glycolipids exerted on HIV-1 trans-infection. The approach utilising pseudo-typed virus 
particles demonstrated how glycolipids from variant Mtb strains can differentially modulate 
trans-infection via the DC-SIGN receptor, through studying Raji-DC-SIGN cells. H37Rv, EU127, 
BCG, M. chelonae and M. marinum glycolipids showed the capacity to block HIV-1 X4 and R5 
trans-infection via DC-SIGN compared to HN878, CDC1551, EX30, EU111, M. smegmatis, C. 
Glutamicum and S. Aureus (Figure 4.2). When comparing the effect on iDCs mediated trans-
infection, we observed similar results for H37Rv, BCG and EU127, suggesting that on iDC the 
DC-SIGN receptor is the main component being blocked by the Mtb glycolipids  (Figure 4.3). 
Various components from Mtb have been described to interact with DC-SIGN receptors such 
as Man-LAM, LM, arabinomannan, glycoproteins, PIM6 and α-glucan (Lugo-Villarino et al., 
2011), suggesting their implication on the phenomena observed in HIV-1 trans-infection via 
iDCs . Variation in lipid proportions in Mycobacterium cell walls could explain the variation 
observed in our Mtb strains tested. However, HN878, CDC1551 and M. smegmatis showed a 
trend towards enhancing iDC mediated trans-infection of CD4+ T cells, suggesting others 
receptors than DC-SIGN may be involved in promoting the process. Interestingly, when 
analysing the effects utilising mDCs stimulated with Poly(I:C), we observed some differential 
effects. Indeed, Mtb HN878 and M. marinum showed a trend towards up-regulating trans-
infection (mainly with HIV-1 X4 virus) (Figure 4.4). This observation implies that receptors 
other than DC-SIGN are involved. The finding that mannan similarly did not impact on 
blocking trans-infection (Figure 4.5) supports the concept that other more diverse receptors 
are involved as mannan binds a wide-array of C-type lectins.   
The sialic acid binding Ig-like lectin 1 (Siglec-1), expressed on DCs, has been identified to be 
involved in HIV-1 trans-infection. Pino et al., described that this molecule is responsible for 
HIV-1 capture by IFN-α-activated DCs (Pino et al., 2015). The maturation of the DCs with 
Poly(I:C) induced production IFN-α (Avril et al., 2009) and could activate expression of Siglec-
1 on the cell surface. By interactions with Siglec-1, glycolipids from HN878 or M. marinum 
could thereby enhance HIV-1 trans-infection. Further studies with H37Rv allowed us to 
further characterise the implication of SL1, TDM, PIM and PDIM lipids on modulating DC-
SIGN mediated HIV-1 capture-transfer. The analyses of lipid fractions (Figure 4.8) from total 
H37Rv cell wall components revealed the interaction of SL1, TDM and PDIM with DC-SIGN, 
since they potently blocked HIV-1 trans-infection. Interestingly, PIM which is known to 
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interact with DC-SIGN, did not show strong inhibition in our in vitro system. However, the 
role of SL1 in DC-SIGN mediated trans-infection was confirmed with using total lipid extract 
from H37Rv mutants delated of SL1 (papA1Δ), where liposomes associated with lipids from 
the mutant complemented with purified SL1 showed again a decrease in HIV-1 trans-
infection with Raji-DC-SIGN cells (Figure 4.9). The Interaction of SL1 and TDM with DC-SIGN 
has not been described in the literature and studying these interaction further would lead to 
a better understanding of the molecular interactions leading to the block. Conversely, the 
role of PDIM in DC-SIGN mediated trans-infection is less clear. Indeed, analyses on HIV-1 
capture-transfer from two H37Rv strains with different origins revealed variant effects and 
where H37Rv, H37Rv MA did not block HIV-1 trans-infection via DC-SIGN (Figure 4.6). 
Compared to H37Rv MA, H37Rv is mutated in the PDIM biosynthesis genes through regular 
passaging in mice, resulting in loss in bacterial virulence (Ioerger et al., 2010). Liposomes 
specifically containing PDIM lipid did not show the capacity to block HIV-1 trans-infection via 
DC-SIGN, suggesting that high levels of expression of PDIM at the cell wall could mask SL1 
interactions with DC-SIGN.  
When analysing the influence of Mtb liposomes on HIV-1 trans-infection on CD4+ T cells via 
iDCs with replicative competent viruses (summarised in Table 4.1), we observed differences 
to the observations made using the pseudo-typed virus particle system. BCG liposomes that 
demonstrated the capacity of blocking HIV-1 trans-infection via DC-SIGN recognition, did not 
significantly impact on HIV-1 X4 or R5 replication on CD4+ T cells following trans-infection via 
iDCs. The same phenomenon occurs for Mtb H37Rv and EU127 liposomes. It is possible that 
when HIV-1 replication was monitored either via p24 production or HIV-1 DNA quantification 
the initial effects on capture-transfer were lost at days 4 and 7. It is important to notice that 
additional in vitro assays were performed where liposomes were only pre-incubated with 
iDCs (similar to the pseudo-typed viral particle system) before HIV-1 X4 and R5 trans-
infection onto CD4+ T cells (presented Appendixes 17, 18, 19 and 20). We did not observe any 
significant impact of Mtb glycolipids on HIV-1 X4 and R5 replication, supporting the loss of 
the initial effect. Interestingly, only HN878 liposomes showed the capacity to up-regulate iDC 
mediated HIV-1 X4 trans-infection in the pseudo-typed and replicative system. This 
observation suggests that similar mechanisms and receptors (Siglec-1 or MR) could be 
involved in the enhancement of HIV-1 replication by HN878 glycolipids. 
During HIV-1 X4 trans-infection, Mtb liposomes induced a global down-regulation of the pro-
inflammatory cytokine production compared to virus alone. These results suggest either a 
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down-regulation of the immune activation from infected iDCs and CD4+ T cells during 
infection in presence of liposomes, or either the induction of pro-inflammatory cytokines 
followed by their subsequent consumption by the cells over time, therefore being removed 
from the culture supernatant. Interestingly, HN878 liposomes demonstrated less down-
regulation of pro-inflammatory responses than other liposomes tested which correlated with 
an increase in HIV-1 replication. Concerning HIV-1 R5 trans-infection, the impact of the 
liposomes were more diverse and demonstrated differences compared to HIV-1 X4 infection. 
Indeed, H37Rv did not modulate cytokine responses from HIV-1 R5 infected cells compared 
to BCG which showed a trend towards increasing the down-regulation of cytokine production 
initiated by infection. HN878, CDC1551 and EU127 presented a trend toward activation of 
pro-inflammatory cytokines, suggesting a positive stimulation of the immune response from 
infected iDCs/CD4+ T cell. However, even if liposomes demonstrated a trend towards 
inhibiting or activating the immune response from infected cells, it did not impact on HIV-1 
R5 trans-infection in vitro. 
The in vitro system of iDC/CD4+ T cell co-culture system, a more physiologically relevant 
scenario, revealed totally different results from the cis-infection assays (Chapter 3) and trans-
infection. Indeed, whereas Mtb H37Rv liposomes showed a trend towards inhibiting HIV-1 
X4 and R5 virus and did not impact on trans-infection to CD4+ T cells, enhanced HIV-1 X4 
replication in co-culture. The up-regulation of HIV-1 X4 replication is associated with a 
significant increase in pro-inflammatory responses, compared to HIV-1 R5 infection, with 
notable production of TNF-α, IL-1, IL-6 and IFN-γ, which have all been described to enhance 
LTR transcription (Falvo et al., 2011). Similar to H37Rv, CDC1551 induced production of these 
cytokines in HIV-1 X4 co-culture infections and which associated with an increase in HIV-1 
replication. BCG and EU127 liposomes, as for HN878, trended to impact less on pro-
inflammatory cytokine production and block HIV-1 X4 replication. These observations 
suggest that production of TNF-α associated with IL-6 and IL-1 production and can modulate 
HIV-1 X4 LTR activation. However, HN878 and CDC1551 showed the capacity to activate HIV-
1 R5 replication, but in this case, without production of TNF-α, suggesting other mechanism 
could be involved.  
We have observed from cis-, trans-infection and co-culture assays, that virus tropism can 
alter the impact of the Mtb liposomes on infection. One explanation could be that Mtb 
glycolipids could interfere with HIV-1 X4 or R5 viral entry. The cis-infection results using 
pseudo-typed viral particles suggests otherwise as Mtb liposomes did not demonstrate 
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reduction in infectivity. This could be confirmed using the viral replicative system and testing 
entry inhibitors specific for blocking R5 or X4 virus. Importantly, the interactions between 
iDCs and CD4+ T cells are essential for the course of infection and the pro-inflammatory 
response induced. Indeed, depending of the assay tested differing panels of cytokines were 
produced which have variant impacts on HIV-1 infection. Future work should focus on better 
understanding DC responses to Mtb glycolipids and the impact on HIV-1 cis- and trans-
infection with in vitro HIV-1 infection using naïve T cells co-cultured with iDCs or mDCs as 
well as iDCs incubated with Mtb glycolipids. Depending of the in vitro system designed, 
variations could be expected in cellular responses which could modulate HIV-1 infection 
(Kedzierska and Crowe, 2001). Indeed, while most of the studies report that Mtb can up-
regulate infection in macrophages (Zhang, Nakata, et al., 1995a; Mancino et al., 1997), others 
described the opposite effect (Goletti et al., 2004).  
Overall the results presented in this Chapter have revealed that the strain origin of Mtb 




Table 4.1 : Luminex Results summary 
Conditions BCG H37Rv HN878 CDC1551 EU127 
CD4+ T cells  






















↓ IL-12 23p40/IL-23 
↓ MIP-1α/RANTES/IL-8 
Block virus replication Increase virus replication Block virus replication 
CD4+ T cells 




























↓ IL-12 23p40 
↓ MIP-1α/RANTES/IL-8 
↓ TGF-β1/2/3 






Table 4.8 continued 
Conditions BCG H37Rv HN878 CDC1551 EU127 
CD4+ T cells 




































↓ IL-12 23p40 
↓ MIP-1α /RANTES/IL-8 
MIG/I-TAC 
↓ TGF-β3 
- - Increase virus replication - - 
CD4+ T cells 
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Table 4.1 continued 
Conditions BCG H37Rv HN878 CDC1551 EU127 
iDCs/CD4+ T co-
culture 










































Block virus replication No clear role Block virus replication Increase virus replication Block virus replication 
iDCs/CD4+ T co-
culture 
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Chapter 5: Exosomes Isolation and impact 
on HIV-1 infection 
 
I. Introduction 
Extracellular vesicles (EVs) is a generic term referring to vesicles secreted into the 
extracellular environment by cells. It includes a variety of vesicle populations characterised 
by their cell origin, biogenesis, function or biophysical properties. Generally, vesicles range 
in size between 150 to 1,000nm and are secreted from the plasma membrane, budding as 
ectosomes, shedding vesicles, micro-vesicles as well as micro-particle. The term exosomes 
typically refers to vesicles with a size ranging from 30 to 100nm and which possess an 
endosomal origin (Gould and Raposo, 2013; Raposo and Stoorvogel, 2013; Colombo, Raposo 
and Théry, 2014; Iraci et al., 2016). The content of EVs varies depending on the cells from 
which they originate and can include the incorporation of functional proteins, lipids or RNAs. 
Once the components of EVs are released, they can either influence the local micro-
environment or either spread in the circulation. EVs can be detected in various biological 
fluids such as blood, urine, saliva, amniotic fluid, ascites, bronchoalveolar lavage, synovial 
fluid, semen and breast milk. A large range of functions have been associated with EVs in 
cancer, signalling, immunity, pathogenesis and infection (Théry, Ostrowski and Segura, 2009; 
Mathivanan, Ji and Simpson, 2010; Bobrie et al., 2011; Colombo, Raposo and Théry, 2014; 
Anderson, Kashanchi and Jacobson, 2016; Iraci et al., 2016). In viral diseases, EVs containing 
viral particles, virus-derived nucleic acids (genomes, cellular and viral mRNAs, miRNAs) or 
proteins can have effects on both infection and disease outcome. Indeed, vesicles containing 
viral components/products can possess a route for viral transmission and provide protection 
against immune recognition (Delabranche et al., 2012; Wurdinger et al., 2012; Hossain and 
Norazmi, 2013; Alenquer and Amorim, 2015; Chahar, Bao and Casola, 2015; Meckes, 2015; 
Schwab et al., 2015; Anderson, Kashanchi and Jacobson, 2016; Petrik, 2016; van Dongen et 
al., 2016).  
In the case of HIV-1 infection, the cargos present in EVs isolated from infected cells can 
include viral components and suggests a role of EVs in facilitating virus replication and 
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pathogenicity (Kadiu et al., 2012; Arenaccio, Chiozzini, Columba-Cabezas, Manfredi and 
Federico, 2014a; Madison and Okeoma, 2015; Hildreth, 2017). For example, the viral protein 
Nef can be incorporated into EVs (McNamara et al., 2018) and once released the EVs have 
been reported to be able to trigger apoptosis of T cells (Muratori et al., 2009; Lenassi et al., 
2010), activate HIV-1 replication (Arenaccio, Chiozzini, Columba-Cabezas, Manfredi, Affabris, 
et al., 2014) or promote inflammation (Lee et al., 2016). HIV-1 RNA molecules have also been 
shown to be encased in EVs (Columba Cabezas and Federico, 2013) as TAR elements (miRNA) 
and have been found in EVs isolated from HIV+ patients and are believed to be involved in 
enhancement of HIV-1 replication and the induction of pro-inflammatory cytokine responses 
(Narayanan et al., 2013; Sampey et al., 2015). Additionally, EVs containing HIV-1 components 
have been hypothesised to play a role in HIV trans-infection via DCs and thereby influence 
viral transmission (Wiley and Gummuluru, 2006; Izquierdo-Useros et al., 2010; Hildreth, 
2017; Kulkarni and Prasad, 2017).  
Concerning Mtb infection, EVs produced from infected macrophages have been described to 
regulate the activity of uninfected macrophages and thereby promote immune evasion or 
other important host defence mechanisms. Various mycobacterial components have been 
reported to be incorporated into EVs such as lipoproteins, lipoglycans, LAM, LM, PIMs as well 
as antigens (Beatty et al., 2000; Athman et al., 2015; Lee et al., 2015; Gupta and Rodriguez, 
2018). These elements incorporated within EVs can contribute to the inhibition of the 
maturation of phagosomes (LAM) or influence macrophage antigen presentation (Singh et 
al., 2011; Kruh-Garcia, Wolfe and Dobos, 2015; Athman et al., 2017; Gupta and Rodriguez, 
2018; Li et al., 2018). However, they have also been described to activate immune responses 
(Bhatnagar et al., 2007; Giri and Schorey, 2008; Singh et al., 2012; Kruh-Garcia, Wolfe and 
Dobos, 2015; Athman et al., 2017; Gupta and Rodriguez, 2018). 
HIV-1 and Mtb have common target cells: namely MDM and DCs. In the context of co-
infection, the role of EVs on influencing HIV-1 infectivity is not well understood. The aim was 
to investigate whether secreted EVs from plasma of HIV-1/Mtb co-infected patients could 
alter the infection and/or replication capacity of either pathogen within the co-infected host. 
Under this perspective we aimed in this chapter to determine whether EVs could be 
successfully isolated form plasma material. Numerous methodologies are currently available 
using EVs properties such as size, density, ultracentrifugation (UC), microfiltration, gel 
filtration or based on interactions between the molecules exposed on EVs surface and 
microfluidic technologies (Théry et al., 2006; Baranyai et al., 2015; Lobb et al., 2015; Nordin 
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et al., 2015; Taylor and Shah, 2015; Hong et al., 2016; Konoshenko et al., 2018). We 
specifically focused on testing whether UC and gel filtration technologies could be used in 
isolating EVs from plasma.  
 
II. Results 
i. Optimisation of EVs isolation from plasma by centrifugation 
Isolation of EVs by differential centrifugation is a common and efficient method previously 
used and well described. The technique is based on utilising the differential density found 
between cells, cell debris, apoptotic bodies, aggregates of biopolymers and EVs that are 
separated with successive centrifugation steps using variant acceleration rates (Théry et al., 
2006; Baranyai et al., 2015; Lobb et al., 2015; Taylor and Shah, 2015; Konoshenko et al., 
2018). We tested two different protocols: one at small scale using 2ml of plasma diluted in 
PBS and a second technique using 20ml of diluted plasma.  
The isolation of EVs using the small scale protocol (2ml of diluted plasma) is represented in 
Figure 5.1 A. The plasma was first centrifuged for 5min to remove cell debris and apoptotic 
bodies. The supernatant from the first centrifugation was then centrifuge a second time to 
isolate the EVs present in the pellet, which was resuspended in PBS. The pellet (1) and the 
supernatant (2), collected from the second centrifugation, were then tested in the HIV-1 X4 
Raji-DC-SIGN trans-infection assay using TZM-bl cells as the reporter cell of infection (pseudo-
typed viral particle system) (Figure 5.1 B). Gradual dilutions of pellet and supernatant were 
tested and compared in the trans-infection assay with the results being compared to 
reference virus alone. We observed that the presence of pellet prior to virus capture by Raji-
DC-SIGN cells significantly decreased efficacy of DC-SIGN trans-infection by 50% (P value= 
0.004, Mann-Whitney test). For the pellet dilutions we observed a loss of the inhibitory effect 
through augmentation of dilutions. Pellet dilution 1/10 showed a trend towards decreasing 
the HIV-1 trans-infection by 20% and dilution 1/100 not showing any significant impact 
(down 10%). However, interestingly the higher dilution 1/1000 inhibited DC-SIGN capture-
transfer efficacy by 50% (P value= 0.0095, Mann-Whitney test) as seen with the non-diluted 
resuspended pellet.  
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Figure 5.1 : Isolation of EVs 
from Plasma by centrifugation 
A. Schematic representation of EVs 
isolated by centrifugation. B. 50μl of (1) 
pellet resuspended in PBS (non-diluted, 
1/10, 1/100 and 1/1000 dilution in 
PBS), (2) supernatant (non-diluted, 
1/10, 1/100 and 1/1000 dilution in PBS) 
from centrifugation, was pre-incubated 
for 30min with 0.5x106 of Raji-DC-SIGN. 
Then the cells were incubated 2h with 
12.5ng pSG3-LAI HIV-1 X4. After the 
capture the cells were washed and co-
cultured with TZM-bl cells. The 
luciferase activity was read after 48h. 
Trans-infection of the virus alone 
where Raji-DC-SIGN were pre-
incubated with PBS, was used as a 
reference. For the data shown, n=8 












































































This result suggests that components present in the pellet can interact with virus binding the 
DC-SIGN receptor on Raji-DC-SIGN cells thereby blocking HIV-1 X4 trans-infection. However, 
it cannot specifically be determined whether the effect is mediated via the isolated EVs from 
the plasma or pelleted proteins/molecules. The presence of supernatant (2), composed of 
contaminants from plasma, demonstrated an impact on the efficacy of DC-SIGN trans-
infection: non-diluted supernatant decreased the efficacy by 85% (P value= 0.004, Mann-
Whitney test). The effect observed was reduced with further dilution, where 1/10, 1/100 and 
1/1000 reduced infection by 25%, 20% and 30%, respectively. This result suggests that 
components present in the supernatant interfere with HIV-1 X4 DC-SIGN trans-infection as 
observed in Appendix 23 when plasma was pre-incubated with Raji-DC-SIGN cells prior to 
capture of virus. From this centrifugation technique, the isolation of EVs from plasma was 
not optimum and did not allow for isolation of EVs from plasma components interfering with 
HIV-1 DC-SIGN trans-infection. 
Secondly, we tested the isolation of EVs from a large volume of plasma (20ml). As described 
by Théry et al., 2006 and represented (Figure 5.2 A), diluted plasma was first centrifuged at 
10,000g for 30 min to eliminate cell debris, with the supernatant further centrifuged at 
100,000g for 2h. The EVs are present in the pellet but contaminant proteins are eliminated 
at this stage through a second UC step using the same conditions. After the second 
centrifugation the pellet was resuspended in PBS. We subsequently tested the influence of 
the supernatant from the first UC, the supernatant as well as the pellet from the second UC 
on influencing HIV-1 X4 trans-infection via Raji-DC-SIGN B. and iDCs C. Figure 5.2.  
It was observed that the supernatant (1) from the first UC step incubated prior to HIV-1 X4 
capture by Raji-DC-SIGN cells decreased trans-infection efficacy by 76% (P value= 0.0286, 
Mann-Whitney test) (Figure 5.2 B), indicating that plasma strongly inhibits HIV-1 trans-
infection. However, the pellet (2) and the supernatant (3) from the second UC step did not 
show any significant impact on HIV-1 X4 capture and transfer when they were present prior 
to virus capture. Indeed, in the presence of pellet resuspended in PBS, the efficacy of trans-
infection via DC-SIGN was inhibited by only 12% thereby having no obvious effect on 
modulating HIV-1 trans-infection.  
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Figure 5.2 : Isolation of EVs from 
Plasma by ultra-centrifugation 
A. Schematic representation of EVs isolation 
by ultra-centrifugation. B. Two plasma donors 
have been utilised. 50μl of (1) supernatant 
from the first centrifugation, (2) pellet or (3) 
supernatant from the second centrifugation 
step, was pre-incubated 30min with 0.5x106 of 
Raji-DC-SIGN cells. Then the cells were 
incubated 2h with 12.5ng pSG3-LAI HIV-1 X4. 
After capture the cells were washed and co-
cultured with TZM-bl cells. The luciferase 
activity was read after 48h. Trans-infection of 
the virus alone where Raji-DC-SIGN were pre-
incubated with PBS, used here as reference 
(n=4) C. 50μl of (1) supernatant from the first 
centrifugation, (2) pellet or (3) supernatant 
from the second centrifugation step, was pre-
incubated 30min with 0.5x106 of iDCs isolated 
either from the same plasma (homologous) or 
from a different plasma donor (heterologous). 
The cells then were incubated 2h with 12.5ng 
pSG3-LAI HIV-1 X4, and after the capture, were 
washed and co-cultured with TZM-bl cells. The 
luciferase activity was read after 48h. Trans-
infection of the virus alone where iDCs were 
pre-incubated with PBS, was used as reference 















































































It was next tested whether there was any influence on HIV-1 X4 trans-infection via iDC rather 
than the Raji-DC-SIGN cell line (Figure 5.2 C), in this case the plasma was from either the same 
iDCs donor (homologous), or from a different donor (heterologous). As observed for Raji-DC-
SIGN trans-infection, the presence of the supernatant (1) from the first centrifugation 
containing most of the contaminants from plasma, demonstrated a trend towards decreasing 
capture-transfer to TZM-bl to 65% for homologous and 28% for heterologous cells. 
Interestingly, the pellet (2) containing the EVs from the second UC step, showed a trend 
towards enhancing HIV-1 X4 trans-infection by 50% for both conditions. This result suggests 
that EVs from plasma could impact on HIV-1 trans-infection via iDCs. The supernatant (3) 
with less amounts of plasma contaminants from the second UC did not show any significant 
impact on virus capture-transfer where iDCs were from the same donor (1.05 relative 
efficacy), but where the EVs were from a different donor than the iDCs, the supernatant 
demonstrated an increase of 30% to trans-infection.  
Compared to the initial technique of centrifugation, the second method, using higher 
amounts of plasma and UC speed, seemed to be more efficient at isolating EVs from plasma, 
and eliminated most of the contaminants that could impact on HIV-1 trans-infection. 
However, from the second technique the presence of EVs needs to be confirmed by further 
analyses through Western Blot and electronic microscopy analyses. The aim is to ultimately 
isolate EVs from plasma of patient infected with HIV-1 and/or Mtb. These samples need to 
be treated and processed within CL3 facilities. In order to eliminate the need of an ultra-
centrifuge in CL3 facilities, the aim was to find an alternative and rapid technique for isolating 
EVs, such as through gel filtration.  
 
ii. Optimisation of EVs isolation by Gel Filtration (SEC) form plasma 
Gel filtration enables the separation of molecules regarding the component’s size, not 
molecular weight (hydrodynamic radius). The SEC is composed of a matrix containing 
heteroporous beads in a cross-linked polymeric support packed into a column forming pores 
and tunnels. The separation of macromolecules occurs by differential exclusion or inclusion 
of the macromolecules as they pass through the column (Taylor and Shah, 2015; Konoshenko 
et al., 2018). We tested two different methods of EVs isolation by gel filtration. The first one 
is a technique of gel filtration paired with a concentration step using Sephadex G-25 as matrix 
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for gel filtration (Figure 5.3). The second is a technique using a different matrix for the 
filtration, sepharose CL-2B previously described by Böing et al., 2014 (Figure 5.4). 
A scheme of the isolation protocol by gel filtration associated with the concentration step is 
depicted (Figure 5.3 A), where the following protocol was used: after a pre-centrifugation of 
the plasma to remove cells debris the supernatant was then passed through a Sephadex G-
25 column. The filtrate obtained from the SEC containing EVs is then additionally 
concentrated using an Amicon 30KDa filter. Sephadex G-25 is a cross-linking dextan matrix 
with epichlorohydrin used to allow the separation of small peptides and proteins of 1-5KDa 
in size. It was used here to eliminate contaminants contained within the plasma. The volume 
of eluate was then concentrated and EVs were then isolated from the remaining proteins. 
The impact of the concentrate (1) and filtrate (2) (from filtration with Amicon 30KDa) on HIV-
1 X4 DC-SIGN specific trans-infection was determined (Figure 5.3 B). The concentrate and the 
filtrate were pre-incubated with Raji-DC-SIGN cells prior to virus capture, where different 
dilutions of concentrate and filtrate were tested and the efficacy of HIV-1 X4 trans-infection 
determined, and where virus alone was used as the reference. 
We observed that the presence of concentrate (1), prior to HIV-1 X4 capture by Raji-DC-SIGN 
cells, was associated with a total inhibition of DC-SIGN trans-infection. This effect was shown 
to be dilution dependent: for 1/10 dilution, the relative trans-infection efficacy was 0.5 and 
for the 1/100 dilution was shown to be 0.82 (Figure 5.3 B(1)). This result suggests that 
elements of the concentrate, where the EVs are expected, can interact with Raji-DC-SIGN, 
inhibiting HIV-1 X4 trans-infection. However, the presence of filtrate (2) on HIV-1 X4 Raji-DC-
SIGN mediated trans-infection was also associated of a decrease of capture-transfer with the 
effect again being lost through dilution. Non-diluted filtrate demonstrated a trend towards 
decreasing trans-infection efficacy by 60% but with 1/10 and 1/100 dilutions, the efficacy 
was partially restored to 0.80. The filter is composed of protein contaminants from the 
plasma that appeared to interfere with HIV-1 DC-SIGN trans-infection (as supported by 
Appendix 23). However, regarding its impact in HIV-1 trans-infection via Raji-DC-SIGN, some 
contaminants and components from plasma were still present on the EVs isolation 
concentrate affecting virus capture. From these observations we conclude that this protocol 
did not allow for optimum separation and isolation of EVs from plasma.
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Figure 5.3 : Isolation of EVs from plasma 
by Gel Filtration and concentration 
A. Schematic representation of EVs isolation by gel 
filtration and concentration. B. 50μl of (1) 
concentrate (non-diluted, 1/10 and 1/100 dilution 
in PBS), (2) filtrate (non-diluted, 1/10 and 1/100 
dilution in PBS) from gel filtration, was pre-
incubated 30min with 0.5x106 of Raji-DC-SIGN cells. 
The cells were incubated 2h with 12.5ng pSG3-LAI 
HIV-1 X4. After capture the cells were washed and 
co-cultured with TZM-bl cells. The luciferase 
activity was read after 48h. Trans-infection of virus 
alone where Raji-DC-SIGN were pre-incubated with 
PBS was used here as a reference. For the data 































































Figure 5.4 : Isolation of EVs from Plasma by SEC 
A. Schematic representation of EVs isolation by SEC.  B. Protein concentration (µg/ml) was measured in each fraction (Bradford assasy). The percentage of particles present within fractions was 
determined by NanoSight and related to the total number of particles passed through the column. C. The mean size (nm) of particles present in each fractions and the concentration of particles 
were determinate by NanoSight. The data shown are representative of two experiments using plasma isolated from one donor. 
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The Sephadex G-25 matrix was switched to a sepharose CL-2B matrix as previously reported 
(Böing et al., 2014; Muller et al., 2014; Baranyai et al., 2015; Hong et al., 2016; Konoshenko 
et al., 2018). This matrix is composed of cross-linked beads of agarose which is routinely used 
for isolation of DNA-protein complexes or virus isolation with a range of 70 - 40,000KDa. 
Plasma (15ml) was first pre-centrifuged at 10,000g for 30min to eliminate the cell debris, 
after which 2ml of supernatant was used as input on the CL-2B column and 26 fractions of 
500µl were collected as described Böing et al., 2014 (Figure 5.4 A).  
To identify fractions where EVs were located and evaluate protein contaminations, protein 
and particle concentrations were analysed within the different fractions. Protein 
concentration was determined utilising the Bradford assay allowing for quantification of all 
proteins, and NanoSight analysis performed to visualise the EVs particles and identify their 
concentration and size. The concentration of proteins (grey) in µg/ml with regard to 
percentage of particles related to the total number of particles (yellow) is shown for each 26 
fractions (Figure 5.4 B). We observed that elution of particles occurred early (from fraction 7 
to 23). The elution of proteins happened later in the elution series from fraction 9. High 
concentrations (superiors to 2500 µg/ml), were observed from fractions 14 to 23. From these 
observations we identified that the higher proportion of particles with the least protein 
contamination being found in fractions 9 to 13. The particle sizes being isolated were found 
to be homogenous and ranged between 50 and 240nm in size. Also, Fractions 10, 11, 12 and 
13 were identified to have the highest particle concentrations, ranging between 1 and 
1.25x1011 particles per ml (Figure 5.4 C). 
 
iii. Characterisation of EVs isolated by Gel Filtration 
To characterise and control EVs isolation from SEC, Western Blot analysis was undertaken. 
This technique allows for the visualisation of EVs protein from various cells of origin. TSG-101 
and CD63 are exosome markers both described to be highly enriched in EVs (Théry et al., 
2006; Böing et al., 2014; Muller et al., 2014; Baranyai et al., 2015; Lobb et al., 2015; Sampey 
et al., 2015; Hong et al., 2016; Konoshenko et al., 2018). We visualised these markers through 
immunoblotting of the 26 fractions from SEC and where two different protocols were tested 
(Figure 5.5). 
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For Protocol 1, fractions 1-7 and 8-13 were pooled and concentrated using Amicon 3KDa 
filters (higher proportions of EVs expected in pool 8-13 as explain above). The samples were 
then denatured (in reduction conditions) and equalised for protein concentration by SDS-
PAGE electrophoresis, transferred to PVDF membrane and visualised by Ponceau red staining 
(Figure 5.5 A(1)). We observed for Protocol 1, homogenous bands for each fraction, 
validating sample input and conditions of the electrophoresis and transfer. For pooled 
fractions 1-7, containing very low concentrations of EVs we did not visualise proteins. From 
TGS-101 immuno-blotting we observed a homogenous protein band profile for each fraction 
indicating unspecific binding of TSG-101 antibodies and no bands at 44KDa where TSG-101 
was expected (Figure 5.5 B(1)). From this observation it can be concluded that the Protocol 
1 immuno-blotting was not optimum to allow visualisation of TSG-101 from EVs. 
In protocol 2 (2) samples from SEC isolation were prepared either in reducing (R) or non-
reducing (NR) conditions. For Western Blot analysis samples were generally reduced in the 
presence of β-mercaptoethanol or dithiothreitol to disrupt peptide interactions. However, in 
some cases antibodies can’t recognise the protein in the reduced form, which is the case for 
CD63 (Théry et al., 2006), tested in this protocol. For this reason both R and NR conditions 
were tested. The SDS-PAGE and transfer were performed similar to Protocol 1. From Ponceau 
red staining of PVDF membrane it was observed that NR disrupted protein migrations 
compared to R condition (Figure 5.5 A(2)). Indeed, in NR condition protein migration was less 
linear than under R conditions. In Protocol 2, we tested visualisation of CD63 markers by 
immune-blotting (Figure 5.5 B(2)). Unfortunately, as for TSG-101, non-specific binding of the 
antibodies to protein was observed. As for Protocol 1, Protocol 2 needs to be optimised to 
allow visualisation of CD63 from EVs. 
We were not able to control and visualise specifically the presence of EVs through SEC 
isolation by Western-blot analysis for detecting TSG-101 or CD63. However, from the 
NanoSight analysis and according to Böing et al., 2014, we assumed that our final product of 




Figure 5.5 : Characterisation of EVs from plasma by Western Blot 
A. Presence of proteins were shown on each Fractions by Ponceau red staining after SDS-PAGE with 13µg (20µl) per well. (1) Protocol 1, all samples were prepared in reduction condition and 
the electrophoresis performed at 100V for 1h30. (2) Protocol 2, the samples were prepared in non-reduction (NR) and reduction (R) conditions and the electrophoresis at 170V for 50min. B. (1) 
Protocol 1, detection of TSG-101 (arrow at 44kDa) and (2) Protocol 2, CD63 (arrow at 50-60kDa) were tested by immunoblotting. The data shown are representative of one experiment using 
plasma isolated from one donor. 
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iv. Influence of EVs from plasma on HIV-1 infection 
EVs isolated from plasma by SEC gel filtration were analysed in HIV-1 infection assays. As 
described above, fractions 9 to 13 were identified as fractions containing EVs. For this reason, 
the fractions were pooled and tested in HIV-1 cis- A. and trans-infection B. assays utilising 
the pseudo-typed HIV-1 viral particle system (Figure 5.6). 
 
Figure 5.6 : Influence of EVs isolated from plasma on HIV-1 infections 
A. One day prior to infection, 3x104 TZM-bl cells per well were seeded in 96-well plates. After 24h, TZM-bl cells 
were infected with 8ng of pSG3-LAI (HIV-1 X4) and pSG3-BAL (HIV-1 R5) with 50µl of EVs isolated from plasma by 
SEC (pool fractions 9-13). In one case, EVs were incubated at the same time as virus and in the second case TZM-
bl cells were pre-incubated for 30min prior to infection. 48h following infection cells were lysed to measure 
luciferase activity (RLU). Cis-infection of the virus alone is used as reference (n=3). B. 50µl of EVs isolated from 
plasma by SEC (pool fractions 9-13) 0.5x106 of Raji-DC-SIGN cells. Cells were incubated 2h with 12.5ng pSG3-LAI 
(HIV-1 X4, black) or 25ng pSG3-BAL (HIV-1 R5, purple). After capture the cells were washed and co-cultured with 
TZM-bl cells. The luciferase activity was read after 48h. Trans-infection of virus alone with Raji-DC-SIGN that were 
pre-incubated with PBS, was used as the reference infection (n=3). The data shown are from one experiment 
using plasma isolated from one donor. 
For the HIV-1 cis-infection assay, isolated EVs were either added at the same time as virus to 
target cells (TZM-bl) or were pre-incubated for 30min with cells before virus was added. Cis-
infection with HIV-1 alone was used as the negative control and as the reference for this 
assay. When EVs were added at the same time as HIV-1 X4 to the target cells, we observed 
that the efficacy of cis-infection increased to 1.2. However, when TZM-bl cells were pre-
incubated with EVs, cis-infection decreased to 0.8 efficacy compared to HIV-1 X4 alone. For 
HIV-1 R5 the opposite was observed where EVs added at the same time as virus decreased 































































increase compared to virus alone. From these observations, the impact of EVs isolated from 
plasma from healthy donors on HIV-1 cis-infection was different when comparing both virus 
phenotypes; however, these results did not reach statistical significance (Mann-Whitney 
test). 
Concerning HIV-1 DC-SIGN mediated trans-infection EVs were incubated 30min with Raji-DC-
SIGN cells prior virus capture (Figure 5.6 B). For both viruses, we observed that the presence 
of EVs from SEC demonstrated a trend towards decreasing DC-SIGN trans-infection efficacy 
to 0.8 for HIV-1 X4 and to 0.6 for HIV-1 R5 virus. This suggests that EVs isolated from plasma 
could reduce HIV-1 DC-SIGN mediated trans-infection, but again as for cis-infection, did not 
reach statistical significance (Mann-Whitney).  
 
III. Conclusion  
Multiple approaches are available to isolate EVs from biological fluids. In this Chapter the 
focus was to analyse two major methods, UC and gel filtration, to study the effects of EVs 
isolated from plasma on modulating HIV-1 infection.  
We demonstrated that the elimination of contaminants from plasma is crucial to study the 
possible impact of EVs on HIV-1 trans-infection (Figure 5.1 and 5.2). Simple centrifugation of 
diluted plasma at 7,000g for 90min, did not allow for the separation of EVs from 
contaminating protein according to (Taylor and Shah, 2015; Konoshenko et al., 2018). 
Indeed, our samples containing EVs (pellet resuspended in PBS) partially inhibited HIV-1 X4 
DC-SIGN mediated trans-infection, as did the supernatant. In order to study the specific 
impact on HIV-1 infection it is crucial to purify EVs from the contaminants. The UC protocol 
described by Théry et al., 2006 is a standard technique allowing for working with large 
volumes. Due to practical application (few consumables and reagents needed) many 
laboratories choose to use this method (Konoshenko et al., 2018). Here it was shown that 
EVs isolated from healthy donors plasma by UC did not significantly affect HIV-1 X4 trans-
infection mediated via DC-SIGN or iDCs. This result suggests that most of the contaminants 
from plasma were eliminated through the differential centrifugation steps as expected. 
However, the UC technique doesn’t allow for optimum purification of EVs from contaminants 
found within plasma such as albumin (Baranyai et al., 2015) and represents a long process 
that potentially damages the integrity of EVs (Lobb et al., 2015).  
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To isolate and purify EVs from HIV-1/Mtb+ patients using UC may well prove problematic due 
to the equipment range in CL3 facilities. Additionally, isolation of EVs from HIV-1 virions in 
HIV+ samples requires particular purification strategies due to a similar size and density of 
both types of particles, again providing a limitation to using this approach (Cantin et al., 2008; 
Madison and Okeoma, 2015; Cheruiyot et al., 2018). An iodixanol (Optiprep) gradient can be 
used but this approach again requires UC steps (Cheruiyot et al., 2018).  
The second method analysed involved the isolation of EVs by gel filtration. Two different 
types of matrix that separate EVs from plasma based on differential hydrodynamic radius of 
macromolecules were tested. Because of the high hydrodynamic radius of EVs compared to 
proteins, lipoproteins or protein complexes, purification from these elements is relatively 
simple (Taylor and Shah, 2015; Konoshenko et al., 2018). We demonstrated that the column 
Sephadex G-25 did not allow for optimum purification of EVs from plasma (Figure 5.3). 
Indeed, the eluate containing EVs, which has been concentrated in an additional step, was 
shown to inhibit HIV-1 X4 DC-SIGN trans-infection. This result suggests that contaminating 
elements from plasma are still present in the eluate blocking viral capture-transfer. As 
Sephadex G-25 allowed separation of 1-5KDa range of proteins, the EVs were expected to be 
eluted at the early stages of the chromatography. However, collection of too large volumes 
during the assay could explain the presence of contaminants in the eluate. The elution of 
volume being too big could lead to the collection of the same molecules (eluting at early and 
late stages of the chromatography) in the same fraction and not allowing for efficient 
separation. Due to descriptions in the literature, it was decided to study another matrix, 
Sepharose CL-2B (Baranyai et al., 2015; Hong et al., 2016; Konoshenko et al., 2018), and 
follow the published protocol Böing et al., 2014. As described the fractions obtained by CL-
2B SEC were analysed using NanoSight technology and the protein concentration assay. 
Similar observations were made to Bïong et al., where particles with less protein 
contaminations were present in the pooled fraction 9 to 13. Sepharose CL-2B SEC is a 
relatively easy and rapid means of generating EVs from plasma (Figure 5.4).  
To control for EV isolation and purification from SEC, Western Blot analyses of all the 
generated fractions was performed (Figure 5.5). Two EV specific markers, TGS-101 and CD63 
were tested for being present in each fraction. Unfortunately, immunoblotting for either 
marker was inconclusive. Indeed we were not able to visualise specifically TSG-101 (44KDa) 
nor CD63 (50-60KDa) being present in EV fractions. For this assay antibodies were used as 
recommended by the manufacturer and as described in the literature (Baranyai et al., 2015; 
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Lobb et al., 2015). Optimisation of antibody concentrations to be utilised may be required 
and should be tested using cell lysates to control for sensitivity and specificity as these 
markers are present on cell membranes. Furthermore, other antibodies should be tested 
against other EV specific markers such as CD9 described to be present at high proportion in 
EVs (Théry et al., 2006). The characterisation of isolated EVs by Western Blot analysis is 
essential to confirm their presence and could be used to control for their purity. Additionally, 
in the perspective of working in HIV-1/Mtb+ patients, Western Blot analysis would represent 
a good method to characterise specific protein cargoes from HIV-1 and/or Mtb integrated to 
EVs.  
NanoSight analysis did show isolation of particles as observed in Böing et al., 2014, suggesting 
EVs were isolated as previously described. The impact of EVs isolated from plasma on HIV-1 
cis- as well as trans-infection was tested (Figure 5.7). The results suggested that EVs isolated 
using CL-2B SEC did not significantly impact on HIV-1 X4 or R5 cis-infection nor trans-infection 
via DC-SIGN or iDCs.  
The role EVs in infectious diseases and in modulating immunity is important. In the case of 
HIV-1 infection, multiple studies have described the ability of virus to use the exosomal 
pathway for cell infection and propagation. The convergence of HIV-1 replication and 
exosome biogenesis leads to the incorporation of viral proteins such as Nef, Env and Gag, or 
HIV-1 nucleic acids and microRNA into EVs (Kadiu et al., 2012; Arenaccio, Chiozzini, Columba-
Cabezas, Manfredi, Affabris, et al., 2014; Madison and Okeoma, 2015; Hildreth, 2017). The 
similarities in biogenesis of exosomes and HIV-1 guides the Trojan exosomes hypothesis 
which suggests that virus uses exosome biogenesis to allow formation of infectious virions 
that don’t require Env for cell entry (Gould, Booth and Hildreth, 2003; Madison and Okeoma, 
2015). Furthermore, EVs produced from infected cells allowing for transfer of viral proteins 
could facilitate HIV-1 infection, such as the transfer of Nef between cells (Madison and 
Okeoma, 2015). As with HIV-1, many studies have described the fundamental role of EVs in 
influencing Mtb infections. Mycobacterial components can be detected in EVs which have 
the potential to modulate the immune response by regulating uninfected macrophage 
responses (Beatty et al., 2000; Athman et al., 2015; Lee et al., 2015; Gupta and Rodriguez, 
2018). In the context of co-infection, the role of EVs has not been described. It could be 
expected that EVs isolated from HIV-1/Mtb+ co-infected individuals could contain 
components from HIV-1 and/or Mtb and could therefore modulate either pathogens 
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infectivity and or replication cycle. The results presented here provide some indicators of 
how EVs can be isolated from plasma of such patients.  
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General conclusion and discussion 
HIV-1 and Mycobacterium (Mtb) co-infection represents a serious diagnostic and therapeutic 
challenge, particularly in resource-limited settings. However, knowledge regarding the 
mechanisms of interactions between the two pathogens still needs to be characterised in 
order to develop preventive measures and treatment strategies against the two diseases 
separately or within a co-infection scenario. Limitations exist in access to effective drug 
therapies and the emergence of resistance. Improvements in drug access and simplified 
treatment regimens are urgently required (Anandaiah et al., 2011; Kwan and Ernst, 2011). 
 
I. Liposomes Technology 
In order to describe and better understand the implication of Mtb glycolipids in HIV-1 
infection in the context of co-infection, liposomes generated from various Mtb strains 
containing total lipids were developed. The artificial vesicle technology is largely established 
and used in pharmacology and in various vaccination strategies (Akbarzadeh et al., 2013). 
The interest of using liposomes here is that the generation of liposomes allows a 
reorganisation of Mtb components close to the original mycobacteria cell wall. Additionally, 
proportions of individual glycolipids are representative and the use of soluble lipids solution 
is avoided. We demonstrated that generated liposomes are composed of Mtb specific 
glycolipid components. 
 
II. Modulation of the immune response by Mtb glycolipids 
We first described the influence of Mtb glycolipids on altering MDM, DC and CD4+ T cell 
responses. In the in vitro systems developed, we observed a strong heterogeneity of Mtb 
liposome effects on modulating immune cells and this was found to be dependent on the cell 
types and Mtb strain of origin. Mtb component glycolipids, glycerol mono-mycolate, TDM, 
PIM, LAM and LM were previously known to modulate immune responses through 
engagements of PRRs pathways (Barnes et al., 1992; Quesniaux et al., 2004; Banaiee et al., 
2006; Andersen et al., 2009). Differences in the proportion and composition of those lipids 
could modulate differentially immune responses from MDM and DC.   
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Mazurek et al. revealed the importance of ManLAM and PIMs in maturation of DCs during 
Mtb infection. Purified ManLAM from the H37Rv Mtb pathogenic strain induce stronger 
responses from iDCs compared to ManLAM isolated from BCG (M. bovis strain used for Mtb 
vaccination) (Mazurek et al., 2012). In our system, we observed variant responses in iDC 
maturation in the presence of H37Rv and BCG glycolipids, supporting Mazurek’s 
observations. This differential impact of ManLAM from H37Rv compared to BCG, could be 
explained by the differential structure of ManLAM (Torrelles et al., 2008). The glycerol mono-
mycolate from the mycobacteria cell wall have been described to activate DCs (Andersen et 
al., 2009). Mazurek et al. revealed also that compared to ManLAM, soluble PIM can induce 
lower responses from iDCs (Mazurek et al., 2012). However, some Mtb components can 
inhibit inflammatory responses, as found for glycolipids isolated from the HN878 Mtb strain 
that showed the capacity to strongly inhibit inflammatory responses from MDM (Reed et al., 
2004). Variations in the proportion of glycolipids being incorporated into liposomes could 
explain for the differences observed in MDM and DC induced responses. However, various 
studies support that ManLAM can indeed inhibit pro-inflammatory responses within DCs. 
Geijtenbeek et al. showed in 2003 that soluble Mtb ManLAM was not able to induce 
maturation of iDCs in their assays (Geijtenbeek et al., 2003). Differences in ManLAM 
structure could explain the divergent impact of ManLAM on MDM and DC activation (Nigou 
et al., 1997; Briken et al., 2004; Pitarque et al., 2005). Interestingly, co-cultures of iDCs with 
CD4+ T cells in the presence of Mtb glycolipids, revealed a global down-regulation of pro-
inflammatory responses. These observations are in correlation with the capacity of Mtb 
components to inhibit pro-inflammatory responses as mentioned above. The inhibition of 
immune responses observed from DCs and CD4+ T cell co-culture, could be explained by the 
impairment of DC antigen presentation to T cells by alteration of CD1b, DC-SIGN and MR 
(Balboa et al., 2010). PIM is associated with altering anti-inflammatory properties by 
inhibiting TLR activation (Doz et al., 2009), such as observed with a 19kDa lipoprotein (Pai et 
al., 2004). By the interaction with DC-SIGN receptor, PIM and ManLAM have been identified 
to impair DC maturation. However, the Mtb mutant lacking both glycolipids demonstrated 
that ManLAM and PIM interaction with DC-SIGN was not crucial for cytokine secretion in vitro 
and for immune protection in vivo. This suggests that other receptors such as MR could be 
involved in the anti-inflammatory responses as well as other Mtb components reviewed in 
(Ehlers, 2010). 
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III. Modulation of HIV-1 infection by Mtb glycolipids 
Variations in glycolipid composition and proportions, depending on the Mtb strains, induce 
differential immune responses from MDM, DC and CD4+ T cells in our in vitro culture systems. 
The influence of Mtb glycolipids were subsequently tested in the context of co-infection with 
HIV-1 X4 or R5 strains. In the three assays developed, we observed strong variations in Mtb 
glycolipid impact on HIV-1 infections depending on virus tropism and the culture system 
being tested. We aimed to identify whether Mtb components could directly affect HIV-1 cis-
infection or trans-infection. From all the analyses, it can be concluded that Mtb glycolipids 
mainly regulate HIV-1 infection by modulation of the immune response induced from the 
infected cells. Indeed, in each case, the introduction of Mtb glycolipids to the culture systems 
infected with HIV-1 induced modifications to cytokine production compared to infected cells 
alone. DCs appeared to play a major role in this modulation of induced cytokine/chemokine 
responses. As explained above, Mtb glycolipids can modulate pro- or anti-inflammatory 
responses from DCs by interactions with PRRs such as DC-SIGN. Analyses of HIV-1 trans-
infection, mediated via DC-SIGN, indicated that Mtb glycolipids from BCG, H37Rv or EU127 
can interact with DC-SIGN and block viral capture and transfer. Additionally, we identified 
SL1 and TDM as potent antigens able to block DC-SIGN receptor mediated HIV-1 trans-
infection. However, the role of DC-SIGN engagement by Mtb glycolipids in modulation of pro- 
or anti-inflammatory response from DCs remains unclear (Ehlers, 2010). Singh et al., 
described that co-infection of DCs significantly reduced IFN-γ revealing impairment in antigen 
presentation (Singh et al., 2016). In our co-culture assay, we observed a decrease in 
production of IFN-γ in HIV-1 R5 infections in the presence of Mtb glycolipids, suggesting that 
perturbation of DC antigen presentation occurred decreasing pro-inflammatory responses 
and HIV-1 R5 replication. However, Van Kooyk and Geijtenbeek described that an impairment 
in DC function by Mtb components could benefit virus replication by decreasing 
internalisation of the DC-SIGN receptor, leading to the enhancement of HIV-1 transmission 
via trans-infection (Van Kooyk, Appelmelk and Geijtenbeek, 2003), but the assays on HIV-1 
trans-infection in CD4+ T cell co-cultures mediated by iDCs did not reveal a major impact of 
Mtb glycolipids on HIV-1 replication.  
With HIV-1 X4 infections we observed a global activation of the pro-inflammatory response 
from CD4+ T cells and DCs, indicating that other mechanisms are involved in the inhibition of 
HIV-1 X4 virus replication. Nieto-Garai et al., recently revealed how lipidomimetic 
compounds can alter HIV-1 fusion during viral entry (Nieto-Garai et al., 2018). We could 
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hypothesise that Mtb glycolipids associated into liposomes could affect viral entry, however, 
our assays using pseudo-typed HIV-1 particles indicate that Mtb glycolipids do not interfere 
with HIV-1 cis-infection.  
The up-regulation of the pro-inflammatory responses by Mtb glycolipids can result in 
enhancement of LTR transactivation (Bafica et al., 2003; Equils et al., 2003; Rodriguez et al., 
2013). This suggests that in co-culture assays, the up-regulation in pro-inflammatory 
responses induced by H37Rv and CDC1551 glycolipids is sufficient to promote and enhance 
replication of HIV-1 X4 strains. This was also observed for HN878 and CDC1551 glycolipids 
when monitoring HIV-1 R5 replication.  
The difference of Mtb glycolipid impact between HIV-1 X4 and R5 tropism is intriguing and 
has major consequences for better understanding virus replication during disease. Our 
results suggest that Mtb glycolipids can differentially modulate immune activation, 
dependent on the Mtb strain and can also modulate HIV-1 replication differentially based on 
co-receptor usage. The findings that Mtb HN878 and CDC1551 up-regulate HIV-1 R5 
replication could have a serious impact during primary infection, where viruses exclusively 
utilise the CCR5 co-receptor, whereas Mtb H37Rv could have more of a detrimental effect on 
enhancing HIV-1 infection during the chronic stage of infection in individuals where X4 
viruses have emerged.   
 
IV. Future perspectives 
To identify and characterise precisely the modulation of Mtb components on the skewing of 
immune responses and HIV-1 infection a number of complementary research approaches 
need to be taken. First, the affect of liposome composition would need to be characterised 
further as some liposomes generated with only PC and cholesterol demonstrated T cell 
toxicity properties. Additionally, Mtb glycolipids should be integrated into liposomes 
separately, such as LAM, LAM, or PIM, in order to characterise their impact on altering 
immune responses and influencing HIV-1 replication individually. Additionally, HPLC analyses 
needs to be performed in order to better quantify and control Mtb glycolipid associations in 
liposomes. Concerning analyses of Mtb components on the immune response, assays should 
be performed using whole PBMC in vitro cultures to characterize sub-population effect and 
interactions between cells and in the context of HIV-1 infection or not. Transformed cell lines 
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expressing specific molecules of signalling pathways, such as TLRs, NF-κB should be tested to 
identify mechanisms involved in the induction of cellular responses and HIV-1 replication. To 
understand better the importance of DC responses induced by Mtb glycolipids on HIV-1 
replication and the involvement of DC-SIGN receptor, in vitro HIV-1 infection could be 
developed using naïve T cells co-cultured with iDCs or mDCs as well as iDCs incubated with 
Mtb glycolipids. The involvement of the DC-SIGN receptor should be then investigated by 
using antagonists of DC-SIGN, thereby blocking its usage by HIV-1 or engagement with Mtb 
glycolipid antigen. To confirm the observations that Mtb glycolipids do not have any impact 
on viral entry, in vitro tests could be developed using HIV-1 replicative system in the absence 
or presence of HIV-1 specific entry inhibitors. This analysis could be complementary to in vivo 
studies using transgenic mice models used to study HIV-1 and/or TB infection.  
Understanding of the role that EVs can play in modulating HIV-1 infection during co-infection 
with Mtb is important. EVs have been shown to influence diseases through modulating 
immune responses. In HIV-1 infection production of EVs are believed to associate with 
production of infectious viral particles that do not require Env for cell entry (Hildreth, 2017). 
However, the implication of EVs in the context of Mtb co-infection has not been described 
and could be involved more so in the modulation of the immune responses being induced by 
both pathogens in the context of co-infection.  
The work presented here demonstrates that variant Mtb glycolipids antigens can 
differentially modulate HIV-1 infection. The characterisation of the Mtb components 
involved in this modulation represents a key point in better understanding the interactions 
between HIV-1 and Mtb and the role such interactions can have on influencing disease. 
Further elucidation of these pathogen interactions will undoubtedly lead to the design of 
new approaches and development of products aimed at limiting the detrimental effects 








Appendix 1 : Steps of HIV-1 cycle 
Adapted from (Maartens, Celum and Lewin, 2014) 
First, virus attachment to target cells is initiated by binding to the CD4 receptor and co-receptor CCR5 and/or 
CXCR4. The fusion of the viral and cell membranes allows the entry of the capsid into the cells. The viral RNA 
genome is then reverse-transcribed into DNA in the cytoplasm and translocated to the nucleus for integration. 
The proviral DNA is then transcribed and subsequently translated to express the viral proteins required for 
production of immature virions containing two copies of viral genome. After budding of new virions, maturation 
occurs, allowing for the production of mature viral particles capable of infecting new cells. Antiretroviral therapy 
target specific phase of the viral life-cycle: viral entry with chemokine receptor antagonist (Maraviroc for CCR5) 
and fusion inhibitors FIs (Enfuvirtide); reverse transcription with nucleotide and non-nucleotide reverse 
transcription inhibitors NRTIs and NNRTIs; integration with integrase strand transfer inhibitors INSTIs and viral 




Appendix 2 : HIV reverse transcription 
Adapted from (Modrow et al., 2013) 
RNA reverse transcription is initiated with binding of transfer RNA (tARN) on the primer binding site PB at the 5’ 
end of the genome. RT allows for the generation of a minus stranded DNA molecule and degrades the 
complementary RNA by its RNase H activity. The DNA-tRNA hybrid subsequently produced is then transferred to 
the 3’ end of the genome and used as a primer for the synthesis of the first DNA strand.  
 169 
 
Appendix 2 continued 
Adapted from (Modrow et al., 2013) 
The ssRNA molecule is degraded by RT, except the PP site that serves for priming synthesis the second DNA strand. 
After degradation of the tRNA, hybridisation at the PB site occurs and for elongation of the second DNA strand 




Appendix 3 : HIV particle assembly, budding and maturation 
Adapted from (Freed, 2015) 
The Env polyproteins are transported from the rough endoplasmic reticulum RER to lipid rafts within the cellular 
membrane via the typical secretory pathways. Gag and Gag-Pol precursors generate viral proteins involved in 
particle assembly. Gag precursors contain MA, CA, NC and p6 domains. Gag recruits the viral genomic RNA (by 
the NC domain) to migrate and multimerise (by the CA domain) at the plasma membrane under the same rafts. 
After incorporation of Env (by the MA domain), the endosomal sorting complex, required for transport (ESCRT-I), 
is recruited via the p6 domain catalysing membrane fission and completing the budding process. Additionally, the 
p6 protein of Gag additionally allows for recruitment of Vpr, Vif and Nef to associate with viral particles before 
budding. The particles released are immature until the protease p11 cleaves Gag and Gag-Pol into the appropriate 
structural proteins. Once maturation is complete the new viral particles are fully infectious and ready to start a 




Appendix 4 : HIV-1 mucosal transmission 
Adapted from (Margolis and Shattock, 2006) 
a. Trapping and inactivation of X4 viruses by mucin and innate antiviral proteins. b. Transcytosis of viruses 
(preferentially R5 viruses). c. Infection of Langerhans cells expressing CCR5 co-receptor preferentially. d. R5 
viruses might demonstrate preferential tropism for memory CD4+ T cells. e. Infection of macrophages by R5 
viruses f. Recognition of virus particles by DCs and migration of the cells to the lymph nodes. g. Presentation of 
viruses to naïve CD4+ T lymphocytes and initiation of the cytotoxic response. h. HIV replication in the lymph node 
and cytotoxic response. 
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Appendix 5 : Signal transduction pathway activated by Mtb components 
Adapted from (Falvo et al., 2011) 
Generalised intracellular cascades after engagement of Toll-like receptors (TLRs), C-type lectins, and NOD2 by the 
indicated ligands derived from Mtb in macrophages and DCs. Receptors are in green; adapter proteins and 
upstream kinases are in blue; downstream kinases are in orange; and transcription factors are in red. HIV-1 LTR 
and activated cytokines are indicated at the bottom. Translocation of TLR4 into the endosome after ligand 





Appendix 6 : Flow Cytometry of iDCs in presence of Mycobacterium liposomes: CD86/CD40 
markers 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with CD-86-PE and CD40-APC antibodies. The 
data shown are representative of two independent experiments using cells isolated from two different donors. 
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Appendix 7 : Flow Cytometry of iDCs in presence of Mycobacterium liposomes: DC-
SIGN/CD80 markers 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with DC-SIGN-PE and CD80-APC antibodies. 





Appendix 8 : Flow Cytometry of iDCs in presence of Mycobacterium liposomes: HLA-II 
marker 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with HLA-II-APC antibody. The data shown 




Appendix 9 : Activation of iDCs by Mycobacterium liposomes 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with antibodies against CD80, CD86, CD40, 
HLA-II and DC-SIGN receptors and percentage of expression are measured for each condition after cell fixation 
with PFA by FACS analyses. The data shown are representative of two independent experiments using cells 




















































































































































Appendix 10 : Flow Cytometry of iDCs in presence of H37Rv liposomes: CD40 marker 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with CD40-APC antibody. The data shown are 





Appendix 11 : Flow Cytometry of iDCs in presence of H37Rv liposomes: DC-
SIGN/CD80 markers 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with DC-SIGN-PE and CD80-APC antibodies. 





Appendix 12 : Flow Cytometry of iDCs in presence of H37Rv liposomes: HLA-II marker 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs were harvested 
and incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, BCG, M. smegmatis, H37Rv, HN878, 
CDC1551 and EU127 liposomes for 18h. Then the cells were stained with HLA-II-APC antibody. The data shown 





Appendix 13 : Activation of iDCs by H37Rv liposomes 
Human blood monocytes were isolated from buffy coats by using Ficoll gradient centrifugation and a subsequent 
CD14 selection step using the MACS cell separation system. Purified monocytes were differentiated into iMDDCs 
in the presence of IL-4 and GM-CSF, 70ng/ml and 50ng/ml respectively. On day 6, 0.5x106 iDCs are harvested and 
incubated with 20µg/ml Poly(I:C), 5mg/ml LPS or 100µg/ml 0.8PC:0.2Ch, H37Rv, papA1Δ, papA1Δ+SL1 liposomes 
for 18h. Then the cells stained with antibodies against CD80, CD40, HLA-II and DC-SIGN receptors and percentage 
of expression are measured for each condition after cell fixation with PFA by FACS analyses. The data shown are 



























































































































Appendix 14 : Toxicity of 0.8PC:0.2Ch liposomes on CD4+ T lymphocytes 
In a 96-well plate, 2x105 enriched CD4+ T lymphocytes were seeded per well and incubated with 5, 10, 20 or 40µg 
of 0.8PC:0.2Ch liposomes. On days 4 and 7 the cells counts were determinate using trypan blue. The data shown 
























Appendix 15 : Comparison of HIV DNA copies during HIV-1 cis-infection 
CD4+ enriched T lymphocytes (2x105 cells/well in 96-well plates) were infected with 200 TCID50/ml LAI-YFP (HIV-1 X4, left)  500 TCID50/ml BAL-GFP (HIV-1 R5, right) and 40μg of Mycobacterium 
liposomes BCG, H37Rv, HN878, CDC1551, EU127, or 100ng/ml of LPS. At day 7 post-infection, quantifications of HIV-1 DNA were determined by PCR and are represented here in log10 HIV-1 
DNA copies relative to the total number of cells with total HIV-1 DNA (black, n=3), HIV-1 2-LTR (blue, n=3) and  number of integrated HIV (grey, n=3). The data shown are from one experiment 






































































Appendix 16 : Toxicity of Mycobacterium liposomes on CD4+ T lymphocytes during HIV-1 
cis-infection 
CD4+ enriched T lymphocytes (2x105 cells/well in 96-well plates) were infected with 200 TCID50/ml LAI-YFP (HIV-1 
X4, black) or 500 TCID50/ml BAL-GFP (HIV-1 R5, purple) and 40μg of Mycobacterium liposomes BCG, H37Rv, 
HN878, CDC1551, EU127, or 100ng/ml of LPS. At day 7 post-infection, the total number of cells were estimated 
by quantification of CD3 expression by PCR (n=3). The data shown are from one experiment using cells isolated 









































































































































































































































Appendix 17 : Influence of liposomes on HIV-1 X4 
trans-infection - liposomes present during 
capture 
8x104 iDCs were pre-incubated with 100μg of Mycobacterium 
liposomes or 100ng/ml of LPS for 30min. Then the cells were 
incubated 30min with 200 TCID50/ml LAI-YFP (HIV-1 X4) and 
washed to be co-cultured with CD4+ enriched T-lymphocytes. 
A. Concentration of total HIV-1 capsid p24 was determinate 
in the supernatant by ELISA at (1) day 4 (n=4)  and (2) day 7 
(n=4) post-infection. B. represents log10 HIV-1 DNA 
quantification determinate by PCR relative to the total 
number of cells at day 7 post-infection with (1) total HIV-1 
DNA (n=2), (2) number of HIV-1 2-LTR (n=2) and (3) number 
of integrated HIV-1 (n=2). The data shown are from one 
experiment using cells isolated from one donor. 
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Appendix 18 : Influence of liposomes on HIV-1 R5 
trans-infection - liposomes present during 
capture 
8x104 iDCs were pre-incubated with 100μg of Mycobacterium 
liposomes or 100ng/ml of LPS for 30min. The cells were 
incubated 30min with 500 TCID50/ml BAL-GFP (HIV-1 R5) and 
washed to be co-cultured with CD4+ enriched T lymphocytes. 
A. Concentration of total HIV-1 capsid p24 was determined in 
the supernatant by ELISA at day 4 (n=4) (1) and day 7 (n=4) (2) 
post-infection. B. represents log10 HIV-1 DNA quantification 
determined by PCR relative to the total number of cells at day 
7 post-infection with (1) total HIV-1 DNA quantification (n=2), 
(2) number of HIV-1 2-LTR (n=2) and (3) number of integrated 
HIV-1 (n=2). The data shown are from one experiment using 








































































































































liposomes during capture and transfer
Appendix 19 : Comparison of 
HIV DNA copies during HIV-1 
trans-infection 
8x104 iDCs were pre-incubated with 
100μg of Mycobacterium liposomes 
or 100ng/ml of LPS for 30min. The 
cells were incubated 30min with 200 
TCID50/ml LAI-YFP (HIV-1 X4) or 500 
TCID50/ml BAL-GFP (HIV-1 R5) and 
washed to be co-cultured with CD4+ 
enriched T lymphocytes (left panel). 
Finally, when liposomes are present 
during capture and transfer (right 
panel), 40μg of the same 
Mycobacterium liposomes or 
100ng/ml of LPS was added per well. 
At day 7 post-infection, 
quantifications of HIV-1 DNA were 
determined by PCR and are 
represented here in log10 HIV-1 DNA 
copies relative to the total number of 
cells with total HIV-1 DNA (black, 
n=2), HIV-1 2-LTR (blue, n=2) and  
number of integrated HIV (grey, n=2). 
The data shown are from one 




Appendix 20 : Toxicity of Mycobacterium liposomes on CD4+ T lymphocytes and iDCs during HIV-1 trans-infection 
8x104 iDCs were pre-incubated with 100μg of Mycobacterium liposomes or 100ng/ml of LPS for 30min. The cells were incubated 30min with 200 TCID50/ml LAI-YFP (HIV-1 X4, black) or 500 
TCID50/ml BAL-GFP (HIV-1 R5, purple) and washed to be co-cultured with CD4+ enriched T lymphocytes (left panel). Finally, when liposomes are present during capture and transfer (right panel), 
40μg of the same Mycobacterium liposomes or 100ng/ml of LPS was added per well At day 7 post-infection, the total number of cells were estimated by quantification of CD3 expression by PCR 















































































Appendix 21 : Comparison of HIV DNA copies during HIV-1 infections – co-culture iDCs and CD4+T cells 
In a 96-well plate, 2x104 iDCs were placed in culture with 2x105 CD4+ T lymphocytes and infected with 200 TCID50/ml LAI-YFP (HIV-1 X4) or 500 TCID50/ml BAL-GFP (HIV-1 R5). 40μg of 
Mycobacterium liposomes or 100ng/ml of LPS was added. At day 7 post-infection, quantifications of HIV-1 DNA were determined by PCR and are represented here in log10 HIV-1 DNA copies 
relative to the total number of cells with total HIV-1 DNA (black, n=3), HIV-1 2-LTR (blue, n=3) and  integrated HIV-1 copies (grey, n=3). The data shown are from one experiment using cells 








































































Appendix 22 : Toxicity of Mycobacterium liposomes on CD4+ T lymphocytes and iDCs during 
HIV-1 infection – co-culture 
In a 96-well plate, 2x104 iDCs were placed in culture with 2x105 CD4+ T lymphocytes and infected with 200 
TCID50/ml LAI-YFP (HIV-1 X4, black) or 500 TCID50/ml BAL-GFP (HIV-1 R5, purple). 40μg of Mycobacterium 
liposomes or 100ng/ml of LPS was added. At day 7 post-infection, the total number of cells were estimated by 
quantification of CD3 expression by PCR (n=3). The data shown are from one experiment using cells isolated from 



















































Appendix 23 : Influence of Plasma on HIV-1 X4 trans-infection via DC-SIGN  
50µl of plasma were pre-incubated 30min with 0.5x106 of Raji DC-SIGN. The cells were then incubated 2h with 
12.5ng pSG3-LAI HIV-1 X4, and washed after the capture to be finally co-cultured with TZM-bl cells. The luciferase 
activity was red after 48h. Trans-infection of the virus alone where Raji DC-SIGN were pre-incubated with PBS, 
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